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Abstract
Hyperglycosylated human chorionic gonadotrophin (HhCG) is a glycoprotein
hormone that reportedly has biological functions different from those of hCG. It is
produced by invasive cytotrophoblast cells at the time of implantation and in
gestational trophoblastic disease. The invasion of cytotrophoblasts and their regulated
proliferation are major determinants of pregnancy outcome: a shift of these
controlling mechanisms has been associated with adverse pregnancy complications.
Altered levels of HhCG may mirror placental dysfunction or impaired placental
differentiation.
This observational cohort study was undertaken to correlate various pregnancy
outcomes with serum and urinary concentrations of HhCG and other hCG molecular
forms, in order to determine whether HhCG is a helpful predictor of adverse
pregnancy outcome. The first cohort included 287 women with spontaneous
conceptions who attended the Obstetrics and Gynaecology Department of Mafraq
Hospital in the United Arab Emirates. Paired serum and urine samples were collected
on a single occasion from singleton pregnancies between 6 and 24 weeks of gestation.
Patients were followed up until the pregnancy outcome was available. HhCG levels in
pregnancies with uneventful outcomes and those with pregnancy complications were
compared. Significantly lower HhCG levels were observed for pregnancies resulting
in miscarriage as compared with late pregnancy complications.
In the second cohort of 128 patients undergoing in vitro fertilisation or
intracytoplasmic sperm injection at the Assisted Conception Unit in Edinburgh, the
usefulness of serum HhCG levels on Day 14 of oocyte retrieval was assessed. HhCG
levels were found to be significantly lower in pregnancies ending in spontaneous
miscarriages and biochemical pregnancies. The potential diagnostic and prognostic
utility of HhCG was confirmed by a receiver operating characteristic curve plot.
The sugar chain heterogeneity of hCG from various sources was also investigated by
SDS-PAGE and immunoblot analyses of pregnancy urine samples to assess their
potential value as new diagnostic tools for predicting pregnancy outcome. Using
monoclonal antibodies and a panel of lectins that can separate N- from O-linked sugar
chains, variations in the hCG glycosylation patterns during different stages of
pregnancy and pregnancy complication were studied. While the differences in the
hCG glycosylation profiles reported here are interesting, whether they can helpfully
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CHAPTER 1. hCG AND RELATED MOLECULAR
FORMS
1.1 Chorionic gonadotrophin and other glycoproteins
The placental human chorionic gonadotrophin hormone (hCG) belongs to the
glycoprotein hormone family including pituitary-derived luteinizing hormone (LH),
follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH). These
hormones are each composed of two non-covalently associated a and p subunits, of
which the a-subunit is common to all (Figure 1). There is considerable homology
among the p subunits, particularly between the first 115 amino acid residues of the P-
subunits of LH (LHP) and hCG (hCGp) (81%) 1,2. HCGp is unique in having an extra
24 amino acids on its carboxy-terminal end which confers its biological activity.
Intact hCG (i.e. the a-p heterodimer) is a highly glycosylated molecule, containing
oligosaccharide side chains which account for >30% of its molecular weight. Only the
heterodimer is able to bind and to stimulate the hormone receptors, as the free
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Figure 1 Schematic diagram showing the positions of N- and O-linked oligosaccharides on
the a- (common) and P- (specific) subunits of glycoprotein hormones. (Figure adapted from
Reference 3).
1.2 Historical survey
The hypothalamic-pituitary-ovarian axis has been studied since the beginning of the
20th century. Early studies involved the use of hypophysectomised animal models and
established that the reproductive organs were governed by the pituitary gland 4'5. The
ovarian hyperaemia and luteotrophic effects of the anterior pituitary were recognised
2
when anterior pituitary tissue from mice, rats, rabbits and guinea-pigs was implanted
into immature female mice and rats, rapidly inducing morphological changes in their
ovaries, uterus and vagina 6'7.
Other investigators of the same period also described the importance of the ovaries in
the maintenance of pregnancy [for review see Reference 8]. In 1927, Aschheim and
Zondek in 1927 identified a hormone in the blood and urine of pregnant women that
luteinized ovarian tissue 9. Believing it to be produced by the anterior pituitary, they
called it hypophyseal hormone ('Hypophysenvorderlappenhormone' in German). A
similar substance was identified in the blood of pregnant mares 10. It only became
apparent after later experiments that the chorionic villi of the placenta rather than the
pituitary was the major source of this hormonal activity 12, which is now known as
hCG.
In the 1950s and 1960s developments in gel chromatography and isoelectric focusing
enabled isolation and characterization of the four glycoprotein hormones. The subunit
structure of LH was the first to be characterized by Li and Starman in 1964 13.
Subsequent work finally established the a- and (3- subunit nature and linear amino
acid sequences of the peptide chains of hCG l4~16. Since then, major efforts have been
devoted to studies of the biochemistry and molecular biology of hCG, and highly
sensitive techniques developed for its measurement. These studies shed light on its
clinical utility in the diagnosis and monitoring of pregnancy.
1.3 Nomenclature of hCG and related molecular forms
There is considerable confusion in the hCG literature due lack of clear nomenclature.
Early radioimmunoassays were termed "phCG" assays to indicate that they were
specific for hCG and did not cross-react with luteinizing hormone (LH). However this
wording can be misinterpreted to mean the P-subunit of hCG. A few commercially
available assays measuring both hCG and hCGp ("total" assays) are called phCG
assays, causing further confusion. To address this problem, clear and user-friendly
nomenclature has recently been developed by the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) (Table 1). This nomenclature clearly
describes each major hCG variant also provides a convenient means of indicating
which molecular forms an hCG assay measures (e.g. hCG or hCG+hCGP etc).
International efforts are currently under way to encourage universal adoption of this
nomenclature, which has also been adopted in this thesis. In an extension to the
3
published nomenclature, for convenience the beta-subunits of LH, FSH and related
molecules are described as LHp, FSHp etc throughout the present thesis.
Molecule Symbol Description
Intact hCG hCG Non-nicked hCG
Nicked hCG hCGn hCG missing peptide bonds in the hCGp40-50 region
a-subunit of hCG hCGa Subunit dissociated from hCG
p-subunit of hCG hCGp Subunit dissociated from hCG
Nicked
P-subunit of hCG
hCGpn hCGp missing peptide bonds in the hCGP40-50 region
p-core fragment
of hCG
hCGpcf hCGp6-40 residues joined by disulphide bonds to
hCGP55-92
Table 1 IFCC nomenclature and hCG and other important hCG molecular forms
1.4 hCGa- and hCGp-subunits
HCGa contains 92 amino acids and has a molecular weight of about 14,500 with
carbohydrate forming approximately 30% of the weight. The subunit contains 10
cysteine residues that maintain its structural integrity by forming five disulphide
bonds. The molecule also contains two N-linked oligosaccharide chains at Asn52and
Asn78 (Figure 2). Within a species, the a-subunit of hCG is able to combine with each
of the other three glycoprotein p-subunits 17
ala-pro-asp-val-gln-asp-cys-pro-glu-cys-thr-leu-gln-glu-asp-pro-phe-phe-ser-gln-pro-gly-








Figure 2 Amino acid sequence of hCGa showing the carbohydrate attachment sites. Arrows
represent nicking positions on the protein backbone. 18
The beta-subunit of hCG (hCGP) contains 145 amino acids and has a molecular
weight of about 22,200, also composed of approximately 30% carbohydrate. hCGp
contains 6 disulphide bonds joining cysteines. The first 121 amino acids of the p-
4
subunit show 81% sequence identity with the p-subunit of LH. The sequence identity
between the beta-subunit of hCG and those of FSH and TSH is 34% and 38%,
respectively. HCGP contains six oligosaccharide chains. Two of these are N-linked to
Asn13 and Asn30 and the remaining four are O-linked attachment sites located on
















Figure 3 Amino acid sequence of the P-subunit with carbohydrate (N) and (O) attachment
sites. Arrow represents a nicking position on the protein backbone. (Adapted from Reference
378).
Structural elucidation of the glycans is possible after their chemical or enzymatic
release from the protein backbone, followed by chromatographic separation and
1 o oq o i on
chemical " or mass spectrometric investigation ' . N- and O-linked
oligosaccharides of hCG show structural microheterogeneity throughout normal and
3 18 23 27abnormal pregnancy as well as in trophoblastic diseases (Figure 4 and 5) ' ' " .
N-linked oligosaccharides purified from urine of individuals with normal pregnancy
are predominantly fucose-free mono- and biantennary sugar chains (Figures 4 and 5).
Low levels of more highly branched, fucosylated biantennary and triantennary
oligosaccharides are also present. The proportions of mono- to triantennary
oligosaccharides are increased in gestational trophoblastic disease (Figure 6) as
18 28
compared to normal pregnancy (Figures 4 and 5) ' .
The heterogeneity of hCG glycosylation is also reflected in the degree of sialylation
and core fucosylation of hCG and its free subunits. N-linked oligosaccharides vary in
the presence or absence of a fucose moiety joined to the serine-linked N-
acetylglucosamine, as well as in the length and composition of the branches. Evidence
suggests that fucosylated structures are secreted more abundantly towards the end of
5
gestation 27. Variation in the degree of sialylation of both N-linked and O-linked
1 8 9Q
oligosaccharides is also seen in diabetic and Down syndrome pregnancies ' .
The carbohydrate composition of hCG molecular forms also differs. Oligosaccharides
containing a non-reducing terminal mannose are associated with the a-subunit only,
whereas oligosaccharides containing fucose are associated primarily with the (3-
30subunit ~ . The carbohydrate composition of the a-subunit of hCG in extra-embryonic
coelomic fluid (EECF) contains two N-linked glycans similar to that seen in the free
hCGa but the asparagine-52 glycosylation site generally contains a single antenna of
sialic acid-galactose-N-acetylglucosamine on the core oligosaccharide and a terminal
31
mannose at the other potential branch site . In addition, hCGa contains much higher
amounts of N-acetylglucosamine, galactose, sialic acid, and fucose 31. Failure to
combine to form intact hCG may be due to the presence of these additional branches
on the glycans of the EECF hCGa, leading to coexistence of high concentrations of
31uncombined free a- and P-subunits in the EECF . Galactose-terminated
oligosaccharides are present on the hCG a-subunit in EECF, so clearance from the
• 39 33
circulation is slower ' .
(a) Gaipi —► 4GlcNAcpi —► 2Mana1
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Figure 4 Fucose-free bi- (a) and mono-antennary (b) sugars of hCGa in normal pregnancy.34
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Figure 5 Fucosylated (a) and fucose free-biantennary (b) sugar chains of hCGp from normal
34
pregnancy.
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Figure 6 Fucosylated (a) and fucose-free (b) tri-and tetrasaccharide core structures found
abundantly in gestational trophoblastic diseases.34
The major structures identified in O-linked oligosaccharides of hCGp, isolated from
the urine of healthy pregnant women and patients with trophoblastic diseases 34 18'34,
o c
as well as the choriocarcinoma cell line are galactose pi—>-3N-acetylgalactosamine
and galactosepi—>3N-acetylglucosaminep 1—>6 N-acetylgalactosamine. Each has 0, 1,
or 2 N-acetylneuraminic acids, which if present are randomly distributed among the
7
four serine attachment sites on the p-subunit. In normal pregnancy, the O-linked
glycans contain predominantly disaccharide-core structure and significant amounts of
highly branched tetrasaccharide-core structure (16%). As for N-linked
oligosaccharides, the tetrasaccharide-core structure of the O-linked glycans can be
more than 4.5-fold higher in individuals with choriocarcinoma, in whom levels of the
18disaccharide core structure may be decreased .
Studies of the crystal structure of hCG demonstrate that the elongated shape of the
hCG molecule is roughly 75A x 35A x 30A in dimension. The subunits are also
elongated (approximately 60A x 25A x 15A for the a-subunit and approximately 65A
x 25A x 20A for the P-subunit) and highly intertwined 23. The a- and P- subunits of
hCG share a remarkably similar tertiary structure. Each is held together by a set of
three disulphide bridges (cysteines 10-60, 28-82, and 34-84 in the a-subunit, and
cysteines 9-57, 34-88, and 38-90 in the P-subunit) from which three p-hairpin loops
project.
The heterodimer is formed by the association of segments of P-sheet structures near
or
the cystine knot of each subunit to form a short seven stranded P-barrel (Figure 7) '
37. The strands likely to be involved are a52-58, a33-38, P97-102, P56-63, P84-90,
P30-38, and P9-15. The heterodimer is stabilized by a segment of the P-subunit, which
wraps around the a-subunit and is linked like a seatbelt by the disulphide Cys (26-
100) 37. The crystal structure of hydrofluoric acid-treated hCG reveals that the fold of
both a- and p-subunits resembles the cystine-knot motif characteristic of the super-
family of cystine-knot growth factors, which include nerve growth factor (NGF),
transforming growth factor-P (TGFP), and platelet derived growth factor-P (PDGFP)
38. These structural similarities suggest that hCG may have growth activities that have
yet to be elucidated.
The disulphide bonds play a major role in stabilizing the tertiary structure of both
subunits as well as the heterodimer association, which is required for full biological
iz on OQ
activity of hCG ' ' . Much work (particularly on the P-subunit) has examined the
importance of individual disulphide bonds in secretion and dimer assembly as well as
their involvement in receptor binding. Site-directed mutagenesis studies and deletion
of disulphide bonds by replacing cysteine with other amino acid residues, such as
serine or alanine, have shown that following mutation at positions Cys 26, 110, 72
and 90 dimer assembly is reduced to <10%. 40. Deletion of the Cys 26-100 bond
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increases the rate of p-subunit secretion whereas deletion of Cys 9-90, 34-88, or 38-57
Figure 7 Schematic representation of the a- and P-subunits assembly to form hCG dimer as
per the crystal structure. Red lines indicate cysteine bridges [Adapted from Reference 36]
When peptides incorporating each of the six disulphide bonds of hCGp and their
linear counterparts were screened for their ability to inhibit competitively the
recombination of a- and P-subunits, it was found that disulphide peptides Cys (9-57),
oz:
Cys (34-88) and Cys (38-90) inhibited ap recombination. ~ . The remaining three
disulphide peptides, [Cys (23-72), Cys (26-110) and Cys (93-100)] could not inhibit
ap dimer recombination, indicating the importance of Cys (9-57), Cys (34-88) and
36
Cys (38-90) of the P-subunit for heterodimer formation with the a-subunit~ .
The multi-loop disulphide structure appears to provide the a-subunit with a large
degree of flexibility by forming an anchoring point (with loops projecting from it in a
finger-like fashion) which is able to change shape to accommodate any of the P-
subunits (Figure 7) 41. This unusual feature appears to be essential for association and
stabilization of the heterodimer. Furthermore, data on the receptor binding inhibition
studies using disulphide peptides of hCGp has shown the involvement of the regions
around the disulphide bonds Cys9-Cys57 and Cys23-Cys72 in receptor binding of the
hormone 39.
The abundance of carbohydrate moieties on glycoprotein hormones suggests a role in
heterodimer assembly and secretion. Protein glycosylation is involved in many




stabilization, heterodimer secretion, receptor interaction and signal transduction, re¬
linked glycosylation of hCG may play an essential role in signal transduction,
stimulating steroidogenesis and cAMP production, but does not appear to affect the
receptor binding affinity 24' 42. Studies of the hCG folding and assembly pathway
show that initial folding influences glycosylation which, in turn, influences further
folding.
Elimination of two N-linked oligosaccharides from the P- subunit reduces the rate of
dimer assembly, possibly by affecting the rate of folding of the subunit 24'43. Removal
of the oligosaccharide in position a52, either by site-specific mutagenesis or using
chemical methods, results in increased capacity of the gonadotrophin molecules to
bind to the receptor, but significantly reduces signal transduction capability. This
indicates that Asn52 plays an important role in the activation of the receptor/signal
transducer G protein system and hence the subsequent biological response of
stimulation of steroidogenesis and cAMP production 33-43-44
In addition, it has been shown that antibodies against hCGp can restore the signaling
activity of deglycosylated hCG, suggesting a conformational role of carbohydrates 45.
Complete removal of the glycan Asn78 in the a-subunit causes the mutant subunit to
be degraded quickly and less than 20% is secreted in dimeric form. The presence of
hCGp stabilizes the a-subunit mutant and allows approximately 45% of the subunit in
the form of a dimer to be secreted from the transfected cells, thus indicating the
importance of glycosylation for protein stabilization 43'46. Furthermore, elimination of
Asn30 glycosylation has been shown to inhibit the secretion of uncombined hCGp,
again highlighting the importance of N-linked sugar chains of hCG in maintaining the
correct conformation of each subunit 43.
Unlike the N-linked oligosaccharides, the O-linked oligosaccharides of the P subunit
do not play a role either in dimer assembly or hormone secretion, but they are
important for hormone bioavailability 4"\ Removal of all terminal sialic acid residues
and other sugar units, e.g. by chemical or enzymatic deglycosylation, makes the hCG
molecule less acidic and able to form a tighter complex with the LH/CG receptor as
compared to wild-type molecular forms. However, the modified hormone is unable to
induce the appropriate conformational changes of the receptor required for its
activation and induction of the cAMP signal-transduction pathway 47. As a result, its
ability to stimulate steroidogenesis is also hampered. Studies on the steroidogenic
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activity of hCG have also demonstrated that activity declines as the length of
oligosaccharide chain decreases 24'45.
Molecular differences in hCG glycosylation or sialylation have little or no influence
on the overall reactivity of hCG molecular forms or its recognition by mono- or
polyclonal antibodies in assay systems. However, the absence of terminal sialic acid
moieties leads to a marked loss of biological activity in vivo, as a result of rapid
clearance of the hormone from the circulation due to the increased binding affinity of
desialylated or deglycosylated hCG forms to hepatocytes 48' 49. Heavily sialylated
glycoproteins circulate for longer periods than less sialylated molecules, affecting the
9f\
plasma hCG bioactivity: immunoreactivity ratio . Differences in the terminal acidic
9^% 97 SO
or sialylated hCG molecular forms between early and late pregnancy ' ' and
between normal and abnormal pregnancy 18-29'51 have been shown to be influenced by
various placental and/or extra-placental factors. These include the enzymatic activities
of N-acetylglucosaminyl transferases and sialyl transferases, changes in progesterone
concentrations and other non-steroidal factors including inhibin, activin and
interleukin-6 (IL-6) 34, 52~54. These physiological or pathological alterations in the
biosynthetic pathways of hCG glycosylation may represent adaptive responses that
provide the target cell with an optimal trophic signal and/ or specific hormone
function.
1.5 The carboxyl-terminal extension (CTP)
HCG possesses an additional 24 amino acid carboxy-terminal extension which
distinguishes it from LH. Sequence analysis demonstrates a one base pair deletion and
a two-base pair insertion in the hCG gene relative to the LH coding sequence, which
accounts for the extended open reading frame of hCG. There are four serine-linked
oligosaccharides at residues 121, 127, 132 and 138 (Figure 8)55.
121 127 132
I I I
Ser - Ser - Ser - Ser -Lys - Ala - Pro - Pro - Pro - Ser- Leu - Pro - Ser - Pro - Ser -Arg - Leu -Pro -
138
I
Gly - Pro - Ser - Asp - Thr - Pro - lie - Leu - Pro - Gin COOH
I
145
Figure 8 Amino acid sequence of the Carboxy Terminal Extension (CTP) of hCGB showing
the positions of the serine linked O-oligosaccharides.3
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The hydrophilic carboxy-terminal extension (CTP), with a repetitive sequence of
proline and serine residues and containing four negatively charged O-linked
oligosaccharide, has an important role in hCG bioactivity. It prolongs the circulating
half-life of the hormone secondary to a decrease in renal clearance, thereby allowing
it to remain in the plasma longer, with a greater likelihood of interacting with its
receptor 55. The secretion rate of a tethered form of hCG is reduced after deletion of
the CTP segment 56. Fusion of the CTP sequence of hCG(3 to FSH(3 significantly
increased the plasma half-life and the biologic potency of the engineered chimeras 57.
In contrast to the well-established role of CTP sequence in extending the circulatory
half-life of hCG, its involvement in maintaining the overall secondary/tertiary
structure of hCG(3 and in receptor-binding, remains controversial. Various findings
support the suggestion that the CTP sequence does not contribute significantly to the
overall secondary/tertiary structure of hCGp, nor does it appear to be involved in
receptor-binding 46-55. These include the fact that the native hCGP or the synthetic
CTP peptide compete for monoclonal antibodies (MAbs) to the CTP at the same
molarity with radio-labelled denatured hCG, the ability of the hCG carboxy-terminal
mutants to combine efficiently with a-subunit, the ability of CTP sequence to be fused
to the FSHp without affecting the signal transduction of the chimera, and the inability
to resolve the CTP region by X-ray diffraction.
The CTP can affect the intracellular behavior of the subunit by altering the post-
translational processing of the mutated P-subunit55. Muyan et al. showed that the CTP
participates in the folding of the newly synthesized subunits, as indicated by the post-
translational changes in processing of the N-linked carbohydrate-processing pathway,
and deletion of the C-terminal extension sequence, resulting in decreased assembly of
the truncated hCGp subunit (hCGpil4) with the a-subunit and increased
heterogeneity of secreted forms of the uncombined subunits synthesized in transfected
Chinese hamster ovary (CHO) cells 55.
A single chain derivative of hCG with the C-terminus of the a-subunit translationally
fused to the N-terminus of the p-subunit has an overall conformation similar to that of
c o
heterodimeric hCG and binds to the LH receptor ~ . However, the mutant single chain
hCGaP lacking five C-terminal amino acids of the P-subunit shows a significant
reduction in its ability to elicit full biological response 58. There is an intra-molecular
interaction between the CTP and the proximal domains of the subunits as
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demonstrated by generation of an hCGp mutant devoid of the native O-linked
acceptor sites 59. Glycosylation occurs at Serl30 in the CTP and the carbohydrate O-
glycosyl units differ from those in the wild type subunit 59. This suggests that CTP
participates in the folding of newly synthesized subunits through site-specific, post-
translational modifications. Despite the close relationship between the LH(3 and hCGp
subunits, their modes of secretion are different and are programmed by a carboxyl-
terminal sequence, which acts as a routing signal for the apical release of hCG from
the placenta to the maternal circulation 60.
1.6 hCG-related molecular forms
1.6.1 Hyperglycosylated hCG
HCG produced in choriocarcinoma or gestational trophoblastic tumors contains larger
triantennary N-linked oligosaccharides and hexasaccharide O-linked oligosaccharides
than does hCG produced during most of normal pregnancy. During pregnancy, hCG
contains primarily mono- and biantennary N-linked oligosaccharides, tri- and
tetrasaccharide-type-O-linked sugar units(i.e. more complex Core 2 than Core 1 O-
linked sugars) 3> l8'28'47'49'61.
The term hyperglycosylated was originally applied to molecular forms of hCG in
which there is excessive branching of the N- and O-linked oligosaccharide side
chains. Due to the presence of additional sialyl-N-acetylgalactosamine antennae,
HhCG hCG is approximately 14% larger than hCG (molecular weight of 41,000 vs.
36,700 Daltons) 18. More recently, the term HhCG has been used for a distinct
structural variant of hCG which was generated against one choriocarcinoma hCG
preparation (hCG Batch C5). 49 This immunogen contained, in addition to larger tri-
and tetra-antennary N-glycans, only Core-2 O-glycan structures and none of the Core
1 glycans predominantly found in hCG prepared from mid-pregnancy urine (Figure 9)
49,62,63
While various forms of HhCG have been reported (Figure 9), characterization of
B152 antibody indicates that it specifically recognizes hexasaccharide O-linked
oligosaccharides attached to Ser 132 on the C-terminal peptide of choriocarcinoma
hCG. Assays using this antibody therefore only measure hCG molecular forms

















Figure 9 Schematic diagram showing the O-glycan of Core 1 sugar of normal pregnancy
urine hCG and the Core 2 sugar mainly produced weeks following implantation and GTD.63.
In an important study in 1998, HhCG was shown not only to be the principal form of
hCG produced in choriocarcinoma, but also the major form produced in the weeks
following normal implantation 65. Several later publications confirm that HhCG
predominates, in serum and urine, for the first six weeks of gestation, after which its
levels rapidly diminish. It is replaced by other hCG molecular forms, both in
spontaneous conceptions and pregnancies achieved following in vitro fertilisation
(IVF) treatment 66-69.
A cellular origin of HhCG has been identified by analysis of placental cell-
conditioned media. Studies have shown HhCG to be predominantly produced by
cytotrophoblasts, which are the principal cells in blastocysts at the time of
implantation, as well as by poorly differentiated trophoblast cells in choriocarcinoma
70cell-lines ; these studies suggest that maternal HhCG is a marker of trophoblast
invasion and HhCG production is directly linked to ongoing trophoblast cell
invasiveness 7I-74. Some authors therefore refer to HhCG as invasive trophoblast
antigen 69>75'76. This may, however, be a misnomer since HhCG is also produced by
18 98 77 78
some germ cell tumours, as well as by other non-trophoblastic tumors ' ' ' ' .
This has encouraged studies investigating the usefulness of HhCG as a marker to
detect pregnancy disorders related to defective extravillus trophoblast invasion such



















Figure 10 Schematic diagram illustrating possible hyperglycosylation sites of hCG. (a) (3-
subunit glycan of standard mid-trimester hCG, containing mainly Core 1 sugar chains; (b)
subunit glycan with hyperglycosylation of N-glycan in normal pregnancy l8; (c)
hyperglycosylated Core 2 O-glycan; (d) hyperglycosylation at N- and O-linked glycans; (e)
hyperglycosylation of hCGpcf 82; (f) hyperglycosylation on the N glycan of the a-subunit64.
[Figure adapted from Reference 63.]
1.6.2 Other hCG-related molecular forms
There are a number of other molecular forms of hCG in which the carbohydrate or
protein moieties are modified. Properties of those currently considered to be most
clinically relevant are summarized in Table 2.
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Molecule MW a-subunit structure P-subunit structure
hCG 37000 92 amino acids, no cleavages
Mono- & biantennary N-linked
oligosaccharides
145 amino acids, no
cleavages.
Biantennary N-linked ± fucose,
commonly tri-& tetrasaccharide
O-linked oligosaccharides
Nicked hCG 36000 92 amino acids, no cleavages
Mono- & biantennary N-linked
oligosaccharides
145 amino acids, cleaved at
P43-44, P44-45 or P47-48.
Biantennary N-iinked ± fucose,
commonly tri-& tetrasaccharide
O-linked oligosaccharides
Hyperglycosylated hCG 41000 92 amino acids, no cleavages
Mono- & biantennary +
fucose N-linked
oligosaccharides
145 amino acids, no
cleavages.




Free p-subunit 22000 Absent 145 amino acids, no cleavages
biantennary N-linked ± fucose,
commonly tri-& tetrasaccharide
O-linked oligosaccharides
Nicked free p-subunit 22000 Absent 145 amino acids, cleaved at,
P43-44, P44-45 or P47-48.
Biantennary N-linked ± fucose,





26000 Absent 145 amino acids, no cleavages




hCG p-core fragment 10000 Absent Two peptides (6-40) p subunit
residues linked to 55-92
degraded biantennary N-linked
& no O-linked oligosaccharides
Free a-subunit 14500 92 amino acids, no
cleavages.
Mono- & biantennary N-linked
oligosaccharides
Absent
Table 2 Major molecular forms of hCG in serum and urine 83'84
1.7 Synthesis and release of hCG
HCGa is encoded by a single gene on chromosome 6q21.1-23 and the specific P-
subunit is encoded by a cluster of genes consisting of six hCGP subunit genes, one
or
hCGP pseudogene and one LHP gene, on chromosome 19ql3.3 . The synthesis of
hCG starts at very early stages of pregnancy. Initiation of hCG transcription was
85
previously observed between the six- to eight-cell stage using in situ hybridization .
In a study using the more sensitive reverse transcriptase polymerase chain reaction
16
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(RT-PCR) technique, expression was detected as early as the two-cell stage . It is
generally suggested that subunit assembly and formation of the heterodimer proceed
in two phases. The first involves pairing of the subunits in the lumen of the
endoplasmic reticulum, with the aid of one or more chaperone molecules, and the
second involves configuration of the final dimeric subunit87 89
The major steps in hCG biosynthesis are summarized in Figure 11 33'90 and involve
the following:
1. Cleavage of signal peptide, by a microsomal endopeptidase, in membranes of the
endoplasmic reticulum.
2. Chaperone-assisted protein folding, formation of disulphide bonds, and refolding
ofmis-folded protein.
3. Stepwise glycosylation which begins in the rough endoplasmic reticulum with co-
translational transfer of a dolichol-linked oligosaccharide precursor to asparagine
residues 52 and 75 of hCGa and 13 and 30 of hCGp.
4. Further modification of the above precursor by glucosidases (exoglucosidases I
and II) and by a mannosidase, generating high mannose intermediates composed
of two N-acetyl glucosamine residues linked to three mannoses.
5. Additional trimming of glucose and mannose residues in the endoplasmic
reticulum and cis-Golgi membranes.
6. Extensive processing of the oligosaccharides attached to the protein core of the
hormone in the medial and trans-Golgi membranes, where N-acetylglucosamine,
fucose, galactose, and sialic acid residues are added sequentially to form the
mature oligosaccharides.
7. Subunit assembly accompanied by conformational changes in both subunits,
which stabilize hCG.
17
Figure 11 Schematic representation of the steps involved in hCG biosynthesis and
degradation.
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It is proposed that ap dimer formation involves two pathways 91. In the 'wraparound'
pathway the a- and P-subunits initially dock before the 'seatbelt' is latched, forming a
loose complex. This undergoes subsequent association-dependent folding (i.e. the
seatbelt is wrapped around loop a2 forming the disulphide latch) to form the stable
biologically active dimer (Figure 12a). In the 'threading' pathway, the seatbelt latch
disulphide forms before the subunits dock. Assembly of the heterodimer is completed
when loop a2 and its attached oligosaccharide traverses the hole in the P-subunit
beneath the seatbelt (Figure 12b). The association of the subunits follows second-
order kinetics and their final folding follows first-order kinetics 91. Association is not
only a necessary precondition of the formation of the biologically active hormone, but
also protects the P-subunit from proteolytic digestion. Interchain hydrogen bonding is
important at the subunit interface.
Figure 12 Pathways of a and P-subunit assembly. In the wraparound pathway (a) both
subunits are initially docked before the seatbelt (i.e. formed by Cys 26-110 shown as cc in
red) is latched. In the threading pathway (b) the disulphide seatbelt latches before the docking
and subunit assembly. The green rectangle represents loop 2 oligosaccharide on the a-subunit
involved in subunit assembly and their folding. [Figure adapted from Reference 91 ]
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The villous syncytiotrophoblast of the placenta is the main site of hCG production '
92 • • 70whereas the invasive cytrophoblasts are the primary source of HhCG . The
cytotrophoblast (undifferentiated stem cells) is dominant in early gestation and the
syncytiotrophoblast (differentiated trophoblast transformed from cytotrophoblast) is
dominant later in pregnancy 85'92. hCG synthesis depends on the rate of differentiation
of cytotrophoblasts into syncytiotrophoblasts.92
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In vitro studies demonstrate that cytotrophoblast cells, isolated from term placenta and
cultured in maternal serum, progress to an advanced stage of trophoblast
differentiation (i.e. multinucleated syncytial structures) and actively secrete hCG 93.
Cytotrophoblasts of the placenta secrete hCG on 7-9 days after conception while after
implantation the placental syncytiotrophoblast starts to produce large amounts of
hCG, of which more than 90% is released into the maternal circulation.
Serum hCG concentrations increase at an exponential rate during normal pregnancy,
with a doubling time of up to two days for the first 5-6 weeks, reaching peak
concentrations of approximately 100,000 U/L between the 7th and 10th weeks of
gestation. After 11 weeks hCG concentrations decrease 10-fold before reaching a
plateau at which they remain relatively constant until near to term, when they increase
slightly before falling rapidly to within the postpartum reference range 94'95.
Histological and immunohistochemical studies demonstrate cells with many
cytoplasmic protrusions containing numerous secretory granules which produce hCG
96. These small granules are seen in the Golgi complex and migrate toward the cell
surface, increasing in size by fusing with each other. They gather in cytoplasmic
protrusions and following liquefaction are liberated by exocytosis into the maternal
bloodstream. These hCG secretory granules arise synchronously on the surface of
almost all chorionic villi. They form only at 8-9 weeks of gestation, coinciding with
the maximal hCG concentration of maternal serum during pregnancy.
The rate of secretion of hCG is largely determined by synthesis of hCGp which peaks
during the first trimester, whereas concentrations of hCGa show a progressive
increase throughout pregnancy. Hoshina et al localized hCGa mRNA in the syncytial
layer and also in differentiating cytotrophoblasts and suggested that the transcription
of these genes is initiated before the completion of syncytial formation, becoming
Q7
attenuated as gestation progresses . HCG is primarily localized to cytotrophoblasts
in 4- 5 week placentas, whereas in 6-12 week placentas these substances are
exclusively localized in the syncytiotrophoblast 85. Many other studies confirm that
the changing pattern of hCG secretion depends on changes in the distribution of
cytotrophoblastic- and syncytiotrophoblastic-cells. This differs from the pattern
observed for other placental products (e.g. progesterone and human placental
lactogen), all of which show a progressive rise throughout pregnancy and, in some, a
plateau towards term 98~100.
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Several studies have been conducted to explain why a peak of hCG occurs early in
human pregnancy. Most of the published data focus on the role of gonadotrophin-
releasing hormone (GnRH), which is synthesized mainly by the cytotrophoblast and
stimulates release of hCG in vitro 101' 102. Pulsatile secretion of hCG has been
measured in first trimester trophoblast explants to which GnRH-I or GnRH-II had
If)-} , .
been added . GnRH-I induced both hCG synthesis and secretion, thus behaving as a
placental GnRH, whereas GnRH-II induced hCG secretion only. The difference in
actions of the two GnRHs might be due to their differential expression during phases
of pregnancy, giving rise to the different pattern of hCG secretion. This may be
possible since GnRH receptor mRNAs have been detected in the human placenta and
are localized to the cytotrophoblast and syncytiotrophoblast cell layers 104. Dynamic
changes in the numberof these mRNA levels in the placental trophoblast cells mirror
the placenta's morphological transformation at various gestation ages, regulating hCG
secretion during pregnancy. There is also evidence for a peak of GnRH receptors in
the placenta at the end of the first trimester l<)5.
HCG regulates its own synthesis in the human placenta by several mechanisms. The
trophoblast has surface receptors for hCG, and binding of hCG to these receptors
down-regulates its own secretion (autocrine action) (Figure 13) l06,107. HCG can also
increase cAMP levels in human placenta, and exogenous cAMP stimulates placental
hCG biosynthesis and promotes differentiation of cytotrophoblasts, thereby regulating
their synthesis of hCG (paracrine action). These findings suggest that cAMP may be a







Figure 13 Factors involved in the regulation of hCG secretion. [Figure adapted from
Reference 107.]
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Figure 14 Stimulatory (green) and inhibitory (red) activities of possible secretagogues on the
secretion of hCG.[Adapted and updated from Reference l09]
Although it is unlikely that all pathways are functional at the same time, Figure 14
illustrates the complexity of the interactions that may occur in vivo. The fact that so
many possible regulators of hCG secretion act in an autocrine and paracrine manner
adds further complexity to this system. The imbalance between the concentrations of
mature hCG vs. free subunits (e.g. in malignancy and ectopic pregnancy) and the
occurrence of aberrant molecular forms (e.g. carbohydrate molecular forms) and
partially degraded molecules raise a question as to how the individual steps of hCG
biosynthesis are coordinated and whether they are regulated separately. Further
investigation of the mechanism of hCG synthesis and secretion in pregnancy-related
disorders should help to improve understanding of these complex phenomena.
1.8 Metabolism of hCG-related molecular forms
HCG in the circulation has a bi-exponential plasma half-life, with a fast disappearance
half-life of approximately 5 hours and a slow half-life of approximately 35 hours "°.
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The a- and p-subunits also demonstrate biphasic disappearance curves, but they are
cleared from circulation much more rapidly. hCGa has a rapid half-life of 13 minutes
and a slow half-life of 76 minutes whereas the corresponding half-lives for hCGp are
41 and 236 minutes, respectively Only 25% or less of the hormone is excreted in
• 119
the urine, with the remainder catabolized by the liver, kidneys and other tissues
HCGPcf is the major urinary degradation production of hCG and its P-subunit.
Although much of the carbohydrate present in hCGp is missing from hCGpcf, its
concanavalin-A-binding activity is retained due to the presence of a fucose core.
During pregnancy hCGpcf is the major immunoreactive component of hCG in urine,
with production of up to 5 mg/day and urinary concentrations 2 to 10 times higher
than that of hCG on a molar basis. HCGpcf emerges as the dominant form only
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during the fifth week after conception . Using a highly sensitive assay, very low
concentrations of hCGpcf [from 2.9-34 pmol/L (i.e. < 0.1% of the concentration
found in urine)] have been demonstrated in the serum of pregnant women "4. Its high
urinary concentration suggests that hCGpcf arises from hCG metabolism in the
kidney114'115.
A study involving intravenous injection of recombinant hCG into healthy, non
pregnant women showed that hCGpcf measured in urine accounted for only 12.2% of
the total of hCG immunoreactivity "6. There is some evidence of formation of
hCGpcf by partial proteolysis of hCG in the tissue where hCG or hCGp is synthesized
117 118
. hCGpcf has also been found in the urine of men, non-pregnant women, and
patients with trophoblastic disease and non-trophoblastic malignancies 118~120.
HCGn (Table 1) is also found in urine and blood of pregnant women and women with















Figure 15 Amino acid sequence of hCGp showing the inter-cysteine loop P38-57 which
contains the major sites of missing peptide linkages or nicks. 121
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HCGn is less stable in serum and urine than hCG and rapidly dissociates to hCG(3n
122and hCGa . It has been suggested that free hCG subunits may be generated by
direct dissociation of hCG and that 'nicked' forms are dissociated into free forms and
degraded into hCGp minus CTP and hCGpcf l23'I24. The hCG degradation pathways
are thought to be more active in abnormal pregnancies, during parturition and in
gestational trophoblastic disease l15' 119' 1 '' 125. Studies have shown very little
biological activity of nicked forms of hCG with up to 80% loss of hormone function
as well as variations in in vitro receptor-binding activity 122'126.
Hyperglycosylated free a- and p-subunits of hCG are also reportedly present in urine
1O Ol 11^
samples of pregnant women and patients with trophoblastic disease ' ' . HhCG is
believed to break down more rapidly than normally glycosylated hCG. This might be
due to steric -effects preventing combination of the larger hyperglycosylated free a-
and p-subunits 115. The presence of terminal sialic acid residues on each of the large
carbohydrate side-chains, is also known to affect the in vivo half-life of hCG 127.
1.9 hCG profiles during pregnancy
Progressive changes in hCG molecular forms throughout pregnancy have been
documented in many studies. On the basis of gel chromatography results, Fien et al.
reported that first trimester hCG was more highly glycosylated than hCG found in the
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third trimester . Wide and Hobson, measured the median charge and the ratio of
bioactive to immunoreactive (B/I) ratio of hCG in serum and concluded that hCG
from early pregnancy and choriocarcinoma has identical median charge with hCG
25from later pregnancy as well as an increased metabolic clearance rate . However the
same authors later demonstrated that a change in the hCG isoform distribution pattern
occurs at around the 13th week of gestation 50.
Kovalevskaya et al. demonstrated progressive changes of the choriocarcinoma-like
hCG isoform from 1 to 4 weeks post embryo transfer which continue through the
remainder of pregnancy 66. Several consecutive reports on HhCG in spontaneous
conceptions further confirm that highly branched hCG molecular forms, produced by
the invasive cytotrophoblasts, predominate during the first six weeks of pregnancy
and account for up to 100% of early pregnancy hCG-related molecules). These
molecular forms rapidly disappear as pregnancy progresses, and are replaced by less
highly branched hCG glycoforms of mature pregnancy, so they form only a minor
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component of hCG-related molecules (<2%) from 8 weeks of gestation until term '
68,129,130
In contrast, Diaz-Cueto et al showed that hCG molecular forms become less acidic as
gestation progresses, with most acidic forms found in samples taken at 10-11 weeks
of gestation 26. Skarulis et al reported that the glycosylation patterns of both hCG and
hCGa change, as pregnancy progresses, due to increased branching and fucosylation
27. These results imply that the activities of placental fucosyl transferase as well as N-
acetylglucosaminyl transferases IV and V may be increased later in gestation. The
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latter two studies contradict the three reports described above ' ' , as they suggest
that in normal pregnancy hCG increases in carbohydrate complexity and becomes less
acidic as gestation progresses, i.e. begins to resemble a choriocarcinoma-like hCG
isoform. Indeed, it has been suggested that enzymatic changes in early gestational
trophoblast cells lead to the biosynthesis of highly branched N-linked
oligosaccharides, and may explain the presence of higher proportions of HhCG during
early gestation 131.
Production of the hyper-branched Core 2 glycan structure, to which MAb B152 is
mainly bound, is attributed to the activity of a glycotransferase enzyme which is also
active in trophoblastic tumors and cells that participate in the immune response. Such
modifications of hCG during the early stage of placental development may indicate a
role in trophoblast invasiveness and thereby implantation 71,72' 132. In contrast, the
decrease in HhCG levels observed as pregnancy progresses parallels the
syncytialization of the trophoblast with advancing gestation. During this process, it
has been suggested that differentiated syncytiotrophoblasts secrete well-processed
glycosylated molecular forms of hCG and fewer choriocarcinoma-like hCG molecular
forms. Hence, alteration of protein synthesis pathway may occur concurrently with
the appearance and the disappearance of a particular trophoblastic cell with advancing
gestational age 20'27-67-128
Nicked hCG molecules account for approximately 9% of serum hCG molecules at the
second month of gestation, the mean proportion rising to 21% of hCG molecules in
the 9th month of normal pregnancy. 126 HCGa is present at low concentrations in
maternal blood by the sixth week of pregnancy, and its concentration increases
gradually to a maximum of about 500 pg/L 133. During the 3rd trimester, free a-
subunits constitute 30-50% of the total hCG in maternal blood. HCG[3 concentrations,
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like those of hCG, peak at around the 10th week of gestation, but are very low,
representing only 0.9% of the total hCG concentration in the 2nd month gestation, and
declining to 0.5% in the 9th month. HCGP concentrations are initially lower than hCG
concentrations but begin to increase sharply at 5 weeks of gestation, and by 6-7 weeks
of gestation they are similar to urinary hCG concentrations (mole for mole), and
increase from then on 83'115'134.
1.10 The physiological role of hCG in human pregnancy
Although an embryo is considered as a semi-allograft in the maternal environment, as
half of its genetic material comes from the father, it is well tolerated due to complex
biochemical and molecular mechanisms that establish a dialogue at the fetomaternal
interface, thus allowing its implantation and development in the uterus. HCG plays
several key roles in the apparent immunological paradox that enables survival of the
semi-allogenic fetus in the maternal environment.
1.10.1 Involvement of hCG in rescue of the corpus luteum
HCG plays an important role in early pregnancy by preventing luteolysis and
extending the functional life of the corpus luteum for a number of weeks, providing
adequate progesterone secretion by the corpus luteum to maintain pregnancy. In
primates, ovariectomy or removal of the corpus luteum prior to the luteal-placental
1 T5
shift causes abortion unless progesterone is replaced . Exogenous administration of
hCG to non-pregnant women and primates to mimic the in vivo pattern of hCG
secretion extends the functional life span of the corpus luteum and prolongs
progesterone secretion. This critical "rescuing" role of hCG is evident as anti-hCG
antiserum administered during early pregnancy results in abortion in primates 136 and
in a fall in progesterone level with subsequent menses in women 137.
The timing of hCG secretion and its continuous increase as the trophoblast develops is
mandatory for luteotropic support of the corpus luteum. In a study assessing the
response of the corpus luteum to different exogenous hCG concentrations during the
mid-luteal phase of the menstrual cycle, failure of the corpus luteum was observed
1 TO
when hCG was injected slowly in a suboptimal manner on Day 8. This mimics the
hormonal environment of a failing embryo, which is characterised by steadily falling
levels of progesterone. Regimes mimicking the situation in normal spontaneous
pregnancies, by giving exogenous hCG starting on Day 7, rescue the corpus luteum
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and induce a sustained increase in plasma progesterone from Day 8 to Day 11. 138
Plasma concentrations of progesterone fall within 24h of the last hCG injection
1 TO
despite the presence of residual circulating hCG . The luteotropic action of hCG is
mediated by 1) prevention of hCG receptor down-regulation, 2) prolonged expression
of steroidogenic acute regulatory protein, 3) cytochrome P450 cholesterol side-chain
cleavage, and 4) prolonged expression of 3p-hydroxysteroid dehydrogenase, all of
which are required for steroidogenesis. 139 In addition, hCG has anti-apoptotic
activity in the late luteal phase, preventing luteolysis. This is achieved by 1)
maintaining luteal blood flow through increased expression of angiogenic factors 140,
2) limiting tissue remodeling by controlling the activity of matrix metalloproteinases
2 and 9 (MMP-2 and MMP-9) and the influx of macrophages 141, and 3) preventing
stromal fibroblasts from undergoing apoptosis by decreasing the pro-apoptotic
protein, Bax, and increasing the Bcl-2/Bax ratio l42' 143. All these functions are
maintained until the luteal-placental shift occurs at approximately 7 to 9 weeks of
gestation, after which time the functional capacity of the corpus luteum decreases, and
placental production of progesterone begins.
1.10.2 Effects of hCG on implantation
HCG also plays an important role in implantation by modulating the uterine micro-
environment to allow trophoblastic invasion and maintenance of pregnancy. The
process of implantation begins about 6-7 days following fertilization and consists
basically of three stages (Figure 16) l44. The first stage is the initial adhesion of the
blastocyst to the uterine wall. At this stage, microprotrusions from the apical uterine
epithelium surface (pinopodes) extend onto microvilli on the apical
syncytiotrophoblast surface of the blastocyst. The next step is adhesion with increased
physical contact between the blastocyst and the uterine epithelium and the
concomitant orientation of the embryonic pole towards the luminar epithelium. The
final invasive stage concludes with penetration of the syncytiotrophoblasts through
the uterine epithelium to invade the entire endometrium, the inner third of the
myometrium and the uterine vasculature, thus establishing uteroplacental circulation.
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Figure 16 Schematic depiction of the process of implantation. Left of picture: The blastocyst
in the pre-implantation stage triggering embryo-maternal cross-talk. Middle of picture: Nine
to ten days post-conception, showing blastocyst invasion, to which HhCG has been suggested
to contribute. Right of picture: Eleven to fourteen days post-conception, by which time the
biological effect of hCG is fully functional. [Figure adapted from Reference 144.]
During the normal menstrual cycle, the uterine mucosa undergoes changes that reach
maximum during the luteal phase, making it receptive for implantation when
embryonic signals are present. Although mechanisms of implantation vary somewhat
among species, in vivo and in vitro studies in animals (particularly baboons) can
helpfully contribute to elucidation of the complex process of implantation in humans.
139In baboons, (as in humans), uterine receptivity may be divided into distinct phases
145, 146 pjiase j js regulated by oestrogens (E) and progesterone (P) and occurs
between post-ovulation Days 8 and 10 of the normal menstrual cycle. In this phase the
uterine lining is neutral toward the implanting blastocyst. The second phase of uterine
receptivity is induced by blastocyst "signals" superimposed on the E/P-primed
receptive endometrium.
Probably through actions on the endometrial receptors, hCG in the receptive phase
causes functional and morphological changes in three major cell types of the
endometrium - the luminal epithelium, glandular epithelium and stromal fibroblasts
l 9, 147, 148 jn jumjnaj epithelium, hCG stimulates the plaque reaction (i.e.
hypertrophy, hyperplasia and differentiation of the surface epithelium) possibly by
infiltration of pro-inflammatory cells into the uterus. hCG also causes glandular
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transformation and stromal cell differentiation by increasing transcriptional and post-
translational modulation of glycodelin. In vitro studies show glycodelin A to be a
paracrine modulator of hCG synthesis as it induces hCG secretion in culture media
containing first and third trimester trophoblast cells. 149 It also regulates the uterine
immune responsiveness by suppressing decidual thymidine uptake. This decreases
synthesis of IL1 and IL2 and expression of the IL2 receptor by mitogen-stimulated
cells, inhibits the cytotoxic activity of natural killer (NK) cells and suppresses both
allogenic mixed lymphocyte reaction and responsiveness to phytohaemagglutinin 149.
A further action of hCG on human endometrium has been demonstrated in novel
experiments in which urinary hCG was infused directly into the uterine cavity of
women during the luteal phase using an intrauterine microdialysis device and changes
in concentrations of various cytokines and growth factors in the uterus were
determined 150' 151. Vascular endothelial growth factor (VEGF) levels increased,
suggesting direct involvement of hCG in the endometrial angiogenesis required for
implantation. Concentrations of leukemia inhibitory factor were also significantly
stimulated. This cytokine is produced by natural killer lymphocytes that interact with
the invading trophoblast and has been shown to activate both urokinase plasminogen
activator and gelatinase, enzymes which have crucial roles in trophoblast invasion 147.
Levels of MMP-9, an enzyme involved in tissue invasion during implantation, were
also significantly increased.
In addition to these stimulatory effects, hCG had inhibitory effects on intrauterine
levels of insulin-like growth factor binding protein-1 (IGFBP-1) and macrophage
colony-stimulating factor. Both these have been shown to restrict trophoblast invasion
into the decidua, highlighting the paracrine role of hCG on endometrial functions
essential for implantation 151'152.
A prerequisite for such a direct effect of hCG on the endometrium is the presence of
functional LH/hCG receptors. HCG receptor mRNA is expressed in the endometrium
at the time of implantation l47'153. Studies using immunohistochemical and in situ
hybridization techniques revealed a cycle-dependent appearance and distribution of
hCG structures and mRNA. No immunoreactive cells were detectable during the
proliferative phase. However, in the secretory phase of endometrium, hCG|3-like
structures are found in glands as well as in stroma l47. Thus hCG secreted by the
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glandular epithelium during the progesterone-induced secretory phase may contribute
to maintaining the corpus luteum, as well as supporting early pregnancy.
In relation to stromal fibroblast modulation, hCG enhances the action of a-smooth
muscle actin. This is possibly in response to integrins on the stromal cell membranes
which bind to secreted extracellular matrix proteins causing stromal cell proliferation
and differentiation l39. The addition of hCG to steroid-treated stromal cells in baboons
has been shown to inhibit apoptosis and enhance differentiation, as reflected by
IGFBP-1 expression and an increase in the transcription of the pro-actin gene, both of
which promote decidualization of stromal cells l39.
1.10.3 Role of hCG in angiogenesis
The cytotrophoblasts situated at the tip of the anchoring villi in the intervillous space
proliferate outwards from the underlying basement membrane to form cell columns
from which cells migrate into the interstitial trophoblast cells and invade the maternal
spiral arteries, thus establishing the uteroplacental circulation 144. For normal
intrauterine fetal development and survival, adequate nutrient supply is mandatory
and disturbances in uterine blood supply are generally associated with higher perinatal
morbidity and mortality e.g. due to preterm delivery, pre-eclampsia, or intrauterine
growth restriction. The vasculature of the uterus and surrounding tissues undergoes
adaptive changes to accommodate the rising needs of the growing fetus by increased
vasodilation, vascular permeability, and neovascularization.
In general, the angiogenic process is initiated by growth factors such as basic
fibroblast growth factor, vascular VEGF, and placental growth factor. hCG is thought
to stimulate endometrial angiogenesis and growth and extend the implantation
window through its actions on IGFBP-1 and VEGF, both of which are considered key
regulators of neovascularization and vascular function l48'151'154. Exposure of human
granulosa cells to hCG stimulates the expression of VEGF mRNA 155' 156.
Furthermore, administration of hCG in women undergoing in vitro fertilization has
been shown to increase urinary VEGF concentrations l56. Incubation of uterine artery
extracts with highly purified hCG not only resulted in a dose-dependent increase in
cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), prostacyclin synthase, and
vasodilatory eicosanoids such as 6-keto-prostaglandin-Fla, but also in a decrease in
thromboxane-A2 synthase, and vasoconstrictors such as prostaglandin-E2, and
thromboxane-B2.
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There was also a significant decrease in the resistance index of uterine arteries 16 hours
after the administration of 10,000 IU hCG for ovulation induction in women, indicating
an increase in uterine blood flow. The angiogenic response is possibly induced through
activation of the protein kinase C-signaling pathway (PKC), which plays an important
role in new capillary formation and survival phases of angiogenesis in different systems.
PKC inhibitors decrease the angiogenic response in endothelial cells l48.
The direct angiogenic actions of hCG on fetomaternal vasculature are thought to be due to
the presence of LH/hCG receptors in the endothelium and smooth muscle of uterine blood
vessels. Indeed, the expression of LH/hCG receptor mRNA is shown to be higher in the
intra-myometrial segment than in extra-myometrial arteries and is higher in endothelial
cells than in the smooth muscle of intra-myometrial arteries l57. The classical signal
transduction pathway induced by hCG (i.e. cAMP-dependent G-protein signal
transduction in gonadal cells) was not detected in a baboon endometrial epithelial cell
line. Instead, an alternative PKA-dependent pathway involving activation of extracellular
signal-regulated protein kinases 1 and 2 was proposed to bring about up-regulation of
COX-2 expression and prostaglandin E2 production 158'l59.
1.10.4 Role of hCG in late pregnancy
There is increasing evidence that hCG also plays a role in maintaining late pregnancy
through the hCG/LH receptors in uterine myometrial smooth muscle cells l6°. hCG
inhibits myometrial contractions by down-regulating gap junctions and decreasing
intracellular Ca2+ levels 161' l62. Gap-junctions allow coordinated myometrial
contractions in labor, their numbers peaking at the time of delivery and then
decreasing thereafter. HCG may act via its receptors to enhance myometrial
quiescence by down-regulating the myometrial-gap junctions and inhibiting
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contractions ~. A direct effect of hCG on gap junction protein may also be exerted
through the connexin protein units (CX) of gap junctions.
Using human myometrial samples obtained during caesarean sections, CX-43 protein
levels have been shown to be down-regulated with increased duration of exposure to
hCG, probably through protein kinase A signaling 161. HCG also reversed the
oxytocin-induced increase in CX-43 protein levels 161. Myometrial LH/hCG receptor
levels are not constant in the pregnant myometrium, as both the receptor protein and
its mRNA level are lower during labour, both in term and preterm pregnancy l64.
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Down-regulation of the LH/hCG receptor during labour may be a prerequisite for
transition of the uterus from a quiescent state to the active stage of labour 163.
HCG can directly act on human myometrial smooth muscle cells, through the protein
kinase A signaling system, to increase both their number and their size in a
subpopulation of cells. This suggests a possible role in the expansion of the uterus in
order to accommodate the growing foetus l65. The angiogenic vasodilatory role of
hCG mentioned earlier is not only critical for implantation but also may be essential
for facilitating nutrient delivery and waste removal during later pregnancy. In a study
using pregnant mice in which preterm labor was induced using prostaglandin F2a, a
single high dose injection of hCG not only resulted in inhibition of preterm labor but
also prolonged pregnancy beyond term 166. A similar tocolytic effect of hCG was
obtained when hCG was administered to a small cohort of women with established
preterm contractions. 167 hCG was shown to suppress uterine contractions and delay
labor without side-effects. These findings collectively suggest a uterotropic and
quiescence- inducing role for hCG which could be further investigated to develop
therapies for preventing or inhibiting preterm delivery.
1.10.5 Other roles of hCG
The role of hCG in ovarian development and differentiation is unclear. However hCG
induces secretion of testosterone by fetal testicular Leydig cells, which is essential for
the development of internal and external male sexual organs prior to the onset of
pituitary LH secretion. This is supported by the following observations: 1) peak fetal
serum testosterone levels coincide with peak maternal hCG concentrations, 2)
testicular tissues from 14-16 week fetuses produce testosterone and cAMP when
incubated with hCG, 3) the fetal pituitary contains an insufficient amount of LH at
this time to account for fetal testicular testosterone production, and 4) the
differentiation of Wolffian duct structures takes place only during the period of
testosterone secretion by Leydig cells l09.
HCG has also been reported to have immunosuppressive properties and to induce
immunological tolerance of the maternal immune system to the trophoblast and
growing fetus 148' 168. In vitro studies demonstrate that the secretion of several
cytokines from peripheral blood mononuclear cells (PBMC) derived from women in
early pregnancy is modified by hCG stimulation. hCG inhibited IL-2 production and
increased IL-ip, IL-6, and TNF-a production, and also significantly enhanced
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interferon y production when calcium ionophores were used as inducers. Additionally,
hCG diminished IL-2 secretion and enhanced release of soluble IL-2 receptor from
PBMC. Basal production of IL-8 by PBMC (along with other cytokines) is increased
very early (4-5 weeks) in pregnancy, after which the levels return to those produced
by the PBMC of non-pregnant women. This, coupled with the finding that hCG
activates monocyte production of IL-8 via a different pathway from the LH/CG
receptor system l48' 168, possibly suggests a role for HhCG in regulating maternal
immune response and preventing immuno-rejection of the developing fetus.
Because of its structural similarity to TSH, hCG can at high concentrations bind to
TSH receptors causing excessive stimulation of the thyroid gland hCG, and
contributes to the increased maternal thyroxine levels sometimes observed in the first
trimester of pregnancy. In normal pregnancy, serum TSH levels fall when hCG peaks
and are a mirror image of hCG levels. Free triiodothyronine (T3) and thyroxine (T4)
levels are significantly elevated at this time, and this may be one cause of
hyperemesis during early pregnancy. This is supported by the finding of thyroid
hyperstimulation in cases of molar and multiple pregnancies, which are associated
with higher levels of hCG l69. Other roles of hCG include stimulation of
dehydroepiandrosterone production by fetal adrenal glands and stimulation of
decidual prolactin secretion. HCG also promotes placental steroidogenesis (by
stimulating the conversion of cholesterol to pregnenolone and progesterone), placental
aromatisation, and hydroxylation of placental steroids, although the precise
mechanisms remain uncertain 109'170.
1.11 The role of HhCG in pregnancy and implantation
As described earlier, the final phase of uterine receptivity is initiated after blastocyst
attachment and implantation, ending in formation of the human haemochorial
placenta, in which blood from the maternal circulation constantly bathes the fetal
chorionic villi. Phenotypically, trophoblast cells are considered to be the physiological
counterparts of invasive malignant tumors but have a controlled program of terminal
trophoblast differentiation. It is unclear whether trophoblast cells utilize the same
molecular growth mechanisms as tumors or whether they also have migratory and
invasive capabilities. However studies have shown that hCG, while regulating its own
biosynthesis, may simultaneously induce multiple signals that control trophoblast
proliferation, in part by regulating the expression of key components required for
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progression through the cell cycle, and in part by controlling protease activity. HCG is
able to modulate parameters of endometrial differentiation such as IGFBP-1, and
influence the invasive pathway by interfering with the production of MMP activators
and their tissue inhibitors 141'150'155'168'171~174. Thus hCG is one factor in the functional
differentiation of human cytotrophoblast cells which regulates their proliferative
potential.
HhCG is exclusively produced by the invasive cytotrophoblast cells at the time of
implantation during pregnancy and accounts for the major proportion of total hCG
forms produced during the period of trophoblast invasion 66' 67' 69' 70' 175. It is also
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produced in high concentrations in choriocarcinoma and testicular germ cell tumors '
77 176
. The immunoreactivity secreted into the conditioned medium of JAR
choriocarcinoma cells is wholly due to HhCG 49. Studies by Lei et al. showed that
JAR cells are invasive in matrigel basement membrane inserts in vitro as well as when
transplanted into athymic nude mice in vivo . When JAR cells are treated with
hCGa antisense cDNA, production of HhCG is blocked and invasion into the matrigel
membrane in vitro and tumorigenesis in athymic nude mice in vivo is also
compromised. These data suggest that HhCG has a critical role in trophoblast cell
invasion.
HhCG has been shown to lack the biological action of hCG in maintaining the
production of progesterone due to its poor binding capacity with the LH/hCG
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receptor, and shows only 4% of the steroidogenic action of hCG . No role during
implantation has as yet been confirmed for HhCG. However due to its cystine-knot
configuration, the molecule may exert some of the cytokine-like action mentioned
above during early pregnancy 23' 37. As hCG has shown to down-regulate Fas, Fas
ligand, Bax and p53, HhCG may be involved in growth and invasion of the
trophoblast during implantation (or tumor development) by similar anti-apoptotic
activity. It has been suggested it might exert such action by acting as an autocrine
antagonist on the TGFp receptor 177'178.
In vivo and in vitro studies have shown that HhCG promotes formation of
cytotrophoblasts and choriocarcinoma cell growth and invasion. Using a matrigel
invasion model, addition of HhCG, but not hCG, has been shown to promote growth
and invasion of pregnancy membranes by cytotrophoblast and choriocarcinoma cells
in culture. In a further experiment, when JEG3 choriocarcinoma cells were
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transplanted into nude mice, growth and progression of newly formed tumors could
be rapidly blocked using mouse MAbs raised against HhCG 72'74.
There is direct evidence of the invasion-promoter action of choriocarcinoma hCG
17Q
from a study by Hamada et al . Transfection of the anti-sense hCGB gene into JAR
choriocarcinoma cells not only suppressed the expression of hCGB mRNA expression
and hCGB protein synthesis, but also resulted in significant inhibition of cell
proliferation by significant increasing the apoptotic rate of cells 179. Indeed, an earlier
study by Lei et al. demonstrated that the tumorigenie effects of choriocarcinoma hCG
did not involve increased cell proliferation, but rather decreased apoptosis leading to
increased invasion of JAR cells in nude mice . It was suggested that this action was
brought about through the cytokine-like action of choriocarcinoma hCG 73. Hamada et
al. concluded that the tumorigenic activity of the hormone involved its action on the
LH/hCG receptor. 179
It remains to be determined whether HhCG exerts its action through LH/hCG
receptors or, due to the cystine knot configuration, to a cytokine-like action on TGFp
receptors that trigger apoptosis 70"72'74'18<). Together with the finding of unduly low
levels of HhCG this suggests that insufficient production of HhCG itself may be the
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cause of ineffective implantation that leads to pregnancy failures ' ' ' .
Binding of hCG to its receptor generates a signal transduction pathway, producing a
classical response. This is characterized by an increase in cAMP and consequent
activation of protein kinase A (PKA) upon activation of the adenylyl cyclase (AC)
pathway and an increase in the intracellular calcium through inositol triphosphate
(IP3)/ phospholipase A2 (PLA A2) pathway. However HhCG is unlikely to be
involved in such a conventional signal transduction pathway because it does not bind
to the hCG/LH receptor. Experiments using endometrial epithelial cell lines from
human and baboon have shown that hCG does not activate the AC-cAMP-PKA
pathway but that it can rapidly induce phosphorylation of the extracellular signal-
regulated kinase (ERK 1/2) in a PKA independent manner leading to an increase in
COX-2 mRNA and PGE2 production 158. This suggests the existence of an alternate
spliced isoform of the hCG/LH receptor or presence of a different form of hCG that
can activate alternative signal transduction pathway. While functional hCG/LH-
receptors are expressed on both cytotrophoblasts and syncytiotrophoblasts,
syncytiotrophoblasts express the highest level of hCG/LH receptors 16<). The fact that
HhCG is dominant around the time of implantation and in the following 3 weeks
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suggests that HhCG may play a key role in embryo-maternal cross-talk, long before
hCG is measurable in maternal blood. If so, whether such action is mediated through
the action on receptor-tyrosine kinases or through increased expression of specific
adhesion receptors and extracellular matrix-degrading proteases such as collagenases
and plasminogen activators, has yet to be elucidated.
Based on available data, hCG can exert a range of local and systemic actions, in and
outside the embryo-endometrial microenvironment, and during different stages,
indicating its important juxtacrine, endocrine and autocrine functions during early
pregnancy. The exact contribution of HhCG in exerting similar is yet to be elucidated.
1.12 Physiology of pregnancy complications
Pregnancy complications may be associated with genetic, nutritional, immunologic, and
infectious factors that lead to pathological changes such as abnormal placentation,
oxidative stress, and endothelial dysfunction (Figure 17), implantation and early
placental development, and under the influence of relatively hypoxic conditions,
cytotrophoblasts proliferate and invade rather than differentiate, causing a rapid
increase in placental mass. While still under a state of physiological hypoxia,
cytotrophoblasts invade the uterine wall and attaches to maternal vessels. By 10-12
weeks of human pregnancy, blood flow to the intervillous space is established. As the
endovascular component of cytotrophoblast invasion progresses, the cells migrate
along the lumina of the spiral arterioles, replacing the maternal endothelial lining.
In normal pregnancy, oxygen tension influences both the differentiation process that
leads to the invasion of cytotrophoblast into the uterus and the degree of oxidative
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stress that in turn modulates placental hormone synthesis " . During normal The
process of placental remodeling of uterine arterioles, which involves the decidual and
inner third of the myometrial portions of these vessels, causes the diameter of the
arterioles to expand. This converts their muscular walls into low-resistance channels,
which can accommodate the demand for increasing blood flow required to support
fetal growth. Failure of endovascular invasion and inability of the cytotrophoblast to
invade to the appropriate depth has been linked with spontaneous miscarriage, pre¬
eclampsia, and fetal growth retardation (FGR).
It has been shown that premature onset of the maternal placental circulation reduces
trophoblast invasion and results in incomplete plugging of the maternal spiral arteries.
This may be due to a primary defect in the trophoblast lineage (e.g. a zygotic
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chromosomal abnormality) or to adverse secondary changes in the endometrium (eg,
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Figure 17 Schematic diagram showing proposed underlying mechanisms and common
pathophysiology of some common pregnancy complications. [Figure adapted from that in
Reference 181.]
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Hence, it is speculated that if syncytial degeneration is extensive, the pregnancy may
be lost as a spontaneous miscarriage. However, if the insult is less severe, sufficient
hormonal activity may be regained through syncytial regeneration from the
differentiation of surviving cytotrophoblast, allowing the pregnancy to continue as a
missed miscarriage. A similar mechanism may be involved in the appearance of later
complications, in which the pregnancy may continue following temporary restoration
of hormone synthesis and containment of initial oxidative-stress related damages. 184.
However, the presence of additional stressors or deficiencies in antioxidant defences
later in gestation may increase the likelihood of placental dysfunction and oxidative
tress-related damages, leading to complications such as pre-eclampsia, FGR, or fetal
death (Figure 17).
Obstetric complications associated with inadequate trophoblastic invasion during the
first trimester may be associated with low placental hormone levels. There are three
contributory mechanisms, existing alone or in combination with one another, that may
lead to elevations in the maternal circulatory placental hormone and protein levels.
One mechanism is the "reactive hyperplasia of cytotrophoblastic cells" as a
compensatory response to reduced blood supply, leading to increased production of
placental hormones in an environment of low oxygen tension. Indeed, the degree of
• i • 181183oxidative stress has been proven to modulate placental hormone synthesis " .
Oxidative stress generated by low concentrations of hydrogen peroxide (H2O2)
enhances cytotrophoblast hCG secretion, whereas higher concentrations of H2O2
181 18^
reduce hCG secretion in a dose-dependent manner ' . Pathological placental
changes and an abnormal trophoblastic secretory response are other mechanisms
through which placental hormone immunoreactivity in the maternal circulation may
be increased. Morphological analyses provide convincing evidence of perturbed
villous development in pregnancies with pre-eclampsia and FGR.
Aberrant features observed include increased cytotrophoblasts, increased syncytial
knots, increased apoptosis, focal cellular necrosis in syncytiotrophoblasts and
increased mitotic activity in syncytiotrophoblasts, accompanied by cellular
proliferation and hyperplasia of cytotrophoblasts along with their differentiation into
new syncytiotrophoblast tissue 186~190. The natural steady state between cytotrophoblast
and syncytiotrophoblast, whereby the syncytiotrophoblast is formed and replenished
by the underlying cytotrophoblast, can be disrupted in late pregnancy complications.
If the balance between the rates of cellular loss and replacement of
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syncytiotrophoblasts changes to favor replacement, this may lead to high serum levels
of hCG. Alternatively, hyperplasia of the cytotrophoblast without the formation of
syncytiotrophoblast may lead to an increase in the levels of one hCG glycoform, a
mechanism that may explain the increase of hCGa levels, which are produced in excess
by the cytotrophoblast following the failure of implantation 187'191.
As hCG synthesis requires both hCGa (produced by the cytotrophoblastic cells) and
hCGP (secreted by syncytiotrophoblastic cells), a growing population of
cytotrophoblasts and excessive amounts of syncytiotrophoblasts derived from the
cytotrophoblast, may lead to high total hCG levels in the maternal circulation. The
third mechanism postulated is that alterations in the surface layer of the
syncytiotrophoblast as a result of ischaemic damage associated with abnormal
trophoblastic invasion lead to a rise of placental hormones as a consequence of their
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"increased leakage" into the maternal circulation
The complex mechanisms involved in pregnancy complications and the unpredictable
placental response in the wake of such complications and the consequent production
of heterogeneous hormones, all together make screening for pregnancy complications
extremely challenging. In general, the data in the literature about the usefulness of
hCG in the prediction of pregnancy complications are discordant. There are many
inconsistencies between study results, which will be the focus of discussion in
following chapters.
1.13 Measurement of hCG and related molecular forms
Urine-based pregnancy tests date back to as early as 1350 BC when an ancient
Egyptian papyrus described a test in which a woman who might be pregnant could
urinate on wheat and barley seeds over the course of several days: "If the barley
grows, it means a male child. If the wheat grows, it means a female child. If both do
not grow, she will not bear at all." Testing of this theory in 1963 found that 70 percent
of the time, the urine of pregnant women did promote growth, while the urine of non¬
pregnant women and men did not. In the literature, this is perhaps the first test to
193detect a unique substance in the urine of pregnant women.
Clinically useful bioassays were introduced by Ascheim and Zondek (1927) 9
Friedman (1931) 194, Hogben (1939) 195 and others. These tests could confirm
pregnancy approximately two months after a missed period but took days to complete
and required the sacrifice of an animal. They were replaced in 1960 by a
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haemagglutination inhibition test m. Purified hCG was mixed with the urine sample
and antibodies directed against hCG. In a positive pregnancy test, the red cells
agglutinated. The test took only two hours to perform and was less expensive than
bioassay. However it was relatively insensitive, with a detection limit of 500 U/L of
hCG, and cross-reacted with LH. The development of radioimmunoassays allowed
detection of hCG at much lower concentrations 193.
Currently available assays for hCG can be broadly classified as methods (measuring
predominantly hCG) or total methods (measuring hCG and hCGP and sometimes
other molecular forms as well). Specific assays are also available for hCGa, hCGp,
1.13.1 General principles
Most two-site immunoassays, whether qualitative or quantitative, are developed using
two carefully selected MAbs directed against different antigenic determinants on the
molecule to be measured. The capture antibody is usually bound to a solid phase
while the detection antibody remains in solution and is labelled with a signal
molecule. In the presence of the antigen to be measured, a "sandwich" complex is
formed. This is separated from the rest of the reaction mixture and the amount of label




Figure 19 Schematic representation of the principle of two-site non-competitive
immunoassay. The amount of analyte (<■) in an unknown sample is determined by comparing
the amount of labelled MAb (h) bound to solid-phased antibody (cm) with a standard curve
prepared using known amounts of antigen.
A variety of solid phase media can be used in immunoassay, including microtitre
wells, beads, and gels. The label is usually enzymatic, chemiluminescent or
fluorometric. Two-site immunoassays have largely replaced the previous competitive
one-site radioimmunoassays because two-site immunoassays are faster, have wider
working ranges and do not use radioactive labels. The specificity of an immunoassay
is determined by the characteristics of the antibodies employed while its performance
is strongly influenced by assay design and calibration.
1.13.2 Quantitative immunoassays for hCG and hCGp
Currently few quantitative hCG assays measure hCG alone, and most are designed to
measure both hCG and hCGp. As they are calibrated against hCG, they may not
recognize hCG and hCGp equally 47'198. For pregnancy applications measurement of
hCG is considered sufficient but for diagnosis and management of trophoblastic
disease and germ cell tumours, assays that also recognize hCGp are mandatory.
Assays with broad specificities similar to those achievable using polyclonal antibody
radioimmunoassays are generally regarded as desirable for these applications.
1.13.3 Quantitative immunoassays for HhCG
HhCG would be an ideal molecule for early pregnancy detection, as it is produced by
the invasive trophoblasts at the time of implantation and during the weeks following
this 66'61'69'U9_ Several immunoassays have therefore been developed for the specific
detection of HhCG using MAb B152 in combination with an anti-hCGp tracer 49-69,
129,199
Most early studies of HhCG measurements in pregnancy, Down syndrome-affected
pregnancy and gestational trophoblastic disease were performed using manual
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enzyme-linked immunosorbent (ELISA) and immunoradiometric (IRMA) assays ' '
71 200 202
. Later studies employed an automated immunochemiluminometric assay
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(ICMA) [Nichols Institute Diagnostics Advantage® platform (San Clemente, CA,
USA)] which is no longer commercially available. While the early manual assays had
~ 60% cross-reactivity with HhCGp and detected all charge molecular forms of
HhCG, the automated assay detected only about 25% of HhCGp and failed to detect
some of the charge variants. These differences may account for some of the variations
HhCG results in the literature. Until an optimal assay is developed and an
International Standard is available, concentrations of HhCG obtained using different
methods will continue to vary.
1.13.4 Quantitative immunoassays for hCG(3cf
HCGPcf has been investigated as a potential cancer marker in urine but large
• • qs ?rn 90^
variations in its day-to-day levels severely limit its clinical utility ' " .A similarly
fluctuating pattern in day-to-day urinary excretion of hCG has been revealed during
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early pregnancy
Even though blood is generally preferred to urine for hCG assays, urinary assays are
clearly advantageous for point of care or home testing as well as for some
epidemiological studies e.g. when investigating the impact of environmental toxins on
fertility.
1.13.5 Quantitative immunoassays for hCGn
Nicked hCG can be detected in small amounts in the serum and urine of pregnant
women from 7 weeks of gestation but is virtually undetectable earlier. Specific nicked
hCG assays have been developed using C5, a choriocarcinoma-derived hCG isoform
with 100% nicking in its P-subunit 18'49. These assays provide valuable research tools
to study the role of hCGn in pregnancy, but a clinical application for specific
determination of hCGn has not yet been demonstrated.
1.13.6 Qualitative immunoassays for hCG
While the assay principle is the same as for quantitative immunoassays, qualitative
hCG assays are marketed for use by non-laboratory personnel, who are - often nurses
in hospital wards (point of care testing) or women who suspect they are pregnant
("over-the-counter" tests) - and do not require complex laboratory equipment.
Urine is placed on a single use assay cassette and is absorbed through changing
densities of nitrocellulose, concentrating the antigens into a narrow band. The urine
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mixes with a dye-labelled anti-hCG tracer antibody, stored in a sponge at the proximal
end of the device. The "hCG + antibody dye" complex formed migrates through the
nitrocellulose, eventually reacting with a stationary band of an immobilized secondary
capture antibody directed against a different part of the hCG molecule. The resulting
complex generates a coloured test line (Figure 20). Coloured lines indicate a positive
test result (usually at a concentration of >20 U/L). Remaining antibody dye migrates
further through the device to a second stationary control line. Excess antibody dye
























figure 20 Schematic diagram of a qualitative test for hCG. Urine is applied onto a
membrane and diffuses until it meets immobilized anti-hCG MAb coupled to a signal dye
molecule. In the presence of hCG a complex is formed. This complex diffuses further
down the membrane and subsequently reacts with a second anti-hCG MAb (Y), and the
complex is deposited colour on the test band. Excess reaction mixture travels further into
an area containing anti-species MAb (Y) with which colour will develop in the presence
or absence of hCG in urine. This serves as the control line.
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The desirable sensitivity for qualitative hCG tests is debatable 95. As hCG may occur
in serum and urine of non-pregnant women at concentrations of up to 10-15 U/L, a
detection limit of around 25 U/L is likely to be optimal. Some experts suggest that
highly sensitive home test kits are undesirable, as up to one third of all pregnancies
906
detectable at implantation ("biochemical pregnancies") may fail very early
Detection of these events is of uncertain benefit to women. Studies have shown that
zrc fi-j
these pregnancies primarily produce hCG, and little or no HhCG ' . If this is
correct, optimizing pregnancy tests so that they detect HhCG may help to distinguish
clinical pregnancies from biochemical ones.
Literature reports suggest that measurement of HhCG may also be helpful in in vitro
fertilization (IVF) programmes in which women are given hCG to promote
maturation of follicles. Exogenous hCG persists for over two weeks, before
endogenous production from a pregnancy (if successful) can be demonstrated.
Specific qualitative or quantitative measurement of HhCG before exogenous hCG has
cleared could help to reduce the anxiety of IVF patients who are eager to learn about
their success or failure in achieving pregnancy.
1.14 Standardization of hCG assays
1.14.1 International Standards for hCG, hCGaand hCG(3
In 1938 the World Health Organization (WHO) established the 1st International
Standard (IS) for hCG. The standard was prepared from pregnancy urine and was
relatively crude, as was the 2nd IS which replaced it in 1964. The 3rd IS (75/537) was
prepared from a more highly purified preparation, also from pregnancy urine, and
used from 1978 to 1999. It was replaced by the current 4th IS (75/589), which was
prepared from the same batch of material. HCG results are currently reported in
International Units (IU) of hCG IS 75/589. International Reference Preparations (IRP)
for hCGoc (IRP 75/569) and hCG(3 (IRP 75/551) were also established.
Ampoules of these standards [which can be obtained from the National Institute for
Biological Standards and Control (NIBSC) (South Mims, UK)] have nominal mass
contents assigned, allowing approximate calculations of relative reactivities (Table 3).
However, these calculations require a number of assumptions to be made and they can
only be considered as approximate. Approximately 9% of hCG IS 75/589 is nicked in
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the region of P-subunit residues 43-48 (Table 3). This is undesirable as variable
recognition of hCGn has been suggested to contribute to the differences in clinical









































Table 3 Properties of the current IS for hCG, hCGa and hCGp
1.14.2 International Reference Reagents (IRR) for hCG, hCGn, hCGa,
hCGp, hCGpn and hCGpcf
Highly purified new International Reference Reagents (IRR) for six important forms
of hCG were established by the WHO in 2001 (Table 4), with ampoule contents
provided in molar units 62. This is desirable since immunoassays reflect molar
concentrations of protein rather than bioactivity 207. It also simplifies comparison of
recognition of the molecular forms in different assays. In addition, HCG IRR99/688
contains no hCGn and negligible amount of free subunits (Tables 5A and B) 62. This
preparation is currently being considered as a candidate replacement for IS 75/589.
1.14.3 Standards for HhCG
As the first report of HhCG only appeared a year after preparation of the six hCG
IRRs began, a standard for HhCG was not included in that project. Manufacturers
produce their own standards for their assays, usually by partially purifying HhCG
from culture fluid from JEG3 choriocarcinoma cell lines. Unlike hCG, for which
starting material is available in abundance from pregnancy urine in abundance or by
recombinant technology, HhCG is present in urine at relatively low concentrations
and peaks in very early pregnancy (3-6 weeks), making efficient extraction difficult. It
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cannot currently be prepared by recombinant technology and other sources of high
HhCG levels in urine, (e.g. choriocarcinoma) are unsuitable, as the HhCG from these
sources is relatively unstable due to high levels of nicking. Establishing an IS for
HhCG remains a priority.
Property 4th hCG IS 75/589 1st hCG RR 99/688
Biological activity 9286 lU/mg 1.1-1.5 times more potent/mg
Polypeptide chain structures Approximately 10% nicked Minimal
Amino Acid analysis Agrees with structure Agrees with structure
Sialic acid content % by
weight
10.6 11.1
hCG related contaminants Significant: hCGn some hCGp
+ hCGp cf
No significant contaminants
Protease activity Present Negligible




hCG IS 75/537 Approximately 70 pg is equivalent to
650 U. Assuming molecular weight of
36.7 kDa.
I U = [70 x 10~6 x 1012] -5-
[36.7 x 650] picomoles =
2.9 picomoles
hCGp IRP 75/551 Approximately 70 pg is equivalent to 70
U. Assuming molecular weight of 22.2
kDa
I U = [70 x 10"6 x 109] -r
[22.2 x 70] picomoles = 45
picomoles
hCGa IRP 75/569 Approximately 70 pg is equivalent to 70
U. Assuming molecular weight of 14.5
kDa
I U = [70 x 10"6x 109]-r






Required assumption: hCG and hCG/3
are recognized in the assay being
considered on an equimolar basis
[1 U hCG/3] t[1U hCG] =
[45 -r 2.9] = 15.5
Table 5A Relationships between International Units (IU) and molar units for the current IS
for hCG, hCGa and hCG(3.
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Preparation Intact hCG % HhCG Nicked
hCG
hCGp hCGa hCGpcf
WHO 3ra IS/4th IS 100 15 9 0.8 1.4 0.8
99/688 (WHO 1st RR) 100 3 <0.1 0.9 1.0 0.2
hCG preparation P9 100 9 <0.1 <0.5 <0.1 2.3
CAP C15 100 0.9 <0.1 0.2 ND <0.1
Table 5B Composition and homogeneity of purified individual hCG preparations and hCG
standards 208
1.15 Limitations of hCG tests
1.15.1 Interference from anti-reagent antibodies
False-positive hCG results may be obtained if interfering substances are present in a
patient's serum. Such results are most often attributable to anti-reagent antibodies. In
two-site (sandwich) immunoassays, a bridge may form between the capture and signal
antibodies in the absence of antigen, as shown below, giving a false-positive (Figure
21a) or false-negative (Figure 21b) result.
a. Anti-reagent Ab ( present





b- Anti-reagent Ab (NM) present




c. Suppression of interference by
addition of non-immune IgG (□ )
CHG
□ □ □ □ □ !.□
□ □ cz>
Correct result
Figure 21 Schematic representation of anti-reagent antibody interference in a two-site non¬
competitive immunoassay. Such interference can result in falsely high (Figure 21a) or low
(Figure 21b) results and its risk is reduced by addition of non-immune immunoglobulin G
(IgG) (Figure 21c) [Analyte =«; labelled MAb = >* ; solid-phased antibody = cm ; anti-
reagent antibody = i—i ; non-immune IgG = □.]
Interference from anti-reagent antibodies is most frequently caused by heterophilic or
human anti-mouse antibodies (HAMA), which can bind the animal antibodies (e.g.
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mouse) used in many hCG assays. Heterophilic antibodies may be induced by
ingestion of cow's milk and other foods of animal origin or by direct contact with
animals, and are reportedly found at low concentrations in 30-50% of healthy
individuals 209. Human anti-mouse antibodies may occur following injection of mouse
antibodies for tumor imaging or therapy, or after administration of unconventional
therapies 209'210. Rheumatoid factors, which are IgM autoantibodies that are present in
serum from some patients with rheumatoid disease, may also react with animal
antibodies but are less likely to cause problems.
Strategies use to minimize these problems include the addition of blocking reagent to
the reaction mixture (Figure 21c), or pretreatment of samples prior to assay with
blocking agents such as polymerized IgG and polyclonal IgG. Blocking agents are not
always effective since some sera contain high concentrations of heterophilic
antibodies that cannot be neutralized 211. Some antibody pairs appear to be more prone
to producing false-positive results and are more difficult to remove 209'211.
1.15.2 Erroneous results due to high dose hooking
The 'hook effect' occurs when analyte is present in such high concentration that most
binding sites on both capture and signal antibodies are occupied. This prevents the
formation of the complex and leads to an erroneously low result (Figure 22). If
undetected, the incorrectly low result reported can result in mismanagement of
patients. This is a major potential limitation of one-step qualitative and quantitative
serum and urine immunometric assays in which both capture and labelled antibody
are added simultaneously. It is less likely to occur in two-step assays, where the
analyte excess is washed away before tracer antibody is added 21°. The concentration
at which high dose hooking may occur depends on the assay.
Assaying specimens at 10- and 100-fold dilutions, introducing a wash step prior to the
addition of second antibody reduces the risk of errors due to the high dose hook or








Figure 22 Schematic representation of the hook effect, which may cause falsely low results in
the presence of very high concentrations of analyte. [Analyte =•; labelled MAb = y* ; solid-
phased antibody = cm ] See text for details.
1.15.3 Interference from complement and other factors
Various complement factors can react with antibodies giving different results
depending on the isotype of the antibody used. In a sandwich assay, the complement
which reacts with mouse IgG2 can cause low results, i.e. the effect is opposite to that
of heterophilic antibodies, because complement reduces the binding capacity of the
antibody. In contrast, complement will cause a false-positive result in an inhibition
assay. Because of this, most assay manufacturers avoid using IgG2 antibodies in their
systems. Other serum factors can also block the antigen-antibody reaction non-
specifically. Lipids, haemoglobin, paraproteins and other serum constituents tend to
be more of a problem in homogeneous assays than in two-site immunometric hCG
assays.
1.15.4 Possible interference following administration of hCG
Anti-hCG antibodies produced by therapeutic use of urinary hCG will cause false-
positive results in inhibition assays and false low results in sandwich assays. In earlier
hCG assays, low false positive levels were noticed when serum LH was elevated (e.g.
in menopausal patients) due to molecular similarities between LH and hCG. False-
positives caused by such crossovers were generally in the 5-10 U/L range and would
quickly be suppressed to less than 5 U/L with oral contraceptive treatment l34.
Intramuscular hCG injections at a dose of 10000 IU given to patients for ovulation
induction in hormone-stimulated cycles can cause serum levels to peak to 200-300
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U/L (500-1000 pmol/L) one day after injection, but levels decrease to <5 U/L within
8-12 days 95. Athletes who use hCG to stimulate gonadal steroid production for
doping purposes also may also present with elevated serum values 134.
1.16hCG antibodies and epitope mapping
Improved comparability of results requires not only correct calibration of methods in
terms of well-characterized IS but also us of antibodies with specificities most
appropriate for particular clinical applications. HCGp, HhCG, hCGn and hCGPn are
important molecular forms of hCG found in Down syndrome pregnancy, gestational
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trophoblastic diseases, and some other cancers ' and it is important that
immunoassays recognize these molecular forms as required.
Epitope mapping workshops have been organized by the International Society of
Oncology and Biomarkers (ISOBM) with the aim of defining appropriate antibody
combinations for different clinical applications. In a collaborative multicentre study,
the ISOBM TD-7 hCG workshop characterized the molecular epitope structure and
198
specificities of a panel of antibodies from various manufacturers . Using
competitive and sandwich RIA, ELISA and Western blotting, 27 MAbs were
characterized using a variety of preparations including the 1st WHO IRR and LH and
1 QR
LHp subunits from various species (Figure 23) . Three-dimensional molecular
epitope assignment was achieved by comparing immunoreactivity of the 27 ISOBM
antibodies with those of an independent panel of 18 reference antibodies.
Five epitopes are located on hCGa (al-a5), and seven on the beta-subunit of hCG.
The (38 and (39 epitopes positioned on the CTP are completely specific for hCG and
hCGP, so many commercial assays utilize antibodies that recognize these two
epitopes. Four epitopes (Ci - C4) are specific for heterodimeric hCG. Two of these (Cj
and C2) are lost in nicked hCG. Epitopes a6 and al are specific for hCGa while P6
and P7 epitopes are specific for hCGp. Epitopes recognized by hCGP MAbs are
located on the first and third loops protruding from the cystine knot of hCGP (P2-P6,
hCGp 20-25 and 68-77), centered around the knot itself (pi), or on hCGpCTP (p8,
hCGP 141-144; p9,hCGp 113-116) (Figure 23) 198.
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hCGpcTP
3D Epitope map of hCG
Figure 23 Schematic diagram of ISOBM TD-7 workshop results, showing assignment of
epitopes of (A) hCGB/hCGGcf/ hCGBCTP and (B) hCG based on their three-dimensional
structure. hCGBCTP is represented as dotted lines. [Figure reproduced from Reference 198
and used with permission.]
Use of assays recognizing a broad spectrum of hCG/hCG(3 molecular forms is
generally recommended for most diagnostic purposes. Low cross-reactivity with
related glycoprotein hormones such as LH is also mandatory. These criteria can be
met by combinations of MAbs directed against epitope located around the cystine
knot (pi) and against those encompassing the top of loops 1 and 3 on hCGp (p2, P4).
Most epitopes recognize antigenic determinants on the protein structure of hCG. Only
two well-characterized MAbs (B152 and CTP 104) detect carbohydrate molecular
forms on hCG. The B152 antibody recognizes the biantennary core 2 O-glycan on
Serl32 and adjacent peptide structures, whereas CTP104 reacts with sialylated glycan
on Serl38 49' 64. Availability of MAb B152, which was prepared using a purified
urinary preparation of hCG (C5) that was 100% hyperglycosylated, enables direct
measurement of HhCG.
1.17Reference values in non-pregnant women
Appropriate reference values are critical for application of tests in patient
management. Concentrations of hCG and its subunits in urine and serum samples of
non-pregnant women and men without evidence of cancer have therefore been
120determined using ultra-sensitive time resolved immunofluorometric assays (Table
6). The levels are about 3-10% of LH concentrations when expressed in U/L and
exhibit a similar fluctuating pattern to LH. Furthermore, an increase in serum LH and
FSH during the menopause is accompanied by a small increase in hCG levels. This
suggests that most hCG in non-pregnant serum is derived from the pituitary. The
genes for both hCG subunits are expressed in low levels in many tissues including
thyroid, bladder, adrenals, breast and skeletal muscle, but it is not known whether
hCG from these sources contribute to the serum hCG level 95.
The upper reference limit for hCG is 8.6 pmol/L (3 U/L) for women <50 years old
and 15.5 pmol/L (5.3 U/L) in those >50 years old. 9? The upper reference limit for
hCG(3 in women <50 years is 1.6 pmol and in women >50 years old is 2.0 pmol/L.
hCGpcf levels in serum are below the detection limit of current assays. In urine, hCG
and hCGP concentrations are on average 50% of those in plasma but there is
considerable hCG immunoreactivity due to hCGpcf, as urine levels are ~4000-fold
higher than serum levels. Upper reference limits of hCGpcf for pre- and post¬
menopausal women are 8.1 and 9.5 pmol/L, respectively. The a-subunit is mainly
derived from pituitary, and its serum concentration does not reflect hCG production
95
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<50 years >50 years
Pmol/L U/L Pmol/L U/L
Serum
HCG 8.6 3.0 15.5 5.4
HCGP 1.6 2.0
Total HCG 9.0 17.0
Urine
HCG 8.8 3.1 11.5 4.0
HCGP 1.7 4.3
HCGpcf 8.1 9.5
Total HCG 13.6 20.4
Table 6 Upper reference limits for serum and urine concentrations of hCG, hCGB and
hCGBcf in non-pregnant women 95
1.18Study aims
The primary aims of the work presented in this thesis are
• To compare the levels of hCG and HhCG in uneventful pregnancies with those
observed in pregnancies with complications.
• To investigate the diagnostic accuracy of HhCG in the prediction of adverse
pregnancy outcome, comparison this with that of other hCG molecular forms
including hCG, hCGP and hCGPcf.
• To study the sugar chain heterogeneity of purified hCG from different sources
using lectins and MAbs and to gain an insight into the spectrum of hCG
glycosylation patterns during different stages of pregnancy and in pregnancy
complications.
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Patient cohorts are described in detail in the relevant chapters. A University of
Edinburgh statistician was consulted about study design and statistical requirements at
an early stage. She advised that as these are observational cohort studies, intended to
establish levels of the relevant analytes across the clinical spectrum, minimum
numbers of patients per cohort cannot be defined.
2.1.2 Ethical approval
Patient studies were approved by the local Ethics Committee. In all cases informed
consent was obtained in accord with the local requirements. [See Appendix for copies
of Patient Information, Patient Consent and Ethics forms.]
2.1.3 Specimen collection
Blood samples were collected into plain collection tubes and sent to the laboratory
within two hours of collection. Serum was separated by centrifugation (2000 g) and
aliquoted into appropriately labelled sterile microtubes (2 x 1 mL). They were stored
at -20°C temporarily prior to being transferred for long-term storage to at -80°C.
Urine samples were collected in wide mouthed sterile containers and sent together
with serum samples from the same patient to the laboratory. Following addition of
preservative (0.05% w/v sodium azide), urine specimens was aliquoted into
microtubes (6 x 1 mL) and stored as for the serum samples.
2.1.4 Specimen transport
Stored samples were transferred on dry ice from the UAE to the Department of
Clinical Biochemistry, Royal Infirmary of Edinburgh. There they were kept at -20°C
and thawed in batches at room temperature immediately prior to analysis. Similar
transport arrangements were used to send serum and urine samples to Quest
Diagnostics, Nichols Institute, USA. In both cases samples were kept in dry ice during
transit by the courier and remained frozen until immediately before they were
assayed.
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2.1.5 Expression of results for hCG molecular forms in molar units
In order to facilitate comparability of results for different hCG molecular forms,
results are generally expressed in pmol/L. Concentrations in terms of IU of the 4th IS
75/589 has been converted to a molar equivalents based on the biological activity of
the standard (Table l).197. Thus hCG assay results, obtained in U/L, were converted to
pmol/L by multiplying them with 2.9. HhCG mass values (i.e. ng/ml or 1 pg/L) were
converted to molar equivalent of hCG using the following calculation: 1 pg/L of
HhCG = 24.39 pmol/L, based on the MW of 41000 Daltons 213.
2.1.6 Corrections for specificity gravity (urine samples)
As spot urine samples exhibit a wide range of densities due to hydration status and the
time since last micturition 2l4, the hormone levels in urine samples were normalized
using the method of Alfthan et al.215 (reviewed in 2I4), correcting hCG concentrations
using the equation hCG corrected = hCG raw x (SpG sample -1) /(SpG target -1),
where SpG sample is the specific gravity of the sample, and SpG target is a target
specific gravity. We used 1.015 as the target specific gravity after calculating specific
gravidity means from our study population, reflecting generally the low density of
UAE-based population urine samples compared to those ofWestern populations 2I4.
2.2 Time-resolved immunofluorescence immunoassays
Serum and urinary HhCG, hCGp, and hCGPcf of hCG (hCGPcf) were all quantified
by ultra-sensitive time-resolved immunofluorometric assay using in-house assay
reagents (kindly provided by Professor U-H Stenman and Dr H Alfthan, Helsinki
University Central Hospital) on the DELFIA automated assay platform (Perkin-
Elmer, Turku, Finland). The same system was used for measurement of hCG, using
commercially available reagents. The experimental protocols are described below and
summarized in Table 7.
2.2.1 Immunofluorometric immunoassay for HhCG
Capture antibody. Solid-phase antibody was prepared by physical adsorption of
purified MAb B152 (4 pg/mL) in buffer (0.1 mol/L sodium carbonate; pH 9.3) onto
the walls of polystyrene microtitre wells.
Detection antibody. Europium-labelled antibody (F95-1B2) was prepared and kindly
gifted by Dr Alfthan. This antibody recognizes the hCGP region in hCG.
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Immunoassay procedure. Assay buffer (150 pL of 0.1M, pH 7.8 Tris-HCl buffered
saline containing 5 g/L bovine serum albumin, 0.5 g/L bovine globulin, 0.15 mol/L
sodium azide and 0.1 g/L Tween-40) was pipetted into each of 96 microtitre wells
coated with MAb B152 as described above. Duplicate aliquots (50 pL) of standard (0,
9, 90, 900 and 9000 pmol/L of in-house standard prepared from a JEG3
choriocarcinoma cell line) or sample (serum or urine) was added to each well and the
plates incubated for 2.5h at room temperature with continuous shaking ("Varishaker",
Dynatech, UK).
Wells were washed four times with wash solution (assay buffer containing 0.5 mL/L
Tween 20) using an automated twelve-channel washing device (Nunc-Immunowash
12, Roskilde, Denmark). Europium-labelled MAb 95/1B2 (50 ng in 200 pL of assay
buffer) was added and the wells incubated for a further 30 minutes at room
temperature. They were then washed six times with wash solution using an automated
washing device. Enhancement solution (200 pL of 6.8 mmol/L potassium hydrogen
phthalate, 0.1 mol/L acetic acid, 50 pmol/L tri-n-octylphosphine oxide, 15 pmol/L 2-
naphtholyl trifluoroacetone and 1 g/L Triton X-100) was then added to the wells
carefully, taking care not to touch the edge of the well so as to avoid contamination.
The wells were then shaken for a few minutes and fluorescence was then measuring
using an Arcus 1230 fluorimeter (Wallac Biochemical Laboratories).
Assay performance: The detection limit was 3 pmol/L of HhCG and the intra-assay
CV 6%. Inter-assay CVs. were 9% at 47 pmol/L and 4% at 1100 pmol/L. Cross-
reaction with hCG is 100%, with hCG|3 11% and with hCGPcf, hCGa, LH and FSH
<0.1%. As there is no available IS for HhCG, a standard produced from conditioned
medium from the JEG3 choriocarcinoma cell line was used as calibrant. These were
in concentrations of 0, 9, 90, 900, 9000 pmol/L and was calibrated against DELFIA
hCG kit standards (i.e. WHO 4th IRP 75/589).
2.2.2 Immunofluorometric immunoassay for hCG|3
Capture antibody. Solid-phase antibody was prepared as described in Section 2.2.1
using MAb F19-9C11 (4 pg/mL), which had been purified as previously described
from mouse ascites 12°.
Detection antibody. Europium-labelled antibody (1B2), which is specific for the
hCGP region of hCG, was prepared and gifted by Dr H Alfthan.
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Immunoassay procedure. The procedure was exactly as described in Section 2.2.1.
Assays standards contained 0, 0.73, 7.3, 73, 730 and 7300 pmol/L of added purified
hCG(3 and had been calibrated against hCG IS 75/589.
Assay performance: The detection limit of the assay was 0.2 pmol/L of hCG(3. The
intra-assay CV was 12%. Inter-assay CVs. were 7% at 1.9 pmol/L and 3% at 27
pmol/L. Cross-reaction with HhCG is 6%, and with intact hCG, hCGpcf, hCGa, LH
and FSH <0.1%.
2.2.3 Immunofluorometric immunoassay for hCGpcf
Capture antibody. Solid-phase antibody was prepared as described in Section 2.2.1
using MAb F52-3C11) (4 pg/mL), which had been purified as previously described
from mouse ascites l20.
Detection antibody. Europium-labelled antibody (F95-1B2), which is specific for the
hCGP region of hCG, was prepared and gifted by Dr H Alfthan.
Immunoassay procedure. The procedure was exactly as described in Section 2.2.1
but only urine samples were assayed. The assay standards contained 0, 2, 20, 100, 200
500 and 2000 pmol/L of added purified hCGPcf and had been calibrated against hCG
IS 75/589.
Assay performance: The detection limit of the assay was 0.2 pmol/L of hCGpcf. The
intra-assay CV was 7%. Inter-assay CVs. were 10% at 7 pmol/L and 4% at 20
pmol/L. Cross-reaction with hCG, HhCG, hCGP, hCGa, LH and FSH are all <0.3%.
2.2.4 Immunofluorometric immunoassay for hCG
Capture antibody. Wells coated with solid-phase antibody (MAb 5008) were
purchased from Perkin-Elmer (Turku, Finland).
Detection antibody. Europium-labelled antibody (MAb 5501) was purchased from
Perkin-Elmer (Turku, Finland). This antibody recognizes the hCGa region in hCG.
Immunoassay procedure. Assay buffer (200 pL of 0.1M, pH 7.8 Tris-HCl buffered
saline containing 5 g/L bovine serum albumin, 0.5 g/L bovine globulin, 0.15 mol/L
sodium azide and 0.1 g/L Tween-40) was pipetted into each of 96 microtitre wells.
Duplicate aliquots (25 pL) of standard (0, 2, 10, 100, 1000, 5000 and 10,000 U/L of
IS 75/589) or sample (serum or urine) was added to each well and the plates incubated
for 2.5h at room temperature with continuous shaking ("Varishaker", Dynatech, UK).
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Wells were washed four times with wash solution (assay buffer containing 0.5 mL/L
Tween 20) using an automated twelve-channel washing device (Nunc-Immunowash
12, Roskilde, Denmark). Europium-labelled MAb 95/1B2 (50 ng in 200 pL of assay
buffer) was added and the wells incubated for a further 30 minutes at room
temperature. They were then washed six times with wash solution using an automated
washing device. Enhancement solution (200 pL of 6.8 mmol/L potassium hydrogen
phthalate, 0.1 mol/L acetic acid, 50 pmol/L tri-n-octylphosphine oxide, 15 pmol/L 2-
naphtholyl trifluoroacetone and 1 g/L Triton X-100) was then added to the wells
carefully, taking care not to touch the edge of the well so as to avoid contamination.
The wells were then shaken for a few minutes and fluorescence was then measuring
using an Arcus 1230 fluorimeter (Wallac Biochemical Laboratories).
Assay performance: The detection limit of the assay was 0.2 U/L of hCG, and the
intra-assay CV <10%. Inter-assay CVs. were 3%, 2% and 2% at 6.1 U/L, 19 U/L and
284 U/L respectively pmol/L. Cross-reactions with HhCG is 6%, <0.1% for hCGp,
hCGpcf and hCGa, and <0.3% for LH and FSH.
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7 standards 5 standards 5 standards
Calibration hCG IS 75/589 hCG IS 75/589 hCG IS 75/589 hCG IS 75/589
Volume of
standards and




150 pL 200 pL 150 pL 150 pL
Incubation time 21/2 hours 1 hour 2 hours 2 hours
Number of x 2 x 2 x 2 x 2
washes
Volume of 200 pL 200 pL 200 pL 200 pL
tracer
Incubation time 30 min. 30 min. 30 min. 30 min.




200 pL 200 pL 200 pL 200 pL
solution
Time on slow 5 min. 5 min. 5 min. 5 min.
shaker
Check concentration by measuring fluorescence
Table 7 Summary of sequential steps in the immunofluorometric assays used
2.3 Chemiluminescent immunoassays
HhCG and hCG were measured in serum and urine using commercially available
methods with chemiluminescent labels.
2.3.1 Chemiluminescent immunoassay for HhCG
HhCG was measured in serum and urine using the Quest Diagnostics immunoassay
(San Juan Capistrano, California). The assay uses MAb B152 as capture MAb and an
anti-hCG(3 mouse MAb labelled with chemiluminescent acridinium ester as a
7 f\
detection antibody. The protocol is as previously described .
Assay performance: The detection limit of the assay was 0.2 pg/L of HhCG. The
intra-assay CV was 7%. Inter-assay CVs. were 10% at 7 pmol/L and 4% at 20
pmol/L. Cross-reactions with HhCG are HhCG(3 are 100% and 60% respectively and
<5% with hCG, hCGpn and their nicked forms. The assay is calibrated in mass units
against an HhCG standard purified from a JEG3 choriocarcinoma cell culture.
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2.3.2 Chemiluminescent immunoassay for hCG
HCG was measured in serum and urine using the Siemens Immulite hCG assay
(Siemens Diagnostics, Los Angeles). The assay is designed for the quantitative
measurement of total hCG (i.e. hCG, hCG(3 and their nicked forms. Details of the
method are readily available.
The detection limit of the assay is 1 U/L of hCG. The intra-assay CV ranged from 3.6
to 5.2% for concentrations between 3330 and 30 U/L respectively, while inter-assay
CVs. ranged from 7.8 to 9.9% for concentrations between 37 and 3569 U/L
respectively.
2.4 Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a
commonly used technique for the separation of proteins according to molecular
weight. It can be applied to molecules with molecular weight ranging from 10-250
kDa. SDS-PAGE was performed as described below.
2.4.1 Preparation of samples for SDS-PAGE
Protein samples were prepared in both non-reduced and reduced forms. For non-
reduced samples, protein sample (approximately 0.5 mg/L; 70 pL) and sample buffer
[Novex NuPAGE™ LDS Sample Buffer (Invitrogen Life Sciences, Carlsbad,
California), diluted four times with distilled water; 50 pL] were mixed with distilled
water (100 pL). Reduced protein samples (approximately 0.5 mg/L; 70 pL) were
prepared by adding (3-mercaptoethanol (5% v/v in sample buffer; 7 pL). Non-reduced
and reduced sample mixtures were then boiled at 70°C for 10 minutes.
2.4.2 Electrophoresis procedure
Reduced and non-reduced samples (purified hCG from Pregnyl or JEG3 cell lines)
were loaded into separate wells in pre-cast polyacrylamide gradient gels (NuPAGE™
Novex Bis-Tris mini-gels, 4-12% 2D well and 1% 12D well). Molecular weight
markers (Bio-Rad; 5 pL) were loaded in the same way. Electrophoresis was then
performed for 30-40 minutes at a constant voltage of 200 V in a vertical slab gel
apparatus (Xcell™ Surelock electrophoresis cell; Invitrogen Life Sciences, USA). The
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inner and outer chambers of the cells were filled with running buffer [NuPAGE™
MES SDS Running Buffer (Invitrogen Life Sciences, Carlsbad, California) diluted
twenty times with distilled water; 50 mL] until the molecular weight markers reached
the bottom of the gel. Gel casts were then opened carefully to release the gels and
immediately soaked in running buffer.
2.5 Western blotting
Western blotting involves electrotransfer of proteins to a solid supporting membrane,
usually nitrocellulose, which can then be probed with either antibodies or lectins to
determine different immunoreactivities or glycosylation patterns. The procedures used
are described below.
2.5.1 Protocol for Western blotting
Four sheets of absorbent filter paper and one sheet of nitrocellulose membrane (Pore
size 0.45; Hybond ECL™, Amersham Biosciences, Germany) were cut to the size of
the gel. The nitrocellulose membranes and support pads were saturated with transfer
buffer [NuPAGE Transfer Buffer (Invitrogen Life Sciences, Carlsbad, California)
diluted twenty times in water containing 20% v/v ethanol]. A transfer sandwich was
assembled in blot module by layering two support pads, one sheet of filter paper, one
nitrocellulose membrane, one polyacrylamide gel, one sheet of filter paper and two
support pads in that order. For transferring two gels in one blot module, the second
sandwich was separated from the first by adding one or two more support pads. All
the components were kept wet, making sure that good contact was established
between the gel and the membrane with no trapped air bubbles. The complete transfer
sandwich was placed in the transfer tank with the membrane closest to the anode.
Electroblotting was performed at 40v for one hour [XCell II™ Blot Module
(Invitrogen Life Sciences, Carlsbad, California)].
2.5.2 Antibody probing of Western blots
After electrophoresis transfer was completed, the nitrocellulose membranes were cut
into appropriately sized strips and labelled with a ballpoint pen. The strips were then
gently rocked in troughs containing blocking buffer [5% w/v non-fat dried milk
powder (Marvel) in phosphate buffered saline containing 0.1% Tween-20] for lh at
room temperature in order to block unoccupied binding sites and prevent non-specific
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adsorption of antibody. The strips were then washed with PBS containing Tween-20
(1% v/v) three times at 5 minute intervals. The strips were then incubated for lh with
the first antibody (1:5000 in blocking buffer) which binds to proteins immobilized on
the membranes. The MAbs used were B152 (gift from Dr S Birken, Columbia
University, NY; specific for HhCG) and hCG.8Fll SMA (Mologic, Bedford, UK;
specific for hCG(3).
The membranes washed as described above and were then incubated for a further lh
with goat (for MAb B152) or donkey (for MAb hCG.8FllSMA) anti¬
immunoglobulin antibody coupled to alkaline phosphatase (1:5000 in blocking
buffer). They were then washed again in the same way.
Following addition of enzyme substrate [200 pL of nitroblue tetrazolium chloride
(NBT, Sigma, UK; 50 mg/mL in dimethylformamide) and 100 pL of 5-bromo-4-
chloro-3-indolylphosphate-p-toluidine salt (BCIP, Sigma, UK; 50 mg/mL in
dimethylformamide) in 30 mLs of Tris-HCl buffer (0.05M, pH 9.5)], deep purple
bands appear within 10-20 minutes. The reaction was stopped by immersing the strips
in distilled water, after which the membrane was allowed to dry prior to scanning
(Hewlett-Packard Printer Digital Scanner 2200).
2.5.3 Lectin probing of Western blots
Following electrophoresis, lectin probing was performed essentially as described for
MAbs in Section 2.5.2, but using different wash (0.5% w/v BSA in PBS containing
0.2% v/v Tween-20) and blocking (2% w/v bovine serum albumin in PBS) buffers.
Lectins (0.1% w/v; 1:1000 in blocking buffer) were used instead of MAbs. The
second incubation used streptavidin alkaline phosphatase conjugate (Sigma, UK;
1:5000 in blocking buffer) following by reaction NBT/BCIP as described in Section
2.5.2. All lectins were obtained from Sigma, UK and are listed in Table 8.
2.5.4 Antibody and lectin probing of patient samples
Frozen urine samples were thawed at room temperature. Creatinine was measured in
the Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, using a
commercially available enzymatic method (Alpha Laboratories Ltd, Eastleigh UK)
adapted from that of 216 for use on the Cobas Fara centrifugal analyzer (Roche
Diagnostics Ltd, Welwyn Garden City, UK) to ensure concentrations were within
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normal reference limits. Within- and between-run CVs. were <3% and <5%
respectively.
Using hCG results obtained with the Perkin-Elmer DELFIA method [Section 2.2.4],
concentrations of hCG in the urine samples were diluted to concentrations between
9,690 and 19,317 U/L.
SDS-PAGE and Western blotting were performed as described in Sections 2.4 and
2.5.1 and probing with antibodies and lectins were performed as above (Sections 2.5.2
and 2.5.3).
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No. Code Lectin Abbreviation
1 2 Lens culinaris agglutinin LCA
2 3 Wheat germ agglutinin WGA
3 4 Galanthus nivalis agglutinin GNA
4 6 Jacalin J
5 7 Soya bean agglutinin SBA
6 9 Sambucus nigra agglutinin SNA
7 10 Lotus tetragonolobulus lectin LT
8 11 Amaranthus caudatus lectin ACL
9 12 Solanum tuberosum lectin ST
10 14 Datura stramonium agglutinin DSA
11 15 Peanut agglutinin PA
12 18 Concanavalin A lectin Con A
13 19 Dolichos biflorus agglutinin DFA
14 20 Ulex europaeus agglutinin I UEA
15 21 Phaseolus vulgaris leucoagglutinin PHA-L
16 22 Pisum sativum agglutinin PSA
17 23 Saphora japonica agglutinin SJA
18 24 Griffonia simplicifolia I lectin GS-I
19 25 Phaseolus vulgaris erythroagglutinin PHA-E
21 27 Succinylated wheat germ agglutinin WGA-S
22 29 Vicia villosa lectin VV
23 31 Lycopersicon esculentum lectin LE
24 32 Erythrina cristagalli lectin EC
25 33 Griffonia simplicifolia II lectin GS-II
26 34 Lathyrus odoratus lectin LO
27 35 Alkaline phosphatase: streptavidin Control
Tab e 8 List of lectins used for protein probing
2.6 Statistical analyses
2.6.1 Data analysis and statistical packages
Statistical analysis was performed using MINITAB (Versions 13 and 14) and S-plus
statistical packages. Normally distributed data are described as means ± standard
deviation (SD) or means and ranges. Non-normally distributed data are described as
medians with the interquartile ranges (i.e. 25th - 75th percentiles) (Ql, Q3). Serum and
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urinary concentrations of all hormonal analytes showed a wide range of distribution;
hence concentrations were log-transformed for easy comparison of data, and plotted
against week of gestation. HCG ratio measurements are displayed on a linear scale.
Comparisons between the groups were made using either two-tailed t-test or non-
parametric Mann-Whitney or Kruskal-Wallis tests as appropriate. P values below 0.05
were considered to be significant. Boxes in the box plots define the 25th to 75th
percentiles. The upper and lower bars indicate the 90th and 10th percentiles,
respectively. A line inside the box marks the 50th percentile value. Lines extending
from upper and lower bar (i.e. whiskers), represent the values, 1.5 times above and
below the range of hormonal data. All asterisks indicate values either lower or higher
than the whisker values.
2.6.2 Receiver-operating characteristics (ROC) curves
Receiver-operating characteristics (ROC) curves and the area under the curves (AUC)
were calculated to assess the diagnostic accuracy of each test for these analytes. ROC
curves represent the full spectrum of possible sensitivity-specificity pairs to evaluate a
test for possible clinical application, with the y-axis representing sensitivity (true
positive) and the x-axis representing 1-specificity (true negative).
The model created by Due et al.217 was used to rank the accuracy of a diagnostic test.
They rated AUC values of 0.91-1.00 and 0.0-0.09 as excellent accuracy (++), 0.81-
0.90 and 0.10-0.19 as good accuracy (+), 0.61-0.80 and 0.20-0.39 as moderate
217
accuracy (±), and 0.40-0.60 as poor accuracy (-)
The performance of various hormonal cut-off values was tested to maximize
218
sensitivity and specificity and expressed using the following definitions :
Sensitivity: The proportion of patients identified as a viable pregnancy (singletons
and twins) when theHhCG cut-off value is above the cut-off point (true negatives).
Specificity: The proportion of women identified as a nonviable pregnancy when an
HhCG value is below the cut-off point also referred to as true positives.
Positive predictive value: The probability that a patient with an HhCG value less than
the cut-off will have an early pregnancy loss.
False-positive rate: The percentage of women with an HhCG value less than the cut¬
off, who have a viable pregnancy.
False-negative rate: Percentage of miscarriage cases that will be missed by the
chosen cut-off point (i.e. nonviable pregnancies wrongly identified as a viable one).
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CHAPTER 3. HYPERGLYCOSYLATED HCG AND
OTHER HCG MOLECULAR FORMS IN




3.1 Background to the Clinical Study in the UAE
Since the development of MAbs against various molecular forms of hCG, the
association between abnormal levels of hCG and adverse pregnancy outcome can be
studied using a range of sensitive biochemical immunoassays. In addition to triploidy
and multiple gestations, the elevation of hCG level has been associated with a series
of obstetric complications that include pre-eclampsia, small for gestational age
(SGA), preterm delivery, and neonatal death. Reports of diminished hCG levels have
113 125 219 225also been linked with unfavourable pregnancy outcome ' Despite such
associations, the clinical use of hCG analytes as a biochemical screening marker of
adverse pregnancy events is limited. Current obstetric practice uses second-trimester
maternal serum levels of hCG along with AFP, and unconjugated oestriol as a
screening tool for fetal aneuploidy " . hCG quantitation is also used in diagnosing
spontaneous abortion, ectopic and multiple pregnancy, detecting and following up
hCG-producing tumors, including trophoblastic disease and certain testicular and
207,212,226,233-243
ovarian tumors
HhCG, with additional sugar residues on its oligosaccharide side chains, is produced
predominantly by phenotypically invasive cytotrophoblast cells. Higher levels of
HhCG are associated with periods of invasive events during the phase of
implantation, and with gestational trophoblastic disease 69'70' 130' 244. Trophoblastic
abnormalities and defective implantation have been previously implicated in the
origin of several pregnancy disorders, including spontaneous abortion, pre-term
delivery, pregnancy-induced hypertension (PIH) and intra-uterine growth retardation.
It therefore seems plausible that abnormal levels of HhCG in maternal serum or urine
may provide an early indication of placental dysfunction and early identification of
failing pregnancy or any other pregnancy complication. This is important in order to
provide appropriate clinical care and counselling before the onset of disease or
pregnancy failure. So far, no parameters have been described that use measurements
of HhCG to differentiate between favourable outcome and pregnancy failures. The
following study aims at evaluating 1st and 2nd trimester HhCG levels in normal and
pathological pregnancies in order to establish its clinical application for the detection
of adverse pregnancy outcome. Also, the levels of HhCG were compared with the
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levels of hCG, hCGp, and hCG Pcf, in order to determine whether it is a better
indicator of pregnancy outcome than other hCG-related molecular forms.
3.2 Study protocol
Pilot prospective cohort study
Pregnant women attending the Antenatal Clinic, In-patient Obstetrics and
Gynaecology wards, and Accident and Emergency Department at Mafraq Hospital,
which is a 500 bed multi-referral centre in Abu Dhabi, United Arab Emirates.
3.2.1 Ethics
Full ethical approval had been obtained from the Ethics Committee at the Mafraq
Hospital before commencing the study. A signed consent was obtained before
enrolling the patient (refer to appendix).
3.2.2 Study group
292 pregnant women (age range 15-49 years) belonging to a multi-ethnic community
including Arabs, Asians and expatriate Westerners were included in this study. Only
spontaneous singleton pregnancies were considered for this study. The gestational age
was calculated from the first day of last menstrual period, unless ultrasonography
before 16 weeks demonstrated a discrepancy of at least 10 days, in which case U/S
dating was used for the calculations. The patients were followed until the outcome of
their pregnancies was known.
3.2.3 Data collection
Between June 2003 and June 2004, 164 first trimester (6-12 weeks) and 136 second
trimester (13-24 weeks) urine and serum samples were collected for this study. The
outcome data were later retrieved from patient records.
Measurement of hCG and related molecular forms was performed in serum and urine
as described in Chapter 2. Unless otherwise stated, all hormonal values are expressed
in pmol/L (medians with the interquartile ranges). Statistical significance was defined
as p<0.05.
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3.3 Denominators of outcome variables 245
3.3.1 Uneventful pregnancy
Spontaneous singleton pregnancies progressed to term (>37 weeks) without any
complications and resulted in the live birth of an infant weighing >2500 gms with no
signs of chromosomal or structural abnormality.
3.3.2 Spontaneous miscarriage
According to the criteria of the World Health Organization (WHO, 1977),
spontaneous abortion is defined as the expulsion of an embryo (blighted ova) or
extraction of a fetus weighing 500g or less. Although this fetal weight will normally
correspond to a gestational age of 20-22 weeks, in Mafraq Hospital due to the lower
survival rate, pregnancy losses up to 24 weeks was included in spontaneous
miscarriage group.
For descriptive purposes, miscarriages were classified according their subtypes
depending on the clinical picture at the time of sample collection, but all the subtypes
eventually ended in spontaneous miscarriage, either spontaneously or after following
medical and/or surgical intervention. This group includes symptomatic patients
presenting with vaginal bleeding (with or without abdominal pain) and a live fetus
with the cervix undilated but who subsequently progressed to spontaneous
miscarriage. The clinical and ultrasonographic diagnosis at the time of serum and
urine sample collection was threatened miscarriage. The non-threatened miscarriage
group included women who at the time of sample collection had a live viable
pregnancy with no bleeding, with or without abdominal pain (asymptomatic), but who
eventually had a spontaneous miscarriage. The missed miscarriage group included
women whose pregnancy failure was identified before the expulsion of products of
conception which were either embryonic (i.e. gestation sac and fetal pole seen but no
fetal heart, in ultrasound) or anembryonic (i.e. gestation sac seen with no fetal pole on
U/S). Women with incomplete miscarriage were those who passed the products of
conception incompletely, with evidence of retained tissue in the uterus. Finally, the
inevitable miscarriage group included women who had bleeding prior to 24 weeks
associated with pain and dilatation of cervix.
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3.3.3 Ectopic pregnancy
Ectopic pregnancy occurs when a fertilized ovum is implanted outside the uterine
cavity. All these patients, at the time of blood and urine test, had an unruptured tubal
pregnancy confirmed on ultrasound and/ on laparoscopy.
3.3.4 Molar pregnancy (hydatidiform mole)
Oedematous and avascular villi and trophoblastic overgrowth was present. The
classical "complete" mole had no fetus. "Partial" moles had focal molar changes in
the placenta. A fetus was sometimes present.
3.3.5 Proteinuric and non-proteinuric pregnancy-induced hypertension
PIH was defined as diastolic blood pressure of >90 mmHg or a systolic presuure of
>140 mm Hg on at least two consecutive occasions, 6 hours apart, in a woman with
no history of pre-existing hypertension or renal disease, and after the 20th weeks of
gestation. Patients with PIH were further subdivided into non-proteinuric and
proteinuric ((i.e. gestational hypertension in the setting of significant proteinuria,
defined as a minimum of 300 mg/24 hours or 0.1 g/L in at least 2 random samples that
were collected >6 hours apart) and included pre-eclampsia/and or eclampsia. Pre¬
eclampsia is the development of hypertension with proteinuria or edema (pitting
edema). Eclampsia is the occurance of convulsions in a woman with symptoms of
severe pre-eclampsia such as visual disturbances, epigastric pain, oliguria, etc 246.
3.3.6 Small for gestational age
Small for gestational age (SGA) was defined as a birth weight 10th or less percentile
for gestational age.
3.3.7 Preterm delivery
Pre-term delivery (PTD) was defined as a delivery occurring before 37 completed
weeks of gestation which included spontaneous preterm labour and or premature
rupture of membrane, or a delivery induced, medically or surgically, due to a maternal
or fetal cause.
3.3.8 Antepartum haemorrhage
Antepartum haemorrhage (APH) was defined as bleeding from the genital tract
between the 28th week of pregnancy and the onset of labour, and included placenta
71
previa (defined as a placenta in which the lowermost edge covered the internal os of
the cervix, either in whole or in part at the time of delivery) and placental abruption
(defined as premature separation of normally sited placenta).
3.3.9 Gestational diabetes mellitus
The diagnosis of gestational diabetes mellitus (GDM) is based on a positive glucose
challenge test, which according to current departmental protocols in Mafraq Hospital,
is performed for all pregnant women between 18th to 24th pregnancy weeks. The two-
stage screening guidelines of the American College of Obstetricians and
Gynaecologists (ACOG) (i.e. a non-fasting post 50-g, 1-h plasma glucose screen
followed by the confirmatory 'gold standard' 100-g, 3-h oral glucose tolerance test as
• • 247
a positive screen
3.3.10 Amniotic fluid index abnormality
Abnormalities in the amniotic fluid volume were determined by using ultrasound to
measure the sum of the deepest pockets of amniotic fluid in the 4 quadrants of the
maternal abdomen to derive the amniotic fluid index (AFI). These abnormalities
include oligohydramnios (an amniotic fluid index < 5 cm), polyhydramnios (AFI
greater than 25 cm), and anhydramnios (absence of amniotic fluid)
3.3.11 Macrosomia
Macrosomia was defined as a birth weight of >4000 grams.
3.3.12 Intrauterine fetal death or neonatal death
As per the Obstetrics and Gynaecology Departmental protocol in Mafraq Hospital, the
official definition of intrauterine fetal death or still birth is a child that has issued forth
from its mother after the 24th week of pregnancy and which did not at any time after
being completely expelled from its mother breathe or show any other signs of life
(given in Section 41 of the Births and Deaths Registration Act 1953 as amended by
the Stillbirth Definition Act 1992) and/ or deaths occurring in utero in which the fetus
or neonate weighs 500g or more. Early neonatal death is demise of a live born baby
occurring less than 7 completed days from the time of birth. The two are considered
together in this study.
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3.3.13 Miscellaneous conditions
These included pregnancies coexisting with medical conditions such as diabetes
mellitus, hypertension and thyroid disorders.
3.4 Results for the UAE cohort
3.4.1 Patient outcome variables
A total of 289 patients were included in this study. 283 (98%) patients had matched
serum-urine samples taken between 4 and 24 weeks of gestation. Only 6 patients (2%)
did not have paired serum or urine samples collected. [An additional 4 cases were
excluded due to non-availability of the outcome data.]
The 289 patients were classified into two groups:
Group 1 ("Continuing group"): 217 patients (75%) whose pregnancy continued
beyond 24 weeks.
Group 2 ("Non-continuing group"): 72 patients (25%) whose pregnancies ended
before 24 completed weeks of gestation due to spontaneous miscarriage, ectopic
pregnancy or molar pregnancy.
Table 9 compares the demographic variables between the two groups. Only in
respecdt of age and parity were there statistically significant differences, with other
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Table 9 Demographic characteristics of the study group. [NS, Difference not statistically
significant]
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The "Continuing group" included 137 uneventful pregnancies (i.e. term deliveries
with no complication), constituting 63% of this group and 47.4% of the total study
population. The remaining 37% had adverse pregnancy complications, occurring
either as an isolated condition or in combination with other complications. Table 10
shows outcome variables of the "continuing group" and their incidences in study
population.
Outcome variables N





Uneventful pregnancy 137 63.1 47.4
Threatened bleeding 18 8.2 6.2
Gestational Diabetes 14 COCD
Non-proteinuric + proteinuric
PIH 14 CONJ"CD










Ante-partum haemorrhage 3 1.3 1.0
AFI abnormality 5 2.3 1.7
Macrosomia 14 COCD
Intrauterine fetal death /
neonatal death 8 3.7 2.7
Other 12 5.5 4.1
Table 10 Outcome variables in the "continuing group" and their incidences in the total study
population as well as in relation to other outcome variable in the "continuing group". Note
that the incidence of each complication is given irrespective of their co-existence with other
pregnancy complications.
3.4.2 Hyperglycosylated hCG levels during uneventful pregnancy
Serum and urine HhCG concentrations for women with uneventful pregnancies in the
"continuing group" (singleton pregnancy with no complication) are shown in Figures
24 and 25.
HhCG levels in the first and second trimester pregnancy samples for the 137 patients
with uneventful pregnancy revealed higher levels of HhCG, in both serum and urine,
during the 1st trimester when compared with the 2nd trimester (Table 11, Figures 24
and 25)
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Figure 24 Display of log-transformed data of hCG (•), hCG(3 (•), and HhCG (•) serum
levels in from uncomplicated pregnancy in Group 1. InintS, log n of intact hCG (serum);
InbetaS, log n of hCG beta-subunit (serum); InHS, log n of hyperglycosylated hCG (serum).]
Scatterplot of InintU, InbetaU, InHU vs Gest. Age
16-i
2-
0 1 1 1 1 1 1 1 1 1 1 T"
4 6 8 10 12 14 16 18 20 22 24
Gest. Age in weeks
Figure 25 Display of log transformed data of hCG (•), hCG|3 (•), and HhCG (•) urinary
levels in from uncomplicated pregnancy in Group 1. [InintU, log n of intact hCG (urine);
InbetaU, log n of hCG beta-subunit (urine); InHU, log n of hyperglycosylated hCG (urine).]
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Gestational
Age N Minimum Q1 Median Q3 Maximum
All 137 5118 70123 186850 301922 761372
hCG 0-12 75 29491 180043 264818 383884 761372
13-24 62 5118 43860 68257 159754 589206
All 137 43.5 497 1347 2343 22430
Serum hCGp 0-12 75 405 1267 2065 3006 22430
13-24 62 43.5 256 417 1177 11985
All 137 66.1 3082 16144 39640 194592
HhCG 0-12 75 2890 18351 32572 66934 194592
13-24 62 66.1 724 2114 7044 113853
All 135 2990 30725 67836 173664 1213527
hCG 0-12 74 18681 67083 134377 257985 1213527
13-24 61 2990 17511 32961 57648 490607
All 135 4463 43131 133354 362104 3490085
Urine hCGpcf 0-12 74 6196 95972 223218 444784 3490085
13-24 61 4463 29362 75677 213887 1253738
All 135 28.5 1143 7243 23544 228062
HhCG 0-12 74 110 9313 16709 35119 228062
13-24 61 28.5 567 1078 3599 74378
Table 11 Serum and urinary concentrations of HhCG and other hCG-related forms in
uneventful pregnancy (n=137). N= number of subjects, Q1 and Q3 represent quartile ranges
of the value (i.e. 25th -75th percentiles)
The median (Ql, Q3) serum HhCG level during the 1st trimester was 32,572 pmol/L
(18351, 66934) and 2114 (724, 7044) pmol/L during the 2nd trimester, indicating a
93.5% reduction in HhCG levels from the 1st to 2nd trimester. Changes observed in
urinary HhCG concentrations were similar to those in serum. Median HhCG was
16709 (9313, 35119) pmol/L during the 1st trimester and 1078 (567, 3599) during the
second, with a 93.5% reduction in levels from the 1st to 2nd trimester of pregnancy.
Overall, median urinary levels of HhCG were 45% lower than in serum. However, the
variations in urine were found to be higher than in serum (28.5-228062 pmol/L and
66.1-194592 pmol/L, respectively).
The other four hCG analytes examined also exhibited a trend of high 1st trimester
concentrations followed by decreased 2nd trimester levels, as for HhCG. HCG and
hCGp levels in serum during the 1st trimester were 264818 (180043, 383884) pmol/L
and 2065 (1267, 3006) pmol/L, respectively. During the 2nd trimester, the median
level for hCG and hCGp decreased to 68257(43860, 159754) and 417(256, 1177)
pmol/L, with a reduction of 74.3% and 80%, respectively. In urine, the levels of hCG
and hCGpcf decreased from 134377 (67083, 257985) pmol/L and 223218 (95972,
76
444784) in the 1st trimester to 32961 (17511, 57648) pmol/L and 75677 (29362,
213887) pmol/L in the 2nd trimester, with a reduction of 75.5% and 66.1%,
respectively (Table 11, Figures 24, 25).
The relationship between serum and urinary levels of HhCG and hCG were analyzed
using Bland and Altman plots which show the difference of results (calculated as
serum minus urine) for hCG and HhCG from serum samples plotted against hCG and
HhCG in urine. For both plots, the mean of the difference between serum and urine
results is greater than zero and most points lie above zero indicating, that serum
results are consistently higher than urine results (Figure 26, 27).
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Figure 26 Bland and Altman plot showing higher levels of HhCG in serum than urine. The
centre line indicates mean of difference and mean ± 2SD is represented by top and bottom
lines.
Levels of HhCG were examined, in relation to other hCG molecular forms, in both
serum and urine, by calculating their ratios (Table 12). In serum, the ratios of HhCG
to hCG (HhCG/hCG) and HhCG to hCGp (HhCG/hCGP) were 0.11 and 16.5 during
the 1st trimester and 0.03 and 4.4 during the 2nd trimester, respectively. In urine, the 1st
trimester median molar ratios of HhCG to hCG and HhCG to hCGpcf were 0.14 and
0.09, and that of the 2nd trimester were 0.03 and 0.01, respectively. Although ratios
decreased from the 1st to 2nd trimester, serum HhCG was lower than hCG but higher
than hCGp. In urine, hCG and hCGpcf levels were higher, as was total hCG in 1st
trimester serum.
77




8 9 10 11 12 13 14
avelnlNT
Figure 27 Bland and Altman plot showing higher levels of hCG in serum than urine. The
centre line indicates mean of difference and mean ± 2SD is represented by top and bottom
lines.
As total hCG immunoreactivity in serum included hCG+hCGp, 69'94'120' 129-248'2495 we
examined the contribution of HhCG to total hCG immunoreactivity. HhCG comprised
11% of total hCG (Ql, Q3: 9%-21%, range: 3%- 60%) during the first trimester,
whereas during the second trimester, the proportion decreased to 3% (Ql, Q3: 1%,
6%, range: 0.08%- 21%). Table 12 shows ratios of HhCG in relation to other hCG
analytes in serum and urine of women with uncomplicated pregnancy during the 1st
and 2nd trimesters.
Gestational
Age N Q1 Median Q3
0-12 75 0.0907 0.1181 0.2208
2
3
HhCG/hCG 13-24 62 0.01779 0.03558 0.06332
0-12 75 8.72 16.53 28.78
DC
til HhCG/hCGB 13-24 62 3.057 4.462 8.903
0-12 75 0.09 0.117 0.2195
HhCG/(hCG+hCGI3) 13-24 62 0.0177 0.03534 0.06294
0-12 74 0.0916 0.1472 0.1962
111
2 HhCG/hCG 13-24 61 0.02537 0.03623 0.07466
DC 0-12 74 0.0463 0.0979 0.1876
3 HhCG/hCGBcf 13-24 61 0.00844 0.017 0.0329
Table 12 Proportions HhCG in relation to to other hCG forms, expressed by calculating their
ratios, in uneventful pregnancy (n= 137).
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3.4.3 HhCG levels in continuing vs. non-continuing pregnancy
The "non-continuing" group was comprised of 72 singleton pregnancies that ended
before the 24 completed week of gestation, and included 62 cases of spontaneous
miscarriage, 7 ectopic pregnancies, and 3 molar pregnancies (Table 13). The
spontaneous miscarriage group included 10 symptomatic pregnancies (threatened
bleeding with or without abdominal pain), 10 asymptomatic pregnancies (no signs of
threatened miscarriage), 26 missed abortions (20 non-viable embryonic+ 6 blighted

















Threatened 10 13.8 3.4
Non-threatened 10 13.8 3.4
Missed 26 36.1 8.9
Incomplete 11 15.2 3.8
Inevitable 5 6.9 1.7
Ectopic 7 9.7 2.4
Molar 3 4.1 1
Table 13 Incidence of pregnancy failures at <24 weeks of gestation in the "non-continuing
group" (Group 2).
The distribution of serum and urinary levels for all hCG analytes in the "continuing
group" (Group 1) and the "non-continuing" group (Group 2) are shown in Figures 28-
33. Levels were unevenly distributed, and are therefore log-transformed for easy
viewing and comparison.
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Figure 28 Log data of HhCG in serum in Groups 1 and 2. [Group 1, continuing group; Group
2, non-continuing group.]
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Figure 29 Log data of HhCG in urine in Groups 1 and 2. [Group 1, continuing group; Group
2, non-continuing group.]
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Scatterplot of Log Intact hCG vs Gest. Age in urine
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Figure 31 Log data of hCG levels in urine in Groups 1 and 2. [Group 1, continuing group;
Group 2, non-continuing group.]
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Figure 32 Log data of hCGP levels in the serum in Groups 1 and 2. [Group 1, continuing
group; Group 2, non-continuing group.]
Scatterplot of Log hCG beta core fragment vs Gest. Age in urine
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Figure 33 Log data of hCG|3cf in urine in Groups 1 and 2. [Group 1, continuing group; Group
2, non-continuing group.]
Group 1 Group 2 95% CI for
difference
P-
valueN Median N Median
Serum
hCG 217 159440 71 7477 (96614, 165365) <0.001
hCGfi 217 1346.8 71 153.3 (654.2, 1310) <0.001
HhCG 217 15785 71 970 (4526, 16092) <0.001
Urine
hCG 211 58727 69 5610 (32728, 63109) <0.001
hCGPcf 211 109116 69 4474 (64582, 122315) <0.001
HhCG 211 5941.2 69 741.8 (1610.8, 6239.3) <0.001
Table 14 Median concentrations of hCG molecular forms with inter-quartile levels and the
differences in Group 1 vs. Group 2, both in serum and urine.
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Table 14 shows median levels of HhCG and other hCG related molecules in both
groups while Figure 34 shows the box-plots for all hCG concentrations in Groups 1
and 2 (continuing group vs. miscarriage group). There is a statistically significant
difference between Groups 1 and 2 with Group 1 having higher results for each of the
hCG molecular forms, in both serum and urine.







































Figure 34 Box-plots of all hCG concentrations in Groups 1 and 2, comparing raw data
irrespective of gestational age. [Median, inter-quartile range (box) and 10lh to 90th centiles
(whiskers) plotted. All asterisks indicate values outwith the whiskers.]
It is evident from the above that all six hormonal parameters investigated were higher
in the "continuing group" than in the "non-continuing group" (p< 0.001 for all
analytes) (Table 14, Figure 34).
Median concentrations of HhCG in Groups 1 and 2 in serum were 15785 pmol/L and
970 pmol/L (95% CI 4526, 16092), respectively, whereas in urine the levels were
5941.2 pmol/L and 741.8 pmol/L (95% CI 1610.8, 6239.3), respectively. This
corresponds to 94% and 88% reduction in serum and urine HhCG levels, respectively.
Similar lower median levels in Group 2 were observed for the remaining 4 hCG
forms, when compared with Group 1. Serum hCG and hCG(3 showed a 93.4% and
88.7% reduction, whereas urinary hCG and hCG|3cf showed 90.5% and 96%
reduction in their hormonal levels during pregnancy failures. Of all types of
pregnancy failures, ectopic pregnancy had the lowest levels for all hCG forms, where
83
as the highest levels were seen in molar pregnancy (Figures 35-36). However, no
significant statistical difference was found between the Group 2 miscarriage-subtypes.




































Figure 35 HhCG Serum concentrations (log data) in various types of pregnancy failures
amongst the non-continuing group. [Threatened#; non-threatened □; missed O; blighted
ovum A; incomplete A, inevitable A; ectopic A\ molar +.]































Figure 36 Urinary HhCG concentrations (log data) in various types of pregnancy failures
amongst the non-continuing group. [Threatened#; non-threatened ■; missed O; blighted
ovum A; incomplete A; inevitable A, ectopic A molar +.]
In contrast to individual hormone levels, the ratios of HhCG/ hCG (serum and urine),
HhCG/hCGp, hCGPcf, and serum HhCG/(hCG+ phCG) remained unchanged in
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Groups 1 and 2. (Figures 37-41). The variability in both groups reduced as the
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Figure 37 Ratio of HhCG/hCG in serum. P-value is NS in Group 1 vs. Group 2. [Group 1,
continuing group; Group 2, non-continuing group.]
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Figure 38 Ratio of HhCG/hCG in urine, P-value is NS in Group 1 vs. Group 2. [Group 1,
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Figure 39.Ratio of HhCG/hCGp in serum, P-value is NS in Group 1 vs. Group 2. [Group 1,
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Figure 40 Ratio of HhCG/hCGficf in urine, P-valuc is NS in Group 1 vs. Group 2. [Group 1,
continuing group; Group 2, non-continuing group.]
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Figure 41 Ratio of HhCG/(hCG+ hCG|3/total hCG) in serum, P-value is NS in Group 1 vs.
Group 2. [Group 1, continuing group; Group 2, non-continuing group.]
3.4.4 Comparison of patients with threatened bleeding in Groups 1 and
2
A total of 18 women whose pregnancy continued past 24 weeks had threatened
bleeding (n=17 on or before 14 weeks, n=l at 22 weeks, total=18) and were compared
with 10 pregnancies presenting with threatened bleeding (n=9 >14 weeks and 1 at 22
weeks) but who eventually spontaneously miscarried at or before 24 weeks of
gestation (Table 15).
Group 1 Group 2 95% CI for
difference
P-
valueN Median N Median
Serum
hCG 18 228558 9 9381 (51614, 270789) 0.003
hCG(3 18 2021.7 9 320.3 (703.9, 2183.0) 0.003
HhCG 18 40018 9 937 (13154, 48600) 0.001
Urine
hCG 16 80410 10 10818 (31323, 191903) 0.005
hCGPcf 16 69124 10 9074 (1005, 154294) 0.048
HhCG 16 17318 10 1602 (1966, 41185) 0.007
Table 15 Median results (95% CI) of all hCG forms showing statistically significant
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Figure 42 Log (HhCG) levels in serum in Group 1 (threatened-continuing group) (*),and

























Figure 43 Log HhCG levels in urine in Group 1 (threatened-continuing group), (•) and
Group 2 (threatened-miscarriage group) (•).[Group 1, continuing group; Group 2, non-
continuing group.]
As seen in Figures 42 and 43 and Table 15, HhCG, and other hCG forms shows
higher levels in pregnancies continuing to term than those which eventually
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spontaneously miscarried, indicating that lower levels of hCG hormones were only
found in pregnancies destined to fail, irrespective of the symptoms of threatened
bleeding.
3.4.5 Embryonic and non-embryonic miscarriages
Of eighteen women with 1st or 2nd trimester bleeding in this study population who
eventually continued their pregnancy beyond 24 weeks of gestation (threatened-
continuing pregnancy), only 72% (n=13) had an uneventful pregnancy outcome. The
remaining 28% were associated with a combination of complications such as PIH,
gestational diabetes, spontaneous preterm deliveries and intrauterine fetal demise.
Both embryonic (gestational sac with dead embryo, n=20) and anembryonic (empty
sac, n=6) missed miscarriages presented with lower maternal and serum
concentrations of HhCG and other hCG-related forms when compared to normal
uneventful pregnancy (P < 0.001). When we investigated the effect of the presence or
absence of an embryo in missed abortion on placental hormonal levels, we found
medians of all 6 hormones were higher in anembryonic, (also known as blighted
ovum), than embryonic missed miscarriages (Table 16). However the differences
were not statistically significant because of the wide range of concentrations.








Embryonic 2186 431 115-1479
0.22
Anembryonic 5472 1408 862-9897
hCG
Embryonic 14863 6839 2876-17877
0.33
§
Anembryonic 26057 12328 4983- 50106
O
04 hCGp
Embryonic 167 102.8 51.1-226
0.22
W
c« Anembryonic 326 128 89.9- 545
HhCG
Embryonic 1382 202 101-963
0.13
Anembryonic 4049 1807 471-9659
hCG
Embryonic 7541 4244 872- 7621
0.07
URINE
Anembryonic 21303 13226 2008-41541
hCGpcf
Embryonic 18602 3456 1090- 11389
0.24
Anembryonic 6695 8457 3113-34789
Table 16 Median concentrations with interquartile ranges of all six hCG analytes. Differences
not statistically significant [p>0.05, Mann-Whitney test]
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3.4.6 HhCG levels in uneventful pregnancy vs. late pregnancy
complications
The "continuing group" consisted of 217 pregnancies, of which 137 were uneventful
pregnancies (i.e. term deliveries with no complication), constituting 63% of Group 1
and 47.4% of the total study population. The remaining 37% had adverse pregnancy
complications, either as an isolated condition or in combination with other
complications. Table 10 shows outcome variables of the "continuing group" and their
incidences in study population.
There were 18 patients in the continuing group who had threatened bleeding during
the first trimester but who continued their pregnancy until term. There was no
statistically significant difference between these 18 pregnancies compared to the 137
pregnancies with an uneventful outcome. However, all hCG levels were significantly
higher in those women compared to the miscarriages group in Group 2, indicating that
irrespective of bleeding during first trimester, pregnancies destined to progress to term
have normal levels of all hCG forms.
Other outcome measures in this group included: pregnancy complications (Table 10):
pregnancy induced hypertension (PIH), with or without proteinuria (n=14), small for
gestational age (SGA) n=l 1, spontaneous preterm (n= 8), gestational diabetes (n=14),
and intrauterine fetal death /neonatal death (n=8). The non-proteinuric PIH included
10 patients, whereas the proteinuric hypertension included pre-eclampsia (n= 3) and
eclampsia (n=l). As seen in Figures 44 and 45, there was no statistically significant
difference in the levels of HhCG in urine or serum between any of the late pregnancy
complications and the uneventful pregnancy group, indicating that HhCG is a poor
indicator of pregnancy adverse outcome in later gestation. Similar results were
observed for the remaining hCG forms in serum and urine.
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Figure 44 Serum HhCG levels in uneventful pregnancy (•) vs. continuing pregnancy with
late obstetrics complications (•). Green dots (•) represent HhCG levels in the non-continuing
group which clearly shows significant lower levels when compared to the previous two.
[InHS, HhCG in serum; TermNOcomp, continuing pregnancy with (1) or without (0)
complications; asterisks indicate non-continuing pregnancy.]
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Figure 45 Urinary HhCG levels in uneventful pregnancy (•) vs. continuing pregnancy with
late obstetrics complications (•). Green dots (•) represent HhCG levels in the non-continuing
group, which clearly shows significantly lower levels when compared to the previous two.
[InHU, HhCG in urine; TermNOcomp, continuing pregnancy with (1) or without (0)
complications; asterisks indicate non-continuing pregnancy.]
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In summary, this study has demonstrated that maternal serum and urinary HhCG
levels between 6-24 weeks were lower in pregnancies resulting in miscarriages, but
no difference in the levels of HhCG was found in pregnancies continuing beyond 24
completed weeks, and in pregnancies that subsequently developed complications such
as PIH, gestational diabetes and growth restrictions, indicating that HhCG may be a
useful predictor for detecting pregnancy failures during the first and second trimesters
but not of any other adverse outcome occurring later in gestation. To test this
hypothesis, HhCG was tested by a ROC analysis for its diagnostic efficacy in
predicting pregnancy failures.
3.5 ROC analysis
By calculating specificity and sensitivity, ROC curves were constructed for the six
hCG analytes measured in serum and urine to establish their diagnostic accuracy in
predicting adverse pregnancy outcome (Figure 46 and Table 17).
Figure 46 ROC curve analysis for hCG parameters to determine whether women will
continue their pregnancy beyond 24 weeks.
hCG variables AUC Std. Error 95% CI DA
hCG 0.880 .029 0.824-0.937 +
Serum hCGIB 0.841 .031 0.780-0.901 +
HhCG 0.764 .034 0.698-0.831 ±
hCG 0.855 .030 0.795-0.914 +
Urine
hCGIBcf 0.873 .029 0.817-0.929 +
HhCG 0.744 .036 0.675-0.814 ±
Table 17 Comparison of hCG molecular forms by ROC analysis. [AUC, area under the
curve; DA, diagnostic accuracy; +, good and ± moderate DA.]
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The molar concentrations of the six hCG molecular forms were used to ROC curves
and the area under the curves were calculated to assess the diagnostic accuracy of
these analytes. ROC curves represent the full spectrum of possible sensitivity-
specificity pairs evaluating a test for possible clinical application, with the y-axis
representing sensitivity (true positive) and the x-axis representing 1-specificity (true
negative).
3.5.1 ROC analysis for miscarriages
The model created by Due et al.2,7 to rank the accuracy of a diagnostic test was used.
AUC values of 0.91-1.00 and 0.0-0.09 are rated as excellent (++), 0.81-0.90 and 0.10-
0.19 as good (+), 0.61-0.80 and 0.20-0.39 as moderate (±), and 0.40-0.60 as poor
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accuracy (-) . AUCs for HhCG in serum and urine were 0.764 ± 034 and 0.744 ±
036 respectively for the group of pregnant women who continued beyond 24 weeks of
gestation vs. the group who miscarried before completed 24 weeks of gestation and
shows moderate accuracy. However the diagnostic accuracy of hCG (in both serum
and urine), hCGP and hCG|3cf were better than HhCG, as the AUC showed good
diagnostic accuracy (0.81-0.90) for the remaining analytes when compared with
HhCG. HCG in serum had the best AUC (0.880) compared to the other hCG analytes
(Figure 46 and Table 17).
The sensitivity represents all patients who are correctly identified as a continuing
pregnancy group, with the specificity representing all pregnancy failures correctly
identified. Hence it is important for a screening test to have a high specificity and
negative predictive value, but without compromising the sensitivity. False-negative
results must be avoided though a moderate number of false-positive results can be
considered as acceptable. When the optimal specificity cut-off value was chosen to
maximize detection of 70% of all pregnancy failures, a HhCG level of 4846 pmol/L
(~ 200 pg/L) had a sensitivity of 66% (i.e. 66% detection of a "continuing
pregnancy", or a positive predictive value) in serum . In urine, the same cut-off value
of 200 pg/L yielded better detection of failures with a specificity of 78% but a lower
sensitivity of 55%. Using the same cut-off value in serum, 100% of ectopic
pregnancies could be detected but at the expense of very low sensitivity (33%),
showing very high negative predictive value to correctly identify miscarriages.
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3.5.2 ROC analysis for ectopic pregnancy
The ability of HhCG to discriminate ectopic pregnancy (n= 7) from spontaneous
miscarriages which include threatened miscarriages, missed abortion, blighted ovum,
incomplete or an inevitable miscarriage (n= 61, one n missing) was tested under the
ROC curve (Figure 47), the AUC was 0.74 which according to model created by Due
217
et al. is ranked as moderately accurate diagnostic test (±) (Table 18). However
wide confidence interval, together with high standards of error obtained due to the
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.742 .088 .570 .915
Table 18 Area under the curve (AUC) showing the moderate diagnostic accuracy of HhCG in
serum with wide confidence interval.
3.6 Comparison of HhCG results from two methods
The relationship between levels of HhCG produced in two different immunoassay
system (DELFIA vs. Quest) was tested using "Bland and Altman plots" that plot the
difference between paired results (calculated as DELFIA minus Quest HhCG result)
vs. the mean of the paired results.
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The Bland and Altman plots (Figures 48 and 49) indicate good qualitative agreement
between the methods, as there is relatively little scatter of results, but very poor
quantitative agreement. However, inspection clearly indicates that for both serum and
urine the line of equivalence between the methods has a significant slope but passes
through zero. This may well be accounted for by differences in calibration between
the methods. There is no International Standard for HhCG so assays are calibrated
against different standards, which is likely to contribute to the differences observed.
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Figure 48 Bland-Altman plot comparing serum HhCG results obtained in the Perkin-Elmer
DELFIA method and the Quest Diagnostics method.
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Figure 49 Bland-Altman plot comparing urine HhCG results obtained in the Perkin-Elmer
DELFIA method and the Quest Diagnostics method.
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3.7 Discussion of results for the UAE cohort
3.7.1 Early pregnancy
3.7.1.1 Uneventful pregnancy and spontaneous miscarriage
In normal pregnancy, the cytotrophoblasts are the dominant placental cells during
early gestation, producing HhCG. The syncytiotrophoblast (syncytiotrophoblast)
(differentiated trophoblast transformed from cytotrophoblast) becomes dominant later
in gestation, and produces hCG 70' 92' 25°: 69' 70' 97' 244. The rate of differentiation of
cytotrophoblast into syncytiotrophoblast appears to be the main factor that leads to the
synthesis of hCG and its subunits by the syncytiotrophoblast 92'93'106. The production
these molecular forms of hCG is under stringent physiological control, and is reported
to be altered under different pathological conditions. Early pregnancy events such as
defective implantation or placentation have been linked to the development of various
complications and diseases during pregnancy including miscarriages, pre-eclampsia,
FGR, leading to possible alterations in placenta hormonal parameters.
The aim of this prospective observational cohort study was to explore the levels of
HhCG in serum and urine, along with other 3 hCG molecular forms: hCG, hCGp, and
hCG (3cf, in normal pregnancy and pregnancy-related disorders, and assess their
diagnostic ability in predicting an adverse pregnancy outcome.
Analysis of matched serum-urine samples from the 1st and 2nd trimester pregnancy
samples in the 'pregnancy-continuing' group, revealed higher urinary and serum
HhCG levels during the 1st trimester compared to the 2nd trimester (Table 11, Figures
24 and 25). This is in agreement with previous studies of normal pregnancies,
conceived naturally or through IVF, showing high levels of HhCG in serum and urine
during early pregnancy, with peak concentrations achieved during the first six weeks
of gestation, then rapidly declining and remaining at lower levels as pregnancy
advances 67'244'251. The decrease of HhCG with advancing gestation is secondary to
70the simultaneous decline in the number of differentiating cytotrophoblast cells .
Throughout pregnancy there are changes in the immunoreactivity of total hCG, first
as a result of production of hormone initially by cytotrophoblasts, then shifting
gradually to the syncytiotrophoblasts 70' 92' 93' 145'222'252. Thus, HhCG during early
pregnancy is replaced by hCG molecular forms characteristic of later pregnancy,
which remain the predominant form for the remainder of the pregnancy. Studies have
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shown that HhCG accounts for >80%, 63% and 50% of the total hCG concentration in
the first, second and third weeks following implantation (i.e. the 3rd to 5th completed
week of pregnancy), respectively. The proportion of HhCG decreases during the
remainder of the first trimester (<25%) and declines much further through the 2nd and
the 3rd trimesters of pregnancy, and by then constituting less than 2% of the total hCG
immunoreactivity. The findings in this study are comparable to previous studies
showing that reported median proportions of serum HhCG (11%) during the first
trimester, (i.e. 6th -12th weeks of gestation), compared to 3% during the second
trimester, in the pregnancy-continuing group. Although 3rd trimester samples were not
included in this study, others have reported a median of 1.7 % HhCG molecules
during the 27th-41st completed week of pregnancy (Table 19)2?l.
Gestational age Median (%) Range
3 weeks + 6 days 92 55-100
4 weeks + 6 days 73 15-100
5 weeks + 6 days 50 10-100
6 weeks + 6 days 26 8-53
7 weeks + 6 days 14 2-21
2nd trimester 2 0-31
3rd trimester 2 0-4
Table 19 The proportion of total hCG immunoreactivity in urine samples due to HhCG
throughout pregnancy.253
Also in this study it was also noted that the proportions of HhCG to other hCG
molecular forms [i.e. HhCG/hCG, HhCG/(hCG+ hCGP), HhCG/hCGp], were all
statistically different from the 1st trimester to 2nd trimester (i.e. fell significantly
between the 1st to 2nd trimester) (Table 12). However the molar ratios of hCG, hCGP,
and hCG Pcf, remained unchanged, probably indicating that the production of hCG
and its related molecules, are regulated differently to the HhCG (which is produced by
the cytotrophoblast and which is significantly reduced following the its differentiation
into syncytiotrophoblast. Altered ratios may reflect the level of differentiation and
hyperplasia of the trophoblast and may help differentiate normal pregnancies from
complicated ones and invasive trophoblastic diseases from the non-invasive ones 75'
207,254,255
It was not possible to show in this study very high proportions of HhCG, as obtained
in other studies 66' 130 during early gestations, since the UAE study population
consisted of spontaneous conceptions presenting at more than 6 weeks of gestation,
(mean gestational age of 9 weeks), at the time of sampling during the first trimester,
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and at 17 weeks in the second trimester. However, the pattern of HhCG production
observed in this study confirms that the glycosylation profile of hCG changes as
gestation progresses 25'26-50-66'130 j^e serum levels of hCG and hCGp, along with
urinary levels of hCG and hCGpcf followed a similar pattern of high concentrations
during the 1st trimester compared to the 2nd trimester (Figure 27-28, Table 16). The
observed decrease in hormonal concentrations as pregnancy progresses are in
concordance with several previous publications 95"113'115'133' 134-256'257.
During normal pregnancy, serum hCG concentrations increase at an exponential rate,
reaching peak concentrations of approximately 100000 U/L ( in relation to 1st IRP)
(~290000 pmol/L in relation to the 3rd IS, 75/537) between the 7th and 10th weeks of
gestation, and decrease 10-fold thereafter, before reaching a plateau of approximately
36000 U/L (~ 104,400 pmol/L) at the beginning of the 2nd trimester and remaining at a
relatively constant level until nearer term, when there is a small increase before
delivery 94'95-207.
The molar ratio of hCGp to total hCG (hCGp/hCGP+ hCG) ranged from 0.3% to 3%
in serum samples of 6-24 weeks of gestation with no statistical difference found in the
molar ratios from the 1st to 2nd trimester (Table 12). This was similar to the range
reported in literature (i.e. 0.1% to 3.6%). Higher ratios were observed in trophoblastic
cancers and invasive neoplasms, and hCGp is thought to be useful in differentiating
malignant trophoblastic tumors from benign ones 75'115'207'255'257-259
The major immunoreactivity in urine is due to hCGpcf, the terminal degradation
product of hCGp, which comprises 50%-100% of total hCG urinary
immunoreactivity. hCGpcf can be detected in serum in quantities as low as 0.3% of
the hCG content but the concentrations in urine are ~4000-fold greater than those in
serum 114116. In this study, the levels of hCGpcf in the 1st trimester of the continuing-
pregnancy group, was 223,218 pmol/L, and fell to 75,677 pmol/L during the second
trimester. The decrease in median concentrations was concurrent with the reduction in
the production of hCG and hCGp with advancing gestation. It has been shown that
hCGpcf concentrations are initially lower than hCG concentrations, increasing
sharply from 5 weeks of gestation, so that they equal hCG concentrations (mol/mol) at
6-7 weeks of gestation, exceeding hCG concentrations thereafter. In this study, the
median proportion of hCGpcf to hCG (hCG Pcf/hCG on a molar basis) during the first
trimester was 60% (25th -75th centiles 49%-72%) and during the second was 68% (25th
-75th centiles 60%-79%), showing no statistically significant difference between the
98
two trimesters (by student's t test for paired samples), and indicating that the pattern
of production of both hormones in relation to one another remains constant (Table
12). These ratios are said to be altered in trophoblastic and non-trophoblastic
neoplasms such as cervical and pancreatic cancers
Many "sandwich assays" used in recent days include multiple antibodies raised to
different sites on hCG and its free subunits, often using one monoclonal antibody to
capture hCG through a specific site which is then detected by separate monoclonal or
polyclonal antibodies raised against a distant site on the hormone. Due to differences
in the combinations of antibodies used, hCG and its free subunits are detected
variably by different immunoassays 115' 197. However, to detect the total hCG
immunoreactivity in serum, an assay should ideally be able to recognize hCG + hCGn
+ HhCG + hCGp + hCGPn l15'208'212-260 Given the specificities of the assays used in
this study, which detect both the nicked- and non-nicked forms of hCG and hCG p,
together with the 100% cross-reactivity with HhCG of the hCG assay used in this
study (Stenman et al., unpublished data), total hCG immunoreactivity in serum was
calculated as (hCG + hCGP). In urine however, this was not possible because hCGp
was not measured. Although, hCGP has been found to be a minor component in urine
in most studies 95'261, variations in urinary hCG results have been found when the
levels of hCGP are altered, as seen in cases of Down syndrome pregnancies and
908 969
gestational trophoblastic diseases ' . While hCGpcf is extremely stable during
storage, hCG dissociates into its free subunits faster in urine than in serum causing
hCGp levels to be elevated 123-263"266 Any change in the levels of hCGP in the stored
urine samples may affect measurements of total hCG immunoreactivity.
The range of HhCG results in serum samples of < 24 weeks gestation was 66-194592
pmol/L (n=137) compared with urine concentrations of 28.5- 228,062 pmol/L
(n=135) indicating a lower range of HhCG values in urine than in serum samples,
though with very wide variations in concentration. The lower values and wider range
in urine concentrations was also noticed for hCG, with urinary levels ranging from
2990-1213527 pmol/L and serum levels varying from 5118-761372 pmol/L. The
levels of human chorionic gonadotrophin in urine reflect the renal excretion of
circulating serum hormone either directly or after being metabolised in the kidneys.
Variations in urinary flow rate lead to a wider reference range for hormone levels in
urine compared to serum 95'214. The hCG concentrations in urine correlate strongly
with those in serum. In early pregnancy, the average urine concentrations are 50-70%
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of those in serum, but after the fifth week, the urine-to-serum ratio of HCG decreases
and hCGGcf becomes the dominant form in urine 95. There is large day-to-day and
within-day variation in urinary hCG concentrations which can be reduced by
normalizing against urine density or urine creatinine concentration. However,
although this eliminates the variation, it partly limits its utility; therefore making
serum assays better suited for quantitative assays 95. Many previous reports confirm a
similar trend of loss of hCG immunoreactivity in urine, accompanied by increased
levels of degraded forms such as hCGG and hCGPcf 95'113'115 66'68-115.
Miscarriage is the commonest gynaecological emergency in England and Wales,
comprising of 70000-90000 cases per year 267. It is estimated that as many as 12%-
15% of clinically recognized pregnancies, and as many as 17%- 22% of all
inf- ^/-o 96Q
pregnancies, result in spontaneous miscarriage ' ' . The vast majority of
miscarriage cases occur during the first trimester with evidence of the presence of
270 972
genetic abnormality in the fetus in approximately 54%- 76% of cases " .
Spontaneous miscarriage after 12 completed weeks of pregnancy (late miscarriage) is
less common, but still affects 1-2% of pregnancies. Early and late miscarriages have
been attributed to several factors including increased maternal age, ethnic origin,
gravidity, parity, pro-coagulant state, luteal phase defect, and prior fetal losses 273-277.
However, approximately 40 % of pregnancy failures remain unexplained l84. In the
current study population, the incidence of miscarriage was higher with the increase of
the maternal age and parity (Table 9).
Serum and urinary samples of 72 women from the UAE population whose pregnancy
ended before 24 weeks of gestation (the "non-continuing group), showed lower levels
of all hCG forms (Figures 28-36 and Table 14). These lower levels were observed
irrespective of whether the patient was symptomatic or asymptomatic (i.e. presence or
absence of the bleeding (Figures 42-43, Table 15) or the presence or absence of a
dead embryo (Table 16), suggesting that the lower production of these hormones by
the trophoblast is independent of embryonic development or the appearance of
symptoms.
The cause of bleeding is unknown but it is said to occur in one fifth of recognized
pregnancies before the 20th week, and over half of these miscarry, with the remaining
half continuing despite the fact that bleeding may continue for a variable period of
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time . In the UAE study population, in women with first trimester vaginal bleeding
and a viable fetus on ultrasound (n= 28), lower concentrations of HhCG and related
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hCG subunits were found in cases of negative outcome (i.e. almost a third eventually
miscarried, n=10) than in those pregnancies continuing beyond 24 weeks of gestation.
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This is in agreement with previous observations ' ' and with Harville et al who
showed that the majority of pregnancies with bleeding progressed to full term (85%)
despite the presence of bleeding often for a considerable period of time 279. Women
who presented with threatened bleeding during the first or second trimester, and who
eventually miscarried (n=10) had lower HhCG levels in serum and urine than
asymptomatic pregnant women (n=137). There was no difference in hCG levels
between pregnancies with threatened bleeding but which eventually ended in live
birth (n=13) and asymptomatic pregnant women (n=137). However, the results for
HhCG in serum and urine as well as hCGp in serum just failed to reach a 5% level of
significance (p= 0.068, 0.086 and 0.089 respectively). Larger studies may show a
significant difference between the two groups, which may indicate that bleeding is
probably the earliest sign of placental dysfunction. As discussed previously [Section
1.12], survival of the implanting embryo depends on the extent of initial insult
experienced during trophoblast invasion. Hence, the presence of additional oxidative
stress-related damages leads to complications such as pre-eclampsia, FGR and fetal
death. This, together with reports of the association of 1st trimester bleeding with
impaired pregnancy outcome, is an independent risk factor for obstetrical and
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perinatal problems later in gestation ' ' , and may well confirm that bleeding is
likely to be associated with some placental dysfunction.
In anembryonic missed abortions, serum HhCG, hCG and hCGp levels were 3.3-, 1.8-
and 1.2-times higher than in the embryonic missed miscarriage group. In urine, the
HhCG, hCG and hCGPcf levels were 9-, 3-, and 2.4-times higher than in the
embryonic missed miscarriage group (Table 16). This interesting finding shows that
the production of HhCG by the cytotrophoblast, including the formation of other
hCG-related molecules by the syncytiotrophoblast, continues regardless of fetal
demise. Similar findings in the literature have lead to the concept that the presence of
a fetus may not be necessary for the growth and development of a definitive placenta,
since persistent placental function could be seen for some time, in spite of fetal
demise during the second trimester 282. Furthermore, complete hydatidiform moles
with no fetus continue to secrete large amount of hCG. It may also highlight different
pathophysiological mechanisms involved in pregnancy failure between the two
missed miscarriage subtypes, with embryonic miscarriage probably caused by
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placental dysfunction, reflected by lower levels of hCG forms, whereas pregnancy
failure in anembryonic missed miscarriage may be precipitated by embryopathic
factors (i.e. fetal-related causes). Indeed, trophoblast cell cultures obtained from
pregnancies with a non-viable embryo (embryonic miscarriage) were severely
282
impaired . In contrast, anembryonic pregnancies were more likely to be aneuploid
and fail at a very early gestation 271'283.
Another possible explanation for higher hormonal levels in anembryonic miscarriage
maybe due to stimulation of hormone production secondary to the hypo-perfusion
caused by increased expression of oxidative stress markers after very early embryonic
demise, exacerbated by the long delay before expulsion l84. This has been confirmed
by Doppler studies showing that only anembryonic miscarriage patients and those
with long retention time, i.e. evidenced by the calcification of yolk sac, show
abnormal intervillous space echoes 284. As discussed earlier, the urinary hCG
concentrations reflect the renal excretion of hormone directly from the circulation or
after being metabolized from the liver. While all the hormonal levels of embryonic
pregnancy in serum were higher than in urine (Figures 26 and 27), such trend was
absent in anembryonic pregnancy (i.e. blighted ovum) indicating that hormones
produced by blighted ovum are resistant to degradation and metabolic clearance from
the circulation (Table 16). This may be due to an increase in the sialyl content, or due
to the action of enzymes produced by macrophages in the trophoblast.
While several mechanisms are likely to be involved in normal and failed trophoblast
invasion, a balancing act between the pro-invasive proteins produced by the
trophoblast and local uterine factors acting to limit the invasion is mandatory for a
successful implantation. As discussed earlier, hCG, cell adhesion molecules, matrix
metalloproteinases (MMPs) and their tissue inhibitors, transforming growth factor P
and its receptors, changes in the oxygen tension, and spiral artery transformation all
play role in the initiation and maintenance of pregnancy. Similarly, HhCG may be a
marker of inadequate placentation during the first trimester or may be, itself, a cause
of pregnancy failure as a result of reduced invasive stimulation. This is due to the fact
that high levels of HhCG are associated with aggressive trophoblastic invasive events
during the early weeks following implantation 70 and in trophoblastic disease, 48' 49
making it a marker of invasive activity of the trophoblast. These and other studies
have reported an association between reduced levels of HhCG during early pregnancy
and adverse pregnancy outcomes, confirming that low levels of HhCG may be a
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marker of inadequate placentation and other pathological events associated with
trophoblastic dysfunction.
The six genes of the hCGp gene family are expressed variably throughout pregnancy.
Although the contribution of individual genes to the production of HhCG subunits is
as yet unknown, it is thought that the total amount of hCG|3 gene expression, rather
than the expression of individual beta genes, is important for the maintenance of
285normal pregnancy . A significant reduction of hCGp gene expression is seen in
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cases of spontaneous miscarriages ' . Hence, it is possible that lower levels of
HhCG and other forms of hCG molecules are due to a reduction in total hCGp
messenger RNA (mRNA). Henderson et al. found that the depressed concentrations of
maternal serum hCG during early pregnancy failure resulted not only from diminished
placentation and/or placental necrosis but also from down-regulation of hCGa and
hCGp genes 287.
In about two-thirds of early pregnancy failures, there is evidence of defective
placentation mainly characterized by a thinner and fragmented trophoblast shell,
reduced cytotrophoblast invasion of the endometrium and incomplete plugging of the
lumen at the tips of the spiral arteries 288' 289. Hence, this anatomical defect maybe
reflected by the reduced levels of HhCG observed here in the "non- continuing
pregnancy" group. Indeed, the impairment of the placental-decidual interface as a
result of premature onset of the maternal circulation throughout placenta accompanied
by major oxidative degeneration, causing further placental degeneration leading to
loss of syncytiotrophoblast function and detachment of the placenta from the uterine
wall 184' 289' 290 may be the cause of the lower levels of hCG, hCGp and hCG Pcf
observed in maternal serum and urine samples in the "non-continuing pregnancy"
population. It is difficult to establish in this study which of the above mentioned
pathological events (i.e. impaired trophoblastic invasion or abnormal uteroplacental
perfusion) preceded one another and which lead to miscarriage. The latter is more
associated with late miscarriage rather than early miscarriage 271'291. However, in line
with several previous reports, the results show that pregnancies which failed
spontaneously before 24 weeks of gestation were all associated with lower levels of
hCG molecular forms, including HhCG 67.81,242,257,292,293
There is presently no definitive test that can identify pregnancies that will
spontaneously miscarry. In today's practice, low levels of hCG, non-doubling of hCG
levels, or hCG levels that fall before the expected time of the hCG peak are used as
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indicators of impending spontaneous miscarriage. Other markers including CA 125
294'295, progesterone 293'296'297, and PAPP-A 227•298•299 have been used, either as a
single measurement or in combination with other markers, but have failed to
discriminate pregnancy failures from ectopic pregnancy solely by means of hormone
measurements.
Serial evaluation of serum hCG levels is one of the important strategies in the
diagnosis and prognosis of early pregnancy. Monitoring the patient involves looking
for increasing levels of hCG, and clinical decisions are facilitated by the well-defined
curve of expected hCG rise first described by Kadar et al in 1981, showing the
minimal rate of increase for a singleton intrauterine pregnancy (IUP) to be a rise of
66% in 2 days 30°. This study used a small sample however (n=20, CI 85%). Other
investigators have redefined the lower limit of the normal hCG rise for a viable IUP to
be 53% in 2 days (CI 99%), based on serial hCG curves obtained from larger
populations of pregnant women presenting with pain with or without vaginal bleeding
who eventually went on to have a viable IUP 220'301-302 Studies of hCG doubling
times indicate that serum hCG levels rise by at least 66 percent every 48 hours during
the first 40 days of gestation in 85 percent of viable intrauterine pregnancies.
Conversely, in 15 percent of viable intrauterine pregnancies the increase is less than
66 percent in a 48-hour period 220'302.The USA hCG Reference Service has reported
cases with a less than 1.5-fold increase in hCG in 2 days that have nevertheless led to
normal term deliveries. In cases of threatened miscarriage, the rise in maternal hCG is
220slower . An increase of 50 percent or less in a 48-hour period is almost invariably
associated with a nonviable pregnancy. In contrast, an inappropriately small increase
in hCG merely indicates a nonviable pregnancy and does not indicate whether the
pregnancy is intrauterine or extra-uterine. As the interassay variability of hCG is 10 to
15 percent, a smaller increase or a decrease may also possibly indicate that the levels
have reached the plateau level "5i208. Due to these variations in doubling time, the
search continues for a single hCG test or alternatively more sensitive marker, not only
to distinguish normal pregnancies from failing pregnancies, but one that can be used
as a better discriminator between ectopic pregnancy and spontaneous miscarriage.
3.7.1.2 Ectopic pregnancy
Ectopic pregnancy is the major cause of morbidity and mortality amongst women of
reproductive age group, and the recorded prevalence worldwide has been increasing
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gradually. Between 1976 and 1993, the incidence in northern Europe increased from
11.2 to 18.8 per 1,000 pregnancies and in Korea, 1 case per 20 to 26 pregnancies is
seen, which is relatively higher than in Western countries 303. In the USA, the
incidence of ectopic pregnancy has increased from 0.5% 30 years ago to 2%, but the
death rate has also fallen to 1 in 2000 detected cases of ectopic pregnancy. Admission
to hospital for ectopic pregnancy increased from 17,800 in 1970 to 88,400 in 1989,
reaching 1 case per 60 pregnancies in the United States ' . In the UK, the incidence
has slowly risen in the past decade from 8.6/1000 to 11 per 1000 estimated
pregnancies but death rates have fallen slightly from 0.6 to 0.4 per 1000 cases of
ectopic pregnancy 304. The Confidential Enquiry into Maternal Deaths in 2004 found
that in the UK maternal deaths from EP accounted for 3.4% of total deaths in 2001.
Fifteen deaths directly attributed to early pregnancy complications were recorded
from 2000-2002, of which 11 deaths (73.3%) resulted from ruptured ectopic
pregnancy (7 tubal and 4 cornual). None of the cases were diagnosed before rupture
304. Many studies have tried to explain these rises, linking them to improvements in
diagnosis, the possible association with the rising incidence of pelvic inflammatory
disease and chlamydial infections, the change in maternal age distribution, smoking,
and IVF treatment 305-307. An incidence of up to 6.5% is recorded amongst the IVF
population 307. Delayed diagnosis of EP can cause rupture of the Fallopian tube, and
intra-abdominal haemorrhage, requiring blood transfusion and emergency
laparotomy. Approximately 30% of women treated for ectopic pregnancy later have
difficulty conceiving, and the rates of recurrent ectopic pregnancy are between 5%-
20%. This risk increases to 32% amongst women who have had two consecutive
ectopic pregnancies 305-308-310_
Early diagnosis of unruptured ectopic pregnancy is paramount for preventing
mortality, reducing morbidity, and preserving fertility. A quick and accurate diagnosis
of ectopic pregnancy is desirable, but at times remains tricky, as no single
noninvasive test is available that will definitely confirm the presence of an ectopic
pregnancy, and since the diagnosis also involves the exclusion of an intrauterine
pregnancy. Diagnosis and management of ectopic pregnancy includes laboratory
assays such as serial quantitative hCG measurements, imaging techniques including
transabdominal and transvaginal ultrasound, as well as surgical interventions (e.g.
"3AC OOQ "111 QOfl
culdocentesis and laparoscopy) ' . A simple pregnancy test is the first step
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in investigating a suspected ectopic pregnancy combined with ultrasound parameters.
Kadar et al were the first to recognize the importance of combining ultrasound with
serum hCG measurements. They introduced the discriminatory serum hCG zone in
198 1 300. This was defined as the minimal hCG concentration above which the sac of
an IUP can always be identified by sonography. The diagnosis of an EP is made when
an intrauterine gestational sac is absent and the serum hCG concentration is above the
discriminatory zone. During earlier days when transabdominal ultrasound was
performed, the discriminatory zone was set at between 6,000 U/L and 6,500 U/L but
due to the improved resolution of sonography and the introduction transvaginal
ultrasound, the discriminatory zone has decreased, bringing the optimal serum hCG
cut-off level down to 1,500 U/L 314'320. Similarly, investigators have redefined the
earlier lower limit of normal rise for a viable IUP from 66% in 2 days to be 53% in 2
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days, based on serial hCG curve obtained later from larger population
However, the use of a more conservative cutoff for minimal rise in hCG, one as slow
<3 19
as 35% over 2 days, has also been suggested in literature
A single measurement of serum hCG has shown to be not only potentially falsely
reassuring but also unhelpful in excluding the presence of an ectopic pregnancy 292,314'
317 321 323
. In normal pregnancy, an intrauterine sac becomes visible on transvaginal
ultrasound by 33 days of gestation, when serum hCG is 500-1000 U/L. A yolk sac is
visible by day 38, followed by fetal heart motion by day 43 32°. In other words, at 5.5
weeks of gestation, or with a hCG level of 2000 U/L (discriminatory zone), the
sensitivity of ultrasound scanning to detect a normally developing intrauterine
pregnancy reaches 100%. Therefore, when an intrauterine pregnancy is not identified
by transvaginal ultrasound scanning and the hCG level is below the discriminatory
zone, a nonviable pregnancy is diagnosed. Similarly, when serial hCG values do not
rise or fall appropriately, an abnormal gestation is suspected. A review by Lozeau and
Potter (2005) comparing the diagnostic efficacy of commonly used biochemical and
ultrasound parameters for detecting ectopic pregnancy indicated that single levels of
hCG or progesterone have low specificity and cannot differentiate between ectopic
and intrauterine pregnancy, and serial hCG(3 levels that do not increase appropriately
are only 65% specific for the detection of ectopic pregnancy. Whereas combined
transvaginal ultrasonography and serial quantitative hCG measurements are
approximately 96% sensitive and 97% specific for diagnosing ectopic pregnancy,
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therefore making the combined testing approach most optimal and cost-effective
OAO
strategy for diagnosing ectopic pregnancies
Unlike the pattern of hCG rise mentioned above for normal pregnancy, no single
curve is available to identify patients with spontaneous miscarriage or ectopic
pregnancy. Similarly, the expected rate of hCG or the normal decline for spontaneous
abortions and ectopic pregnancy is also not well-characterized. The rate of decline is
dependent on the initial hCG level, which has a mean clearance time of 12- 16 days
324. Standard curves of expected hCG decline for gestations that were later confirmed
to have resulted in complete spontaneous miscarriages showed a rapid rate of decline
in 710 women with higher initial hCG concentrations ranging from 21% to 35% at 2
days, and a slower decline than this value was indicative of an EP wherein
intervention was necessary to exclude this diagnosis . The data presented in Table
20 was suggested by the authors as a rule of thumb to compare the drop in hCG over
324the course of time . The average time for the serum hCG concentration to decline to
less than 15 U/L is 33.6 days but may take up to 109 days depending on the initial
hCG levels 308-315-325.
Initial hCG Week 1 Week 2 Days to hCG
(U/L) <5 U/L
250 93 100 12
500 94 100 13
1000 95 100 14
1500-3000 96 100 15
4000 97 100 15
5000 97 100 16
Table 20 Expected mean % decline in serum hCG levels indicating the higher the initial hCG
value, the faster is the decline in levels.324
Another large study analyzing serial hCG levels in 200 women who were ultimately
confirmed to have ectopic pregnancies showed that 60% of subjects had an initial rise
in hCG, but 40% had an initial fall 31'. The rise in hCG for women with ectopic
pregnancies (75% increase in 2 days) was slower than the mean increase reported for
a viable intrauterine pregnancy. The decline in hCG for women with ectopic
pregnancies (27% decline in 2 days) was slower than the mean reported for completed
spontaneous abortion. However, 20.8% of women presented with a rise in hCG values
similar to the minimal rise for women with a viable gestation, and 8% of women
presented with a fall in hCG values similar to women with a completed spontaneous
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abortion. They concluded that the hCG profile in 29% of women with ectopic
pregnancy can mimic that of an intrauterine pregnancy or a completed spontaneous
abortion and that a "normal" hCG rise (53% increase in 2 days) alone does not
confirm the presence of intrauterine pregnancy. Although these curves aid clinicians
in the prediction of failing pregnancies that may be managed expectantly, a draw back
of these curves is the erroneous diagnosis or misclassification of spontaneously
resolving EP-patients with patients of spontaneous miscarriages, both of which show
a spontaneous decline of hCG to >5 U/L 3I2. Furthermore, a slower rate of rise has
been reported in women undergoing fertility treatment wherein care was advised
while evaluating the change in hCG 248.
Two other entities in clinical obstetrics wherein interpretation of hCG values may
become tricky are: 'heterotopic pregnancy' and pregnancy of unknown location
(PUL). 'Heterotopic pregnancy' is one where an ectopic pregnancy coexists with an
intrauterine pregnancy. The range of occurrence for this type of pregnancy is
estimated between 1:7963 and 1:30000 in the general population, with the incidence
rising to 1 in 100 in pregnancies conceived through IVF treatment 326. This type of
pregnancy is challenge to diagnose using hCG measurements since subnormal
hormone production from ectopic gestation may be masked by the higher placental
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production from intrauterine pregnancy ' . The other phenomenon 'Pregnancy of
unknown location' (PUL) is defined as having a positive pregnancy test with no sign
of a pregnancy on transvaginal ultrasound (TVS). The availability of low-threshold
hCG testing helps in the diagnosis of EP before the rupture, but leads to "inconclusive
ultrasonographic scans" in which the intrauterine pregnancies (IUP) can be missed at
initial stages that are too early to visualize or even in failing process. It is estimated
that 11% to 43% of women who present to an early pregnancy unit are classified as
having a "pregnancy of unknown location" (PUL) 323. The varying prevalence of PUL
might be attributable to the experience of the radiologist, quality of the ultrasound
equipment, prior knowledge of the woman's risks and symptoms and the presence of
323
physical factors such as uterine fibroids and multiple pregnancies and obesity
Four clinical outcomes can be seen in PUL: a failing PUL, an intrauterine pregnancy
(IUP), an ectopic pregnancy (EP) or a persisting PUL wherein there is a plateau in
serum HCG levels without visualization of an IUP or EP 328. It has been reported that
biochemical indices (doubling serum hCG) can be used to predict which PUL become
108
IUP and failing PUL with PPV of 96.6 and 87.5%, respectively. However, these
indices (i.e. a discriminatory zone >1500 U/L and/or sub-optimally rising serum hCG
levels) are is not reliable for predicting PUL that become EP and persisting PUL 328.
Currently, clinicians apply different approaches not only to distinguish between viable
and nonviable pregnancies but also to identify patients at high risk of having an extra¬
uterine pregnancy. The absence of a gestational sac on transabdominal sonography
coupled with a serum level of hCG > 6500 U/L, or the absence of a sac on TVS. with
hCG > 1500 U/L are considered indicators of ectopic pregnancy in 87% of cases,
whereas a complex adnexal mass in the presence of a positive pregnancy test without
a visible sac is highly suggestive of EP in 96.3% of cases 319. Another study
recommended a cutoff level of 2000 U/L in patients without an ectopic mass or fluid
in the pouch of Douglas 32Serum levels of hCG correlate with the diameter of the
adnexal mass because the increased trophoblastic placental bed and vascularity in the
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site of the ectopic gestation allow increased hCG secretion ' . A slight increase in
the risk of tubal rupture was shown if the hCG concentration rises above 1300 U/L
and the ectopic mass diameter increases to > 24 mm . However, another study
looking at the relationship of serum hCG levels in unruptured vs. ruptured tubal
ectopic pregnancies had shown that serum hCG by itself cannot predict whether a
tubal ectopic mass is likely to rupture and there was no safe lower limit in hCG titer
below which ruptured ectopic was not seen
When considering all the above drawbacks, it is clear that an alternate biochemical
marker is required for clinical care and medical diagnosis, the use of which will
facilitate and optimize the care of women, particularly with an undiagnosed
symptomatic first trimester pregnancy. In this study we tested the validity of HhCG
measurements along with other hCG analytes (including their ratios), to see whether it
can reliably detect EP. Levels of HhCG in this study in serum were significantly lower
in 7 women with ectopic pregnancy (median 108 pmol/L; IQR, 62.7- 1027) than in
those with a normal pregnancy (n=137, median=186850 pmol/L, IQ range: 70123-
301922 pmol/L) (Figures 35 and 36). Similar finding was seen in urine samples of
women with ectopic pregnancy (i.e. median=50.8 pmol/L, and interquartile range IQ
of 31.8 -512 pmol/L) when compared with samples from normal pregnancy (i.e.
median=7243 pmol/L, and interquartile range IQ of 1143- 23544 pmol/L).
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Considerable variation in individual patient results was seen in urine in spite of
corrections for the specific gravidity probably indicating that serum levels may be far
better discriminators of EP than urinary concentrations due to the tighter distribution
of values around the median. Serum and urinary levels of hCG showed similar
statistically significant difference between ectopic pregnancy and pregnancies with
uneventful outcome. Serum hCGp was <250 pmol/L in all women presenting with
ectopic pregnancy compared to >500 pmol/L in the vast majority of women with
viable pregnancies. This is consistent with the findings of Holman et al. 330 and
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Borrelli et al. All women with ectopic pregnancies in their study had hCGp
concentrations of less than 1250 pmol/L and 500 pmol/L, respectively. In the current
study the median level of hCGPcf in patients with EP was 191 pmol/L, which is also
far lower than urinary levels in uneventful pregnancy outcome patients. Borrelli et al.
showed that a very high cutoff of 14201 pmol/L for hCGpcf gives 100% sensitivity,
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however this was at the expense of a very poor specificity of 48% . Cole et al.
indicated that no urinary analyte apart from hCGBcf was found to be a good predictor
of ectopic pregnancy, and proposed that hCGBcf could predict up to 84% of all
331
ectopic pregnancies with only 1 % false positives . The study group in this report is
too small to show any statistical difference between the ability of HhCG and other
hCG subunits to discriminate ectopic pregnancy (n= 7) from spontaneous
miscarriages (n= 61). Moreover when performance of HhCG in serum was tested
under the ROC curve (Figure 47), the AUC was 0.74 which according to model
created by Due et al. 217 is ranked as moderately accurate (±) diagnostic test (Table
18). Small number of ectopic pregnancy samples yielded wide confidence interval
(0.5- 0.9) with a very high standards of error, making the findings of HhCG
performance under the ROC curve less reliable. Since women with spontaneous
miscarriages had dramatically lower concentrations of the hCG molecular forms in
this study, similar to those seen in ectopic pregnancies, it is unlikely that these two
entities would be distinguished from one another. A larger study is required to
compare the abilities of HhCG and other hCG molecular forms to differentiate ectopic
pregnancy from spontaneous miscarriage. HhCG, in combination with ultrasound and
other serum markers may be a more useful test for ectopic pregnancy than current
diagnostic algorithms.
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Using a cut-off value of 13 pg/L, measurement of HhCG identified 73% of pregnancy
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failures (miscarriages as well as ectopics) at a 2.9% false positive rate
corresponding to a predictive value positive (PPV or prediction of failures) of 85%.
The same serum cut-off value could predict 100% of EP with a similar PPV. When
HhCG levels were compared with hCG results using the same false positive rate
(15%), hCG detected 43% of failures with PPV of 39% concluding that a significant
improvement in accuracy was obtained by measuring HhCG rather than hCG for the
81detection of pregnancy failures . Applying the value of 13 pg/L (~316 pmol/L) in
the population of current study gave a high sensitivity of 98% but at the expense of
poor specificity of 57%. The performance was poorer in urine (i.e. 90% sensitivity
and 40% specificity) (Figure 47 and Table 25) further confirming the non-reliability
of urinary hormonal measurements for screening tests.
The observation of reduced HhCG levels in serum as well as urine of patients with
ectopic pregnancy compared to normal intra-uterine pregnancy was most likely a
result of reduced secretion of HhCG, due to derangement of trophoblastic division in
patients with ectopic pregnancy 70'100' 106<222-332 Moreover, the sialic content of HhCG
allows it to be more easily degraded by nicking or degradation enzymes in patients
with ectopic pregnancy than in normal pregnant women. Likewise, HhCG may
dissociate faster due to an increased activity of degradation enzymes in urine, and this
may result in urinary levels being lower than the serum levels. It is unlikely that any
of the previous two scenarios is the reason for lower HhCG levels in current study
since hCGPcf, which is an end degradation product of hCG, did not contribute to the
major immunoreactivity in urines of patients with EP when compared with normal
pregnancies.
Not only is the diagnosis of ectopic pregnancy is dependant on hCG values, but its
management is also dictated by serum hCG levels along with the clinical presentation
and transvaginal ultrasound findings. Ectopic pregnancy can resolve spontaneously
through regression or tubal abortion and expectant management is 47 and 82%
effective. However, about 90% of women with ectopic pregnancy and serum hCG
levels greater than 2000 U/L require operative intervention because of worsening
symptoms or actual tubal rupture. There is also the risk of tubal rupture even if serum
308hCG levels are low and/or declining the concentrations fall below 15 U/L .
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Expectant management is said to be more effective when the serum hCG level is
declining and is less than 1000 U/L. Also other criteria such as an ectopic mass of less
than 3 cm, no fetal heartbeat, and patient's compliance for the follow all play role in
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successful expectant management of ectopic pregnancy ' . Patients who do not
meet these criteria are treated surgically, in most cases by laparoscopy. Surgical
treatment is particularly appropriate for women who are haemodynamically unstable;
however 8% of patients have been reported to have signs and symptoms of persistent
ectopic pregnancy following the salpingostomy procedure (i.e. the gestational sac is
removed without the tube) and follow-up hCG determinations are advocated until the
levels in serum become undetectable 333' 334. Medical treatment most commonly
involves Methotrexate therapy (MTX), a folic acid antagonist that inhibits DNA
synthesis in actively dividing cells, including trophoblasts. When administered to
selected patients, it has a success rate of up to 94%. Again, the treatment success is
dependant on the initial hCG concentration; the lower the hCG levels at the time of
treatment initiation, the higher the success rate of methotrexate therapy. A meta¬
analysis of data for 1327 women with ectopic pregnancy treated with MTX confirmed
that resolution was inversely associated with hCG level with treatment success rate of
more than 90% when the initial level is below 5000 U/L. 325.
In summary, a balanced approach is needed to reduce morbidity and mortality from a
nonviable gestation such as an ectopic pregnancy, alongside a more conservative
clinical approach, allowing clinicians to distinguish between a viable and nonviable
pregnancy with a very low likelihood of prematurely interrupting a desired pregnancy.
Ultrasonography is the diagnostic test of choice, with limitations largely based on
availability and the gestational age of the pregnancy. To date, no single-point cutoff
value for hCG has been proposed as a discriminator of ectopic pregnancy. This pilot
study suggests that a single measurement of HhCG (in serum and urine) may provide
information on the fate of a pregnancy that is destined to fail, but no single-point
cutoff could be used to pin point ectopics from spontaneous miscarriages. The study
group in this report is too small to show any statistical difference, and future larger
studies in combination with ultrasound or other biochemical markers are required
using HhCG. Furthermore, serial quantitative measurements of HhCG may prove to




Hydatidiform mole belongs to a spectrum of disorders known as gestational
trophoblast disease. These are rare pre-malignant conditions that also include
persistent invasive mole, gestational choriocarcinoma and placental-site trophoblastic
tumor. Molar pregnancy is the most common form of GTD, with an incidence that
varies from 0.5- 4.6 per 1000 pregnancies, depending on regional, ethnic, and
socioeconomic factors as well as age and parity . The trophoblastic lesions are
characterised by a hydropic (ie. vacuolar) swelling of the chorionic villi, which is due
to the poor development or regression of the villous vasculature that makes the
drainage of fluid supplied by the trophoblast impossible, and by trophoblastic
proliferation 335. Based on gross morphology, histopathological features and
karyotype, it is classified as either complete hydatidiform mole (CHM) or partial
hydatidiform mole (PHM) (Tables 21 and 22).
Cytogenetic
features





46XX (90%) 69XXY (58%)
46XY (10%) 69XXX (40%)
69XYY (2%)





Trophoblast cell type CTB, STB & intermediate CTB & STB CTB, STB& intermediate
Trophoblastic
hyperplasia




Diffuse focal Not present
Table 22 Histopathological characteristics of complete and partial moles and
choriocarcinoma [CTB, cytotrophoblasts; STB syncytiotrophoblasts].335
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CHM is characterised by diffuse hydropic swelling and trophoblastic hyperplasia of
the syncytiotrophoblasts, cytotrophoblasts and intermediate trophoblasts on the
chorionic villous surfaces. Most CHM are cytogenetically diploid, with a 46XX
karyotype derived from the paternal genome 335. The total absence of a maternal
genetic contribution results in unopposed action of paternally expressed genes,
leading to excessive trophoblastic proliferation and a very early cessation of
embryonic development. Hence, no embryonal or fetal tissues can be found in CHM.
In contrast, partial moles (PHM) are almost all "diandric" triploids, with 1 maternal
set and 2 paternal sets of chromosomes; they present with two populations of
chorionic villi, one with normal morphology, and the other with scattered hydropic
villi and focal trophoblastic hyperplasia. The excess paternal genetic dose causes
trophoblastic proliferation but is presumably kept in check by the maternal genetic
contribution, permitting the fetus to develop much further than in complete moles,
• 336 33Vsometimes well into the second trimester
Histologic examination and secondary tests for ploidy or karyotype of the molar and
nonmolar portions of the placenta provide definitive confirmation, though this may be
subject to inter- and intra-observation variations 336. Ultrasound can detect villous
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hydatidiform transformations, but provides no information on trophoblast activity
Furthermore, during the second trimester, the ultrasound picture of placental molar
transformation raises several diagnostic and management dilemmas in differentiating
classical hydatidiform mole from complete mole in a multiple pregnancy, partial
triploid mole, hydropic abortion, and focal benign villous hydatidiform (pseudomolar)
transformation associated with Beckwith-Wiedemann syndrome 338.
15% to 28% of women diagnosed with complete hydatidiform molar pregnancy and
4-9% of women with partial moles are at risk of developing persistent gestational
trophoblastic neoplasia (PTD) (i.e. trophoblastic activity remains after evacuation of
the HM, as reflected by persistent low or even rising hCG concentrations in blood).
These patients benefit from prophylactic chemotherapy, reducing the incidence of
PTD to 4-12% 255. As approximately 1 in 5 of these pre-malignant cases transforms
into gestational trophoblastic neoplasia or choriocarcinoma 235'339, correct diagnosis
of HM and identifying women at risk for developing PTD following their evacuation,
remains a challenge in a clinical setup. In the UAE cohort in the current study, there
were 3 cases of molar pregnancy, of which two were complete and one was partial
mole. Both diagnoses were confirmed by histopathology.
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It is difficult to distinguish the hydropic abortion from hydatidiform mole (diagnostic
tool) and to separate the low risk partial mole from the higher risk complete mole
(predictive tool), using biochemical parameters. However, hCG measurements play an
essential role in the assessment of prognosis following molar evacuation and for
detecting recurrences of disease (monitoring tool). Multiple forms of hCG have been
reported to exist in GTD including 207' 257' 340' 341 and several investigators have
explored the utility of hCG analytes in the management ofGTD. Jauniaux et al. found
that the concentration of hCG and hCG(3 was high (>2.5 MoM) in both complete and
partial moles 338. Berkowitz et al. showed that trophoblastic cells in complete and
partial moles differed significantly in the manner in which they secreted the free
subunits of hCG. Complete moles had significantly higher concentrations of hCGp
and an increased ratio of hCGp to hCG than partial moles, whereas partial moles had
higher levels of hCGa than complete moles along with an increased ratio to total hCG
342. Both the free subunits and their ratios to total hCG were lower in normal
pregnancy than in HM. However these findings were not helpful in distinguishing
persistent disease from non-persistent disease 342. They suggested that the ratio of
hCGp to total hCG represented the extent of differentiation and hyperplasia of the
trophoblast. More promising results based on a larger study by van Trommel et al.
showed that hCGp in serum, and the ratios of hCGG/hCG + hCGG and hCGo/hCGB
were excellent diagnostic tests to distinguish biochemically between hydatidiform
mole and normal pregnancy at a 100% specificity level at more than 90% sensitivity.
However, none of the investigated hCG parameters had adequate diagnostic accuracy
in the prediction of PTD to justify the initiation of prophylactic chemotherapy
r - • 255
treatment for its prevention
The usefulness of hCGPcf in monitoring of patients with GTD was also explored
since evidence was detected of its production by cancer cells in vitro, including
343choriocarcinoma cell lines and in the culture media of hydatidiform mole tissues,
hCGPcf was shown to be a useful tumour marker in cases of metastatic placental site
trophoblastic tumour, when serum hCG levels were near to or below the limit of
detection 234. In another study, serum hCGPcf levels rapidly declined and became
undetectable after uterine evacuation in patients with hydatidiform mole with
subsequent spontaneous resolution, but remained elevated or started to rise before
persistent GTD could be diagnosed by a rise in hCG levels. While it was inferred that
persistence of viable trophoblasts may be detected using hCGpcf, the same study had
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shown that hCGPcf measurements may not be suitable for the follow-up of patients
receiving chemotherapy, since it became undetectable more rapidly than hCG because
of its rapid clearance from the circulation as compared with hCG 344.
The two cases of complete mole in this study had higher levels of HhCG, hCG and
hCGP in serum and urine, which is in agreement with results of Jauniaux et al 338 and
255Van Trommel et al . The reason why higher hCG and hCGp are synthesized in
complete hydatidiform mole than in partial moles or normal pregnancy is unknown,
but altered biosynthesis of hCG and irregularities in trophoblastic differentiation have
Q9 TT8 ^4S ^4f\
been suggested ' Jauniaux et al suggested that placental overgrowth could
explain the increased maternal serum and urinary hCG concentrations whereas the
opposite may be true for partial mole, where fetal overgrowth could overtake
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trophoblastic hyperplasia . Furthermore, both trophoblastic hyperplasia and villous
hydatidiform change are focal and milder in degree in partial moles 243. This further
supports why levels of hCG subunits may be lower in partial moles compared to
complete hydatidiform moles.
Elliott et al. found higher levels of nicking of hCG in cases of persistent trophoblastic
disease (trophoblastic neoplasia) and suggested that nicked hCG may be useful in the
identification of trophoblastic neoplasia l8. Data from a study by Kohorn et al. showed
that at the time of presentation in 45 patients with gestational trophoblastic disease,
more than 80% of hCG was intact and less than 20% was nicked. These proportions
were reversed as hCG declined spontaneously after hydatidiform mole evacuation or
following chemotherapy in patients with post-molar trophoblastic tumour or with
metastatic trophoblastic disease. They concluded that the proportion of hCGn
compared to hCG increased with the resolution trophoblastic disease. However they
also inferred that measurement of hCGn did not seem to have additional clinical value
in those few patients who had reappearance of their trophoblastic tumour as measured
by an increase in total hCG immunoreactivity after an apparent disappearance of hCG
to negative levels 119. Nicking leads to rapid dissociation of hCG and HhCG, releasing
hCGPn. In cases of trophoblastic disease and other hCG-producing tumors (testicular
cancer and other germ cell malignancies), when hCG results fall below 100 U/L, the
combination of nicked hCG and its dissociation product, hCGPn, become the major or
sole sources of hCG immunoreactivity 347. Considering the heterogeneity of hCG
analyter in gestational trophoblastic diseases it is essential to use an hCG test that
measures all forms of hCG and its free subunits as cases have been reported in which
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a recurrence of invasive disease or persistence of a hydatidiform mole have been
completely missed using an assay that does not detect nicked hCG or free p-subunits
341
In most of the centres, hydatidiform moles are evacuated as soon as possible using
suction curettage, and hCG is monitored on a weekly basis in order to diagnose
metastatic sequelae as early as possible 348' 349. A plateau or rise in hCG levels
indicates persistent disease and the need for chemotherapeutic management. Complete
remission is typically declared if the hCG level spontaneously declines to
undetectable levels and remains there during a 6-month follow-up period 349.
According to FIGO (Federation Internationale de Gynecologie et d'Obstetrique)
guidelines in 2000, the diagnosis of post-hydatidiform mole trophoblastic neoplasia
should be considered when any of the following is observed 349:
1. A plateau of hCG is observed over a period of 3 weeks or longer, i.e. for Days 1,
7, 14 and 21.
2. A rise in hCG level is observed for three consecutive measurements or longer,
over a period of at least two weeks or more, i.e. on Days 1, 7 and 14
3. There is histological diagnosis of choriocarcinoma
4. hCG level remains elevated for 6 months or more
It is however important to exclude the possibility of heterophilic antibody interference
[see Section 1.1.15.1] which may lead to inappropriate treatment if not recognized.
There are also guidelines for risk-factor scoring and a staging system that classifies
untreated patients into distinct prognostic categories (high-risk or low-risk) so that
treatment outcomes can be objectively compared. However, there is lack of
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uniformity in the use of these staging and scoring systems ' . In an effort to
establish hCG levels that were predictive of outcome, several investigators have
evaluated hCG regression curves post-evacuation to determine whether patients will
go on to have persistent disease or go into remission 348. However several centres
recommended prognostic scoring systems, that were different from the others, are a
result of differences in the study methods, treatment selection criteria, treatment
regimens and outcome measures. Hence a universally accepted hCG regression curve
like those available for ectopic pregnancy and miscarriage is unavailable 350'351. The
decline in hCG levels after molar evacuation has an underlying biologic basis.
Women with molar pregnancies who have trophoblastic tissue confined to the
endometrial cavity are likely to have a rapid fall in their hCG level after the
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trophoblastic tissue is removed at surgery and are at a low risk of developing
persistent disease. In contrast, women whose trophoblastic tissue has invaded the
uterine wall, or metastasized beyond the uterus, will have a slower fall in their hCG
level after surgery due to the presence of the residual hCG-producing tissue and are
probably at a higher risk of developing persistent disease. A slow decline in hCG
levels after molar evacuation may, therefore, reflect the presence of invasive or
metastatic trophoblastic tissue
The new FIGO 2000 staging system combines anatomical staging and a modified
WHO prognostic risk score, for stratifying patients into a low- or high-risk group and
has suggested investigations for metastatic surveillance 349. The system is a step
forward in unifying the diagnostic and prognostic modalities between centres for the
management of GTD, however the performance of this system in different clinical
setups needs to be field-tested to see if such a goal has been achieved or not.
Surveillance of the hCG levels remains the primary tool for clinicians to appropriately
manage and treat GTD. While the prognostic risk score according to the new FIGO
2000 staging system stratifies low-risk group with the pretreatment level of hCG to be
less than 1000 U/L (i.e. score 0) and high-risk group have pretreatment level of hCG
to be less than 100000 U/L (i.e. score 4), yet there remains a grey area between low-
risk and high-risk groups. Since HhCG is only produced by invasive cytotrophoblast
cells during early pregnancy and by malignant forms of gestational and non-
gestational neoplasms, its presence is considered to be a significant virtual marker of
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ongoing invasion and malignancy ' ' ' .
Khanlian et al. evaluated 114 patients referred to the USA Reference Service with
persistent low levels of hCG. Based on their findings, 45% of cases were found to
have false-positive hCG results caused by interfering antibodies and the remaining
55% (63 patients), had real persistent low-level hCG titres (usually <50U/L) 20°. After
prolonged surveillance of these low hCG titres, they found that the levels persisted
despite chemotherapy or surgical interventions, and HhCG accounted for less than
21% of total hCG immunoreactivity amongst these women. However, in four cases
that experienced abrupt and steep rises of persistent low serum hCG concentrations,
HhCG accounted for 81%-100% of the detected hCG immunoreactivity and
trophoblastic malignancy was confirmed pathologically. They further analyzed stored
serum samples from women with confirmed gestational trophoblastic neoplasms and
found that in all cases, HhCG immunoreactivity exceeded 30% of the total hCG
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immunoreactivity. Their results lead to the conclusion that HhCG measurements may
be used to differentiate preinvasive gestational trophoblastic disease with low hCG
titres (quiescent GTD) from malignant disease 200. Several subsequent reports from
the USA Reference Service indicated similar results and showed that HhCG was a
reliable marker to distinguish quiescent GTD from invasive disease 175' 235' 339.
However, the confidence of the USA Reference Service was not shared by two recent
consecutive studies, by Due et al 217 and Van Trommel et al 75. In another study, a
retrospective analysis of HhCG as a tumour marker for the prediction of PTD prior to
the evacuation of molar pregnancy using receiver-operating characteristics (ROC)
curve analysis showed that the diagnostic accuracy of HhCG was only moderate and
no different from that of hCGP and total hCG. Hence, it was inferred that HhCG and
other hCG parameters tested had limited diagnostic accuracy for the prediction of
217
subsequent development of persistent GTD . In the second study, the time course
and disappearance rate of HhCG following the evacuation of moles was compared
longitudinally with total hCG (hCG +hCG|3) in serum samples from 3 groups
comprising uneventful post molar regression, patients who developed GTD and were
managed with mono-chemotherapy, and patients developed GTD and were managed
with poly-chemotherapy 75. They found significantly longer mean serum half-lives for
total hCG and HhCG in the poly-chemotherapy group as compared to the mono¬
chemotherapy and the uneventful regression groups. However no significant
differences were observed between the mono-chemotherapy and the uneventful
regression groups. Since significantly shorter mean half-lives for HhCG than for total
hCG were observed in all three groups of patients, they questioned the use of HhCG
as a tumour marker due to its rapid clearance from the circulation, and suggested that
it may not be suitable for following up patients after molar evacuation or who are
receiving chemotherapy.
Clearly, identifying patients at increased risk for developing PTD after evacuation of
hydatidiform mole is of great importance. It is challenging to find an adequate pre-
evacuation diagnostic test that establishes a patient's risk of developing persistent
GTN or of achieving remission within a few weeks of molar evacuation, or that can
reduce the interval between the diagnosis of molar pregnancy and the diagnosis of
persistent disease, and so allow initiation of chemotherapeutic management for
specific high-risk groups whilst reassuring women who are at low risk of persistent
disease. HhCG may be a promising candidate that can differentiate invasive from
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noninvasive disease, since it is only produced by the invasive trophoblast cells 70'244.
However, because of conflicting findings in the literature, the value of HhCG
measurements in predicting PTD needs to be further established in larger prospective
trials.
3.7.2 Hyperemesis gravidarum
3.7.2.1 Background to the condition of hyperemesis
Nausea and vomiting in pregnancy is a mild form of hyperemesis gravidarum, and is a
common problem affecting 50% to 80% of all pregnancies within the first 4-12 weeks
of gestation. It is characterized by episodic vomiting that is more pronounced in the
morning (morning sickness). It is prevalent during the first trimester of pregnancy
when both the placenta and the corpus luteum are actively secreting hormones and the
body is adapting to the pregnant state, but also can be seen in approximately 9% of
patients continuing beyond week 20 of gestation 353. Between 0.3% and 2% of
pregnant women develop hyperemesis gravidarum, which is characterised by
intractable nausea and vomiting leading to fluid, electrolyte and acid-base imbalance,
nutritional deficiency and weight loss often severe enough to require hospital
admission hence compromising activities of daily living l69-353.
Hyperemesis is associated with positive pregnancy outcomes such as a lower risk of
spontaneous miscarriage, but has also been linked to adverse obstetric outcomes such
as lower infant birth weight and fetal death 354' 355. The data in the literature are
conflicting. However, since excessive vomiting may cause nutritional deficiencies,
maternal weight loss, fluid and electrolyte imbalances, concerns are raised about
possible adverse perinatal outcome which has been the basis of extensive research.
Many different factors have been considered as a cause of hyperemesis gravidarum,
including endocrine factors, hepatic dysfunction, changes in lipid metabolism,
immunological factors, defective mesenteric nervous control affecting gastric
emptying; nutritional deficiencies and psychological factors, but consensus the exact
aetiology has not been reached l69-356. Due to the close temporal relationship between
peak maternal hCG levels and peak occurrence of nausea and vomiting symptoms,
TS7 TSQ
hCG is often stated as the most likely cause of hyperemesis gravidarum " .
Conditions such as multiple gestations, trisomy 18 and hydatidiform mole are
characterized by higher production of hCG levels and are more commonly associated
with hyperemesis gravidarum
120
Structurally, hCG is related to TSH, LH and FSH except that hCG contains a carboxy-
terminal portion not shared by others l7'90. Because of its structural similarity to TSH,
hCG is considered to stimulate the thyroid gland during pregnancy. Acidic molecular
forms of hCG have more thyrotrophic activity than hCG. The degree of biochemical
hyperthyroidism as measured by thyroid stimulating hormone suppression correlates
closely with the severity of nausea and vomiting of pregnancy
The rapid increase in HhCG concentrations in the early part of first trimester may be a
factor in, or an early marker of, hyperemesis gravidarum. Therefore in this study, we
investigated the association between hyperemesis gravidarum and HhCG levels (both
in serum and urine), to see whether any such associations exist.
3.7.2.2 Methods used to assess hyperemesis in the UAE cohort
In a cohort of 137 patients recruited in the UAE with term delivery and no adverse
obstetric or perinatal complication, 31 had hyperemesis (22.6%) (Study group). As all
pregnant women admitted with hyperemesis gravidarum were at or below 14 weeks of
gestation, they were compared with 66 healthy pregnant women without hyperemesis
gravidarum of similar gestational age (< 14) who also had term delivery and no
adverse pregnancy effect (Control group). Pregnant women in the first trimester who
could not take oral nourishment, had ketones in their urine and vomited at least four
times a day were included in the study group. The inclusion criteria included
persistent vomiting in the first 14 weeks of gestation, with ketonuria (2+ or more) (10
mg/ml) on dip stick examination requiring admission to the hospital. The data were
analyzed for statistical significance using the student t-test (or the Mann-Whitney U-
test when non-parametric data were involved) and significance was set at P<0.05.
The 6 hCG analytes were compared in two groups with respect to age, ethnicity, BMI,
parity, gestational week on admission, and delivery outcome. Chi-squared tests have
been used to determine if there is any association between these variables and the
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Table 23 Demographic characteristics of the study group and their association with HG. S=
statistically significant p<0.05, NS=non-significant. Note that the number of N in each group
does not represent the total number of cases in the HG- and non-HG group, due to missing
data. [HG, hyperemesis gravidarum],
3.7.2.3 Results for the UAE hyperemesis cohort
The average gestational age at admission for the hyperemesis group was 8.4 weeks
and there was no significant difference in the characteristics of the two groups in
relation to presence or absence of hyperemesis. However, the only evidence of
association was seen for the BMI group; with the association of hyperemesis
gravidarum in pregnant women with higher BMI (i.e. >25) (Table 23).
The level of HhCG in serum and in urine was higher in the hyperemesis group than in
the non-emesis group, as was hCG in serum as well as urine and serum hCGp. All
measurements, apart from hCGpcf showed a statistically significant difference
(Figure 50-53, Table 24).
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Figure 51 Urinary HhCG levels of women with HG (•) vs. no HG (•).
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HG = No HG =Yes 95% CI for
difference
P-
valueN Median N Median
Serum
hCG 66 204403 31 289633 (-152011, -37518) 0.003
hCGp 66 1671.3 31 2285.2 (-1536.6, -223.2) 0.008
HhCG 66 24277 31 33673 (-22072, -1204) 0.032
Urine
hCG 66 90984 30 187154 (-146443, -29273) 0.002
hCGPcf 66 206069 30 362669 (-248188, 23747) 0.165
HhCG 66 10172 30 24479 (-18373, -2966) 0.006
Table 24 Levels of HhCG and other hCG molecular forms showing statistical significance.






















Figure 52 HhCG and other hCG subunit levels in serum and urine (0= Non-hyperemesis and
1= hyperemesis). Data includes maximum hormone levels. [IntactS, intact hCG (serum);
hCGpS, hCG beta-subunit (serum); HhCGS, hyperglycosylated hCG (serum); IntactU, intact
hCG (urine); hCGpu, hCG beta-subunit (urine); HhCGU, hyperglycosylated hCG (urine);
HG, hyperemesis gravidarum.] [Median, inter-quartile range (box) and 10th to 90th centiles
(whiskers) plotted. All asterisks indicate values outwith the whiskers.]
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Figure 53 HhCG and other hCG subunit levels in Serum and urine (0= Non-emesis and 1=
Emesis). [The maximum concentration for hCG[3cf (coded hCG[3u) in the graph was
>10000000. The upper value therefore does not appear in the above graph.] [IntactS, intact
hCG (serum); hCGflS, hCG beta-subunit (serum); HhCGS, hyperglycosylated hCG (serum);
IntactU, intact hCG (urine); hCG[3U, hCG beta-subunit (urine); HhCGU, hyperglycosylated
hCG (urine); HG, hyperemesis gravidarum.] [Median, inter-quartile range (box) and 10th to
90th centiles (whiskers) plotted. All asterisks indicate values outwith the whiskers.] [Median,
inter-quartile range (box) and 10th to 90lh centiles (whiskers) plotted. All asterisks indicate
values outwith the whiskers.]
3.7.2.4 Discussion of hyperemesis in the UAE cohort
Many endocrine factors have been hypothesized to be involved in the pathogenesis of
hyperemesis gravidarum, including hormones of placental origin. It is not known if
hCG directly or indirectly participates in the triggering of vomiting but several
theories have been suggested.
Because of its structural similarity to TSH, increased hCG levels can cause excessive
stimulation of the thyroid gland. It has been suggested that the high incidence of
transient hyperthyroidism amongst patients with HG is caused by elevated circulating
hCG levels either through triggering the thyroid hormone receptors hypersensitive for
hCG or the production of a type of hCG that is more potent in stimulation of the
thyroid gland ' ' . During peak HCG levels in normal pregnancy, serum TSH
levels fall and are a mirror image of the HCG peak. Free triiodothyronine (T3) and
(T4) levels are significantly elevated at this time 169-358. Several reports show that free
T3 or T4 levels are significantly elevated at the time when hCG levels are maximal. In
a review investigating the relation between hCG and hyperemesis gravidarum that
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compared circulating hCG levels in hyperemesis gravidarum patients, 23 studies were
identified in a literature search between 1968-2004 l69. 11 out of 15 studies published
showed a significantly higher level of serum HCG in hyperemesis gravidarum
patients than in controls. Patient who had hyperemesis gravidarum had higher phCG
concentrations and more heavily suppressed TSH. The highest suppression occurred
TCQ
during 9-13 weeks of gestation . A prospective study of 57 consecutive patients
with hyperemesis in Los Angeles compared hyperemesis patients with 57 women of
similar gestational age 362. Amongst hyperemesis patients, TSH was suppressed in
60%, free T4 was increased in 46%, while the free T3 index was increased in only
12%. Serum hCG levels were three-fold higher in the hyperemesis patients than in the
controls. For the entire group, the degree of biochemical hyperthyroidism and the
hCG concentration correlated with the severity of vomiting. An inverse correlation
between the serum hCG and the serum TSH levels and a direct correlation of hCG
with free T4 levels, has also been found 358'362. All of the above findings imply that
hCG plays an important role in causing hyperthyroidism and is further supported by
the finding of presence of thyroid hyperstimulation in cases of conditions with
extremely high levels of hCG such as hydatidiform mole and multiple gestations 169'
360. In a rare condition of hyperplacentosis, in which the placenta is enlarged and hCG
concentration is very high, clinical hyperthyroidism has shown to remit promptly after
358
delivery of the placenta . In vast majority cases of hyperemesis gravidarum, the
increased thyroid function spontaneously remits when the vomiting stops, usually
during the later half of pregnancy 358, hence anti-thyroid drug therapy not required.
Although some patients with hyperemesis, having frank clinical hyperthyroidism
known as 'gestational thyrotoxicosis', may benefit from the treatment
The rate of hyperemesis in pregnancy has been difficult to estimate. As many as 30%
of all conceptions are thought to be lost before 24 weeks and 20% of these are not
even clinically recognized, most databases exist at present as the ratio of hyperemesis
to live births, rather than a ratio of hyperemesis to pregnancy rate. Also, many women
have nausea and vomiting during their pregnancy that is considered normal and is
treated as an outpatient. In Mafraq Hospital, all cases of hyperemesis gravidarum are
first given anti-emetics as well as IV fluids in the A/E department. If electrolyte
imbalance persists they are then admitted to the antenatal ward. Hence, only clinically
meaningful hyperemesis, i.e. hyperemesis that was severe enough to require hospital
admission, could be captured. In spite of not including out-patients, the rate of
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hyperemesis in our hospital was 6.2% (62/1000 delivery). This is higher than
previously published reports of hyperemesis gravidarum (0.3%- 2%) 169'353 but it is in
agreement with the findings in a Kuwait population, where an incidence of 4.5% has
been reported. This is in accordance with reports that hyperemesis gravidarum is
associated with low maternal age, primigravidity and high maternal weight 364.
Furthermore, the effect of long-term environmental factors or genetic influences has
been explained for the differences in incidence of hyperemesis gravidarum between
populations. A higher incidence of hyperemesis gravidarum has been observed in
New Zealand Pacific Island women, United Kingdom Indian and Pakistani, Asian and
African American women compared with ethnic European women, and lower
358incidences are found in American Indian and Eskimo populations
Except for the hCGPcf, increase in the concentrations of all hCG forms in serum as
well as urine in women with hyperemesis was found in this study (Figure 50-53 and
Table 24). This may be secondary to excessive trophoblastic secretion by the
expanding trophoblasts during the first trimester 70-222-252'257 As the levels of hCG in
urine reflect renal excretion of circulating serum hormone into the urine either directly
or after being metabolised in the kidneys 110>3445 it is possible that in hyperemesis
gravidarum, the hCG produced is more resistant to degradation. Indeed, an alternate
hypothesis for the appearance of transient hyperthyroidism during pregnancy suggests
that hyperemesis gravidarum could be caused by a variant of hCG with increased
thyroid stimulating activity rather than the absolute amount of hCG. This was
supported by the finding that the hCG fraction containing asialo-carbohydrate chains
was significantly increased in a population of hyperemesis gravidarum patients with
gestational thyrotoxicosis compared with a control group of pregnant women with no
ire
emesis . In addition, extensive variations in the sialic acid content of
oligosaccharide side chains has shown to contribute not only to considerable
heterogeneity of hCG, but also affects the biological activity of the hormone. It may
be possible that hCG molecular forms produced in hyperemesis gravidarum have a
higher sialic acid content which is known to protect the galactose residues of the
carbohydrate chains from metabolic degradation by neuraminidases, resulting in less
metabolic breakdown, hence, no difference in the concentrations of hCGPcf was
found in this study between the hyperemesis and non-hyperemesis group l27' 366.
Indeed, hCG in serum from early pregnancy as well as from tumor patients, are often
highly acidic 2 '47>50 and studies indicate the acidic variants exhibit a dose-dependant
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stimulation of T3 release and cAMP generation from human thyroid slices, hence act
as functional stimulators of the human thyroid in vitro . The evidence of significant
increase in hCG fraction containing asialo-carbohydrate chains amongst hyperemesis
gravidarum patients with gestational thyrotoxicosis compared with a control group of
pregnant women with no emesis, further supports that presence of certain molecular
forms of hCG, rather than an increase in the absolute hCG concentration, is
responsible for the thyrotrophic activity, hence, nausea and vomiting during
pregnancy . Evidence of potent thyrotrophic activity of asialo-hCG in animal as
iro
well as human bioassays, has also been shown ' . While it is not possible in
current study to ascertain this hypothesis since the differences in sialylation do not
affect the overall reactivity of hCG in the immunoassay system or its detection by
poly- and MAbs 47. However, since HhCG, found in abundance in choriocarcinoma
and during first trimester of pregnancy, also varies in its sialic acid content 18,64j from
the above presented arguments, it may be possible that HhCG may be responsible for
hyperemesis gravidarum during pregnancy. Whether the action is through direct
stimulation of thyroid axis or possibly via any other biologic effect, is yet unknown
and should be a topic of further investigation.
3.7.3 Late pregnancy complications
Many pregnancy complications occurring late in gestation may have their origin very
early in gestation, associated with abnormal placentation. A considerable proportion
of pregnancy outcomes such as proteinuric and non-proteinuric pregnancy-induced
hypertension (PIH), FGR, preterm labour, and stillbirths are associated with abnormal
levels of hCG and other placental markers. There has been much debate in literature
whether these are related or independent conditions, but most agree that they share
some similar risk factors and are associated with high maternal and fetal-neonatal
consequences 369. Hypertension complicates approximately 9% of all pregnancies,
with pre-eclampsia occurring in approximately 2% of pregnancies. World wide, 40
000 women die each year with hypertensive complications, with eclampsia
contributing 2% to maternal mortality and 8% to fetal mortality 370. According to the
confidential enquiry into maternal deaths in the United Kingdom between 2000 and
2002 (Why Mothers Die, 2004), hypertensive disorders of pregnancy were second
only to thromboembolism, accounting for 14 deaths (i.e. 8 maternal deaths from pre-
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eclampsia and 6 from eclampsia)304. The incidence of FGR is increased 2- to 3-fold in
women with hypertensive disorders, and the severity of hypertension correlates
directly with the presence of FGR. Epidemiological studies even suggest that size at
birth is related to the risk of developing disease in later life, particularly increased risk
of coronary heart disease, diabetes, hypertension and stroke in adulthood 37l~374.
Another important cause of neonatal mortality and morbidity with possible long term
adverse effect later in life is preterm delivery. The reported incidence in the USA is
11%, 5%- 7% in Europe and approximately 7% in the UK 375'376. Estimates of
preterm birth in developing countries have shown even higher rates (up to 25%),
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reflecting the geographic differences in the magnitude of problem " . Preterm birth
is a major public health concern because prematurity accounts for approximately 56%
cases of neonatal mortality and almost half of long-term birth-related neurologic
-57c
morbidity
An increase of 17% in the rate of preterm birth was recorded in the USA between
1980 and 2000 with similar increases in other countries such as Canada and UK 378.
Although much of the increase is attributed to the rise in multiple births as a
consequence of assisted conception techniques, improved identification of at-risk
pregnancies, closer monitoring of the fetus and earlier intervention may also have
contributed to the increase. Coincidental with the increase in preterm birth has been a
marked reduction in neonatal mortality: for England and Wales, neonatal mortality
fell by 54% between 1975 and 1988 and by a further 20% between 1988 and 2000. As
a consequence of improved survival, the proportion of children with cerebral palsy
-270
and other neurodevelopment problems who were born preterm has increased
As discussed in chapter 1, many causes (i.e. genetic, nutritional, immunologic, and
infectious) and their pathologic mechanisms (i.e. abnormal placentation, oxidative
stress, and endothelial dysfunction) have been proposed, but due to the heterogeneous
nature of the pathology of late pregnancy complications, prediction before the onset
of signs and symptoms has been a challenge, with no single method being completely
satisfactory. In a series of 5776 pregnancies, Muller et al.379 showed maternal serum
hCG (MoM) was higher in patients with small-for-gestational-age neonates and pre-
eclampsia and his earlier report showed, in addition to chromosome abnormalities,
those with a hCG above the 95th centile were found to be at increased risk of
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miscarriage, pre-eclampsia and premature rupture of the membranes. In one study
serum hCG levels below the < 10th percentile in the first trimester was associated with
miscarriage, gestational hypertension, growth restriction, and gestational diabetes 299,
and in another large study, a significant increase in PIH, preterm delivery, miscarriage
and intrauterine fetal death but not in FGR, oligohydramnios or abruptio placenta was
demonstrated 381. Walton et al. 382 demonstrated that elevated hCG was associated
with higher rates of stillbirth, PIH and preterm delivery, where as Basirat et al showed
mean third trimester phCG levels in pre-eclampsia were higher compared to normal
383controls . Similar observations were seen using other hCG molecular forms such as
a-subunit of hCG 191'222, urinary hCGpcf and nicked hCG 125-223<384.
Given the apparent association in the literature between abnormal hCG levels and
adverse pregnancy outcome, we sought to evaluate whether first and second trimester
levels of HhCG were also predictive of adverse outcome. If diseases occurring later in
gestation originate from common patho-physiology of placental insufficiency and
inadequate placentation, then the levels of placental hormone (including HhCG) may
be altered. In group 1 of the UAE study population, consisting of 217 pregnancies
continuing beyond the 24 weeks of gestation, 199 had a term delivery of which 137
were uneventful term delivery with no complication throughout pregnancy. The
remaining 80 pregnancies were associated with adverse pregnancy complications
including: proteinuric and non-proteinuric PIH, FGR, spontaneous preterm delivery,
gestational diabetes, ante-partum haemorrhage, amniotic fluid index abnormality,
intra-uterine death and neonatal death (Table 10), occurring either as isolated
conditions or in combination with other pregnancy complications.
In contrast to the low levels of HhCG, HCG, and hCG in serum, as well as HhCG,
hCG, and hCGpcf in urine seen in cases of spontaneous pregnancy ending before 24
weeks of gestation, levels in late pregnancy complications remained unchanged
indicating their poor predictive value in detection of adverse pregnancy outcomes of
later gestation (Figures 44 and 45). This finding is in agreement with many previous
reports showing poor associations of urinary and serum hCG levels with adverse
pregnancy complications. A study including 1,622 consecutive singleton pregnancies
undergoing first trimester testing for Down syndrome showed lower levels of hCGP
associated with a higher incidence of spontaneous miscarriage, but this was a poor
predictor of other pregnancy complications including, pre-eclampsia, preterm birth,
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236FGR etc . Another larger study comparing 26,524 unaffected pregnancies with
3,728 pregnancies affected by low birth weight, FGR, preterm delivery and stillbirth,
found that raised hCGB was not associated with an increased risk for any of the
9o,
pregnancy complications investigated , and there are many other examples in the
literature showing that the levels of hCG and hCG-related molecular forms do not
predict the development of late pregnancy complications 224'239'240'242'385. Flowever,
data regarding the usefulness of HhCG in the prediction of late pregnancy
complications is scarce. As HhCG is secreted by invasive stem cytotrophoblast cells
70,72,244^ most studies so far have focused on looking at its levels to determine early
/re fL~i Z:Q oi TO/:
pregnancy outcome and identify pregnancy failures ' ' ' , in the detection of
Down syndrome pregnancies (which are known to be associated with poor trophoblast
differentiation) 79'80' 129'201-251'387-3895 an(j as a tumor marker for malignant or invasive
gestational trophoblastic disease, to discriminate active from quiescent disease, and
assess the need for chemotherapy 72'74'75'175'217'260'341' 39°. Only one previous study
involving 568 spontaneous pregnancies undergoing mid-trimester genetic
amniocentesis showed a significant correlation between low urinary HhCG levels and
subsequent development of pre-eclampsia 71. The current study failed to confirm this
result as no statistically significant difference was found between the levels of HhCG
and hCG-related molecular forms in uneventful pregnancy and pregnancy associated
with hypertensive disorders. These data included 11 women who became
hypertensive for the first time in the 20th week of pregnancy (pregnancy induced
hypertension) and 9 women who had pre-existing essential hypertension. In the
former group, 4 women (36%) developed pre-eclampsia (proteinuric PIH) and 33% of
the women with pre-existing hypertension developed proteinuria (superimposed pre¬
eclampsia). For analysis, women with superimposed pre-eclampsia were considered
together with the proteinuric- and non-proteinuric- PIH group, and essential
hypertension was included with other medical disorders such as DM and thyroid
disorders for analysis. This classification methodology may itself lead to a flawed
result due to non-segregation of severe cases from the milder ones or early-onset
disease from late ones, or by failing to take into account demographic variables
known to be confounders of adverse pregnancy. Not only were the maternal and fetal
outcome variables different within the syndrome of hypertension of pregnancy, but
OQI
the underlying etiopathological mechanisms are thought to be different ~ . It is
well recognized that first pregnancy, pre-pregnancy weight, previous history of
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obstetric complications such as miscarriage, preterm and pre-eclampsia, chronic
hypertension, and insulin-dependent diabetes mellitus, are all risk factors for the
development of pre-eclampsia-eclampsia, all of which may be maternal triggers for
the genesis of hypertensive disorders and which should therefore be separated from
the placental genesis which is caused mainly by reduced placental perfusion 394.
Early onset of pre-eclampsia is associated with a higher risk of perinatal morbidity in
subsequent pregnancies. Lopez-Llera and Horta examined 110 women in whom the
onset of eclampsia was divided into gestational age ranges of less than 35 weeks, >35
to 38 weeks, and >38 weeks. With earlier onset during pregnancy, recurrent pre¬
eclampsia and small-for-gestational-age (SGA) infants in subsequent pregnancies
were more common (42%, 15%, and 10% of infants were SGA in the three groups)
395. Similarly, Sibai et al. showed that earlier-onset disease in first pregnancy was
associated with more frequent perinatal death in subsequent pregnancies.
Perinatal mortality rates were likely to be four times higher extremely poor in the pre¬
eclampsia group compared to those groups with non-proteinuric gestational
hypertension and chronic hypertension
An immunopathological study on the placenta from women with hypertensive
disorders showed no positive staining for a- and P-subunits of hCG in the syncytio-
cytotrophoblast of placentas from mothers with spontaneous hypertension, and only
weakly positive staining in mild pre-eclampsia. However, positive staining for hCG
was seen in placentas obtained from severe pre-eclamptic cases 397. Indeed, a recent
immunostaining study of placentas from pre-eclamptic patients also confirmed a
generalized increase in the secretory activity of the syncytiotrophoblasts 99. Many
clinical studies have confirmed that the severity of the disease is associated with
altered placental hormonal levels. Lee et al. 398 demonstrated that midtrimester hCG
levels were significantly correlated with the severity of pre-eclampsia, as women with
mild pre-eclampsia had two and a half times greater chance, and women with severe
pre-eclampsia had a six-fold greater chance of having hCG exceeding 2.0 MoM.
Underlying maternal diabetes and hypertension adversely affect perinatal outcomes,
but pre-eclampsia superimposed on these maternal disorders has even greater adverse
perinatal consequences. Caution is needed before pooling data into specific groups, as
the presence of a mixture of disorders may lead to difficulties in analysis and produce
heterogeneous and non-specific results. A systematic review by WHO evaluating pre-
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eclamptic screening methods in use from 1996 to 2003 showed that the majority of
screening tests (including hCG) have low predictive potential 399.
During normal implantation and the early stages of placental development, the
cytotrophoblasts proliferate and invade rather than differentiate, under the influence
of relatively hypoxic conditions, causing a rapid increase in placental mass than the
embryonic lineages. Failure of endovascular invasion and inability of the
cytotrophoblast to invade to the appropriate depth has been linked with spontaneous
miscarriage, pre-eclampsia, and FGR181"183. Thus, from a biological stand point,
obstetric complications that are associated with inadequate trophoblastic invasion
during the first trimester may be associated with low placental hormone levels. The
finding of low urinary levels of HhCG by Bahado-Singh et al. amongst the pre¬
eclamptic group, may be explained by the involvement of similar mechanism 71.
Conversely, the pathophysiological mechanisms discussed in chapter 1, existing alone
or in combination with one another, may lead to elevations in the maternal circulatory
placental hormone. The compensatory response due to the reduced blood supply,
leading to reactive hyperplasia of cytotrophoblastic cells in an environment of low
1 o 1 ioi
oxygen tension " , along with aberrant morphological changes in the placenta
leading to abnormal trophoblastic secretory response and hyperplasia of
1 Rfi 1QO
cytotrophoblast without the formation of syncytiotrophoblast " may all lead to an
increase in the levels of hormones produced by the cytotrophoblast such as HhCG.
Another plausible mechanism by which levels of placental hormones may be
increased is that abnormal/altered hormone metabolism and excretion, (either due to
active degradation as a result of nicking and dissociation or due to conformational
changes of the placental hormone) lead to rapid clearance. A significant increase in
urinary hCGPcf levels in the pre-eclamptic group has been attributed to the activity of
Elastase from leukocytes around the trophoblastic tissue which increase in pre¬
eclampsia and trophoblastic disease, leading to increased nicked levels of hCG which
125 257 384 400
readily dissociates, releasing free a-and P-subunits and hCGpcf in urine '
The oligosaccharide structure of glycoprotein hormones is important not only for
folding, assembly and signal transduction, but also for heterodimer secretion and
33metabolic clearance . The carbohydrate side chains, each ending with a sialic acid
residue, stabilize the hormone, decreasing the dissociation rate and increasing the
circulatory half-life 18' 123. Differences in terminal sialylation between normal and
1 R
aberrant pregnancies have been found and the glycosylation pattern is affected by
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the activity of different oligosaccharide-processing enzymes such as sialyl- and
glycosyl-transferase, which have been shown to be altered in conditions associated
with poor vascular supply such as pre-eclampsia 401, gestational diabetes 18,
chromosomally abnormal pregnancies 401 and choriocarcinoma 35' 402. In diabetic
pregnancy, sialylation of both N- and O-linked oligosaccharides is significantly
decreased compared to normal pregnancy l8, and in pre-eclampsia, the bioactivity of
serum hCG was lower than in normal pregnancy, however, immunoreactivity tended
to be higher 403. When Frendo et al. studied hCG glycosylation in cultured trophoblast
cells from second-trimester control- and trisomy 21 (T21) affected-placentas, they
found abnormally glycosylated, highly acidic and weakly bioactive molecular forms
of hCG were synthesized by T21 placental cells. Fucosyl-transferase-1 and sialyl-
tranferase-1 transcripts were also abnormally high in T21 trophoblasts 40In another
histopathological study, in choriocarcinoma cell lines formation of abnormal
biantennary sugar chains of HhCG was shown to be due to high N-
acetylglucosaminyltransferase-IV (GnT-IV) activity 35'402.
The basic pathology of gestational diabetes remains unclear and debate continues over
whether gestational diabetes represents a pregnancy-induced state of glucose
intolerance or only the exacerbation of a pre-existing insulin resistance that would
become evident in the future regardless of pregnancy 404. There is no consensus on
selective screening for GDM in different populations, nor is there universal agreement
on diagnostic testing procedures. There is even uncertainty about the merits of its
early detection and intervention, as the associated maternal and fetal consequences are
less profound than in pregnancies with hypertensive disorders 405-407. it is known that
risk varies in different countries and in women belonging to certain ethnic groups,
such as Asians and South Asians who exhibit a higher risk of developing GDM 2'406.
In the current study from the UAE, 10.6% of the "continuing-pregnancy" group had
pregestational diabetes and 6.4% developed GDM (controlled by diet or insulin)
during pregnancy. This is in agreement with previous studies showing a high
prevalence of diabetes and gestational diabetes (i.e. 20% and 11.3%, respectively) in
association with maternal obesity and high-order multiparity in this significantly
diverse multi-ethnic population 2' 408' 409. In populations with a high prevalence of
gestational diabetes (GDM), any form of oral glucose testing for screening or
diagnosis excessively strains the health care system. Additionally, these tests are
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conducted later in pregnancy because it is more likely that abnormal carbohydrate
tolerance will be detected later in gestation since the physiological changes of
pregnancy exert a greater strain on a woman's ability to maintain normal carbohydrate
tolerance with advancing pregnancy. As a consequence of enhanced insulin
production by the fetal pancreas following an excessive transplacental glucose load,
infants of diabetic mothers may become macrosomic (defined as infants weighing
more than 4,000 g at term), and are more susceptible to infant respiratory distress
syndrome, cardiomyopathy, hypoglycaemia, hypocalcaemia, polycythaemia and birth
trauma 4I(). 8 out of 12 macrosomic infants seen in this study were born to mothers
with diabetic disorders, amongst whom there was increased medical and/or operative
delivery intervention, shoulder dystocia, spontaneous preterm and even one intra¬
uterine death. Effective screening is important for early identification of an
individual's susceptibility to gestational diabetes before the onset of glucose
intolerance, in order to prevent excessive fetal growth/ neonatal complications
through early intervention. Therefore, the search continues for a biochemical
screening test that can be performed sufficiently early in pregnancy to detect
pregnancies at risk ofGDM and discriminate low-risk from high-risk women, in order
to avoid conducting a provocative glucose challenge for every pregnant woman in a
population with high prevalence of GDM. Although uteroplacental metabolic
derangements caused by deregulation of glucose and oxygen metabolites have been
proposed to explain the altered levels of placental hormones and proteins that precede
a diagnosis of GDM, none of them provide a sensitive prediction of gestational
diabetes 404'4U. This study too failed to demonstrate that HhCG levels (or any other
hCG analytes), was altered in pregnancies with pre-existing diabetes or in those
women who subsequently developed gestational diabetes. This is in agreement with
many other previous reports ' . There is continuing controversy as to whether
calculations should be corrected for AFP, unconjugated oestriol, and inhibin- A, most
studies now agree that hCG and hCGp are not significantly different in pregnancies
with and without IDDM, indicating that metabolic derangements in diabetic
pregnancy do not affect hCG levels 4I2~414. Compared to hypertensive disorders, fewer
studies have shown association between diabetic disorders in pregnancy and altered
hCG levels.
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A computerized search of the PUBMED database up to February 2007 excluding
reviews, and using as key words "Hypertension", "pregnancy", and "hCG" vs.
"Diabetes", "pregnancy", and "chorionic gonadotrophin") was published by Raty et al
and demonstrated that women with GDM exhibit lower mid-trimester serum hCGp
and AFP MoM values than healthy controls 415. Similar lower levels of phCG, PAPP-
A and inhibin A, during the first trimester were reported by Tul et al. , lower phCG
and PAPP-A by Ong et al. 299, and lower unconjugated oestriol and hCG levels by
Palomaki et al. 416. A comparative longitudinal study throughout pregnancy of
maternal serum levels of hCGa, between well-controlled insulin-dependent diabetic
patients matched with non-diabetic controls showed that a- hCG was significantly
lower in pregnancies affected with IDDM compared to non-diabetic pregnancies until
the 24 weeks of gestation, after which it was higher until delivery 417. One possible
explanation for the apparent difference in serum concentrations of hCGa is that low
levels during the 1st and 2nd trimesters are a consequence of impaired placentation and
smaller placental mass, whereas high levels in the 3rd trimester may be the result of
hypoperfusion-related stimulation of production of this hormone reflecting a
compensatory mechanism. The same study also showed the although hCGa levels did
not correlate with fetal macrosomia, the duration of diabetes, PIH or premature
delivery, increased levels of hCGa in type I diabetic pregnancies during the third
trimester were found in pregnancies associated with pre-existing hypertension,
suggesting that established diabetes may have a more profound effect on normal
placental differentiation than diabetes appearing during pregnancy as it may share
common pathophysiological mechanisms with those underlying hypertensive
vasculopathy 417. Indeed, placental vascular changes such as impaired relaxation,
reduced nitric oxide synthesis leading to reduced blood flow and increased placental
vascular resistance, and increased oxidative stress have been reported for both
A1R
conditions . Other morphological investigations of the placental bed in diabetic
pregnancy have shown varying degrees of change in the syncytiotrophoblast,
cytotrophoblast, trophoblastic basement membrane and fetal vessels 41'. There is
evidence that diabetic pathophysiology is associated with an alteration of expression
markers for terminal placental differentiation 419. Moreover, ultrastructural and
ultrahistochemical studies of placentas from women with pre-gestational diabetes
have shown patchy focal syncytiotrophoblast necrosis with marked cytotrophoblast
hyperplasia and focal thickening of the villous trophoblast basement membrane 41'.
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Placentas from well-controlled diabetic pregnancies are not heavier than those from
normal pregnant women. However, diabetic placentas from the subgroup of poorly
controlled diabetes particularly in the presence of macrosomia, have a larger fetal
capillary bed of greater length, diameter and exchange surface area between mother
and fetus. This is in contrast to the finding of incomplete/ or absent transformation of
the decidual and myometrial portions of the spiral arteries found in diabetic women
complicated by chronic hypertension and/or superimposed pre-eclampsia, and in
diabetic pregnancies complicated by fetal growth retardation showing more frequent
syncytial knots along with lower percentage of vasculo-syncytial membranes, and
thicker trophoblastic basement membrane 41'. All of these data indicate that
developmental changes of placenta secondary to pre-gestational or gestational
diabetes are differentially affected depending on the active underlying
pathophysiological mechanism, explaining why the discordant data in the literature on
levels of hCG in diabetic pregnancies and why two different patterns of abnormal
fetal growth (i.e. macrosomia and FGR) are seen amongst them.
FGR is known to originate from multifactorial heterogenous pathologies that make
the task of its prediction extremely difficult. While the importance of normal placental
function in regulating many aspects of embryonic and fetal development cannot be
denied, the actual cause-and-effect relationship is too complex to recommend a single
guideline for its detection 183' 190'404'420'421_
Additionally, a growing number of studies show that up to 20% of FGR may be due
to "fetal factors" including chromosomal abnormalities which may constitute up to
7% and fetal infections may be seen in up to 10% of FGR cases 420. At the
biochemical level, many studies have shown altered levels of placental hormones due
to shallow or inadequate trophoblastic invasion, an underlying pathophysiological
mechanism which is also attributed to other pregnancy disorders such as spontaneous
miscarriage, pre-eclampsia and spontaneous preterm delivery. The majority of these
studies associate higher 223-238'379-422 or lower levels 423>424 of hCG, hCGp and hCG
pcf with an increased risk of an adverse pregnancy outcome. As FGR is closely
associated with pre-eclampsia, preterm labor and gestational diabetes mellitus, altered
placental secretion of hCG may not give a clear-cut clue to the underlying pathology
unless further tests are carried out. Current strategies to identify FGR foetuses involve
performing early pregnancy scans for accurate dating, good antenatal surveillance in
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the form of abdominal palpation and symphyseal-fundal height measurement
followed by ultrasound biometry, with an emphasis on Doppler analysis as the most
important tool to grade the severity of the fetal disease 421'425. Using ultrasound
technology, FGR due to placental insufficiency can be diagnosed on the basis of
reduced amniotic fluid volume, abnormal umbilical artery Doppler and evidence of
growth failure on serial growth scans, provided that chromosomal abnormalities,
malformations and infections are excluded. The role of biochemical screening
remains controversial.
The cause of spontaneous preterm birth is multi-factorial, with infection being
implicated in up to 40% of cases and the remainder are labelled as idiopathic 426. In
the UAE study population, 8% of women delivered before completed 37th gestational
week, only 4% (n=10) of which were spontaneous. Current methods to identify
patients at risk for preterm delivery have not been very effective with screening
427 428efficacies ranging from poor to moderate ' . These include plasma levels of
oestradiol, progesterone, AFP, prolactin, corticotrophin-releasing hormone and C-
reactive protein, and salivary oestriol 429'430. To date, the most effective marker for
predicting preterm labor involves measuring cervico-vaginal fetal fibronectin levels,
assessed serially or at specific gestational ages 43'. As hCG in both maternal serum
and amniotic fluid is the result of hCG diffusion from the placenta throughout
pregnancy, it has been suggested that the hCG level in vaginal fluid is a useful marker
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of preterm delivery . hCG is present in high concentrations in amniotic
fluid during pregnancy. The levels are similar to those in maternal serum in early
pregnancy, then decline to 20% of maternal serum levels and follow a similar
gestational pattern. From the time of conception, concentrations of hCG in amniotic
fluid rise to peak (approx.54,000 U/L) between 8 and 12 weeks gestation and then
decline to plateau levels (2,000 U/L) at approximately 18 weeks where they remain
for the rest of the pregnancy 434. Anai et al documented low and stable hCG levels,
secreted by cervical glands, in the vaginal washings of normal pregnant women in the
second and third trimesters 435. The median hCG level in vaginal washings of women
with confirmed premature membrane rupture increased 44- to 67-fold compared with
normal women in the 2nd and 3rd trimesters. Their study concluded that, in the
microscopic absence of blood contamination which might increase the levels of hCG
in vaginal washings, measurement of hCG levels in vaginal fluid may confirm an
accurate diagnosis of premature membrane rupture, in cases of equivocal membranes
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rupture. Bernstein et al followed 77 women at high risk for preterm delivery through
the course of their pregnancy, and compared the levels of hCG in the secretions of the
cervix and vagina in those who delivered before 34 weeks gestation, and those who
delivered at term 436. A single hCG value >50 U/L obtained between 24 and 28
weeks' gestation predicts a 2-fold increase in the risk of delivery before 34 weeks
gestation (P= .03). This cutoff value had sensitivity, specificity, PPV, and NPV for
predicting delivery before 34 weeks gestation of 50%, 87%, 33%, and 93%
respectively. This study confirms that the hCG level in cervicovaginal secretions may
be a useful predictor (a negative predictor rather than positive one) of preterm
delivery. A similar conclusion was drawn from a study by Guvenal et al., but the cut¬
off value of cervicovaginal hCG level used in this study (>28 U/L) had a sensitivity,
specificity, PPV, and NPV of 87%, 65%, 28% and 97% respectively, for predicting
preterm delivery 437. A number of studies have shown increased rates of preterm
delivery in relation to increased hCG levels 231' 381' 438 440. However the reported
sensitivities, specificities, positive and negative predictive values varied considerably
and were far from optimal, some showing no association at all 236>239-299'441
The consequences of preterm delivery vary depending on prematurity, with a higher
risk of neonatal mortality and morbidity for early preterm births (< 32 weeks of
gestation) compared to those born between 32-37 weeks of gestation 375' 442. As
discussed earlier, the underlying mechanisms involved in the onset and severity of
FGR and pre-eclampsia may also be involved in preterm birth bringing about variable
outcomes depending on the timing and severity of the insult. Studying hormonal
parameters in small numbers of spontaneous preterm births along with coexistence
with other pregnancy complications in this study, not surprisingly lead to inconclusive
results.
Whilst the involvement of hCG in the maintenance of myometrial quiescence is well
established (reviewed in chapter 1), the role of HhCG in this regard is unknown. HCG
exerts most of its biological functions by acting on the LH/hCG receptors found on
luteal, endometrial, cervical and myometrial cells, and on many other reproductive
and gestational tissues l60'l61'443, whereas it is suggested that HhCG exerts a cytokine-
like action involving the TGFp receptors which are differentially expressed in the
uterus and placenta 444. TGFpi inhibits cytotrophoblast cell migration and
invasiveness through the up-regulation of the tissue inhibitors of MMPs (TIMPs)-l
and -2, while TGFP3 potently inhibits trophoblast outgrowth, and inhibition of TGFP3
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expression or activity results in increased outgrowth, elevated MMP
production/activity and fibronectin deposition 444. The pre-eclamptic placentas show
some characteristics of reduced trophoblast invasion and increased expression of
TGF03, the blockade of TGFP3 restores invasive potential, a mechanism supporting
the involvement of TGFP3 in the pathogenesis of this disorder. Until future studies
confirm this, similarity in the tertiary structure of HhCG with the transforming growth
factor and other cytokines may indicate a likely role of HhCG in the maintenance of
pregnancy and/or may be even involved the pathophysiological mechanisms of
pregnancy disorders such as pre-eclampsia, FGR, and preterm labor. This needs to be
the subject of future investigations.
The use of hCG and its related molecules, (or any other placental marker for that
matter), in the prediction or the diagnosis of any of the late pregnancy complications
remains unproven, because of their low predictive value, coupled with discordance in
study results caused partly by the heterogeneity of the underlying pathology. In the
wake of such diversity, and the small number of such late pregnancy complications in
the current study cohort, it is not surprising that no significant association was found
between levels of HhCG and the incidence of proteinuric and non-proteinuric
pregnancy induced hypertension, gestational diabetes, FGR, preterm births,
oligohydramnios, polyhydramnios and stillbirths (p < 0.05). It is unlikely that a single
marker or hCG alone will be useful. The combination of serum markers and uterine
Doppler ultrasound improves the identification of women at risk for subsequent
pregnancy complications 422. Although studies have shown that the sensitivity of
screening improves when hCG isoform measurements are combined with other
biochemical tests such as inhibin A, unconjugated oestriol and uterine artery Doppler,
there is disagreement regarding the accuracy of these tests and their predictive values.
A study by Wald and Morris gave a 55% detection rate with a false-positive rate of
5% using a combination of inhibin-A, hCGp and unconjugated oestriol during the
second trimester of pregnancy 445. Another study estimated a pre-eclampsia detection
rate of 49% with a 10% false-positive rate if free hCG hCG was used in combination
with inhibin-A before 20 weeks 446. Prediction of pre-eclampsia in a study by Spencer
et al. using uterine artery Doppler ultrasonography and maternal serum pregnancy-
associated plasma protein-A, hCG(3, activin A and inhibin A at 22 + 0 to 24 + 6 weeks
gestation had detection rates of 50%, 5%, 10%, 44%, and 35% respectively, with a
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false-positive rate of 5%. However, when these markers were used collectively, the
test detected 75% of patients who subsequently developed pre-eclampsia, with a
similar false-positive rate 447. Large systematic reviews and meta-analysis studies
have shown that, in spite of the many studies showing an association between
abnormal serum markers and late adverse pregnancy outcome, the sensitivity of these
tests is too low or modest to be applied for generalized screening 448-450.
It may be concluded that, due to the heterogeneous nature of the pathology of
pregnancy complications caused by various etiological factors proposed in the
literature, and lack in the exact mechanisms underlying such pathologies, coupled
with unpredictable placental response in the wake of any complication and the
consequent production of heterogeneous hormones, all together make screening for
pregnancy complications extremely difficult before the onset of signs and symptoms
with no single method being completely satisfactory.
3.7.4 Screening performance of HhCG in spontaneous conception
The significance of HhCG level predicting pregnancies which may eventually
miscarry was compared with other common forms of hCG in urine and serum. HhCG
measurements showed only moderate diagnostic accuracy for the prediction of
pregnancies ending before 24 weeks of gestation compared to normal pregnancies and
when compared to the remaining 5 hCG analytes, all of which showed good
diagnostic accuracy. With AUC values in the range of 0.698-0.831 (0.764 ±.034) in
serum and 0.675-0.814 in urine (0.744 ±.036), HhCG was a worse predictor of
adverse pregnancy outcome than hCG and hCGPcf in both serum and urine.
Recently, Sutton-Riley et al. studied the utility of serum HhCG measurements in the
diagnosis of early pregnancy failures 81. They found that using a serum HhCG cut-off
value of 13 pg/L they could identify 73% of all pregnancy failures at a 2.9% false-
positive rate. Using the same cut-off in urine they reported 75% detection at a 15%
false positive rate. When we tested this level in our study population after converting
it to the equivalent unitage 213 (HhCG 1 pg/L = 24.3 pmol; 13 pg/L = 316 pmol/L),
HhCG detected only 30% of all failures below 24 weeks of gestation but had an
excellent sensitivity of 98% (2% false-positive rate). In contrast to the study of
Sutton-Riley et al., a cut-off value of 316 pmol/L, had poor diagnostic efficacy in this























Corresponding cut-off concentration 13 pg/L 316 pmol/L 13 pg/L 316 pmol/L
Corresponding detection rate of
failures (specificity)
n = 33 n = 71 00CMIIC n = 69
a. All failures 73% 30% 75% 41%
















Sensitivity (all continuing) 85% 98% 52% 90%
Area under ROC curve ± SE 0.88 ± 0.003 0.764 ± 0.034 0.83 ± 0.049 0.744 ±0.036
ROC 95% confidence interval 0.83-0.99 0.78-0.90 0.73-0.92 0.67-0.81
Table 25 Comparison of results using an HhCG cut-off concentration of 13 pg/L (~ 316
pmol/L) for predicting pregnancy failures in the current study.
Sutton-Riley et al. used the Nichols Advantage automated assay for the detection of
HhCG so the observed differences in results may reflect differences in the assay
procedure or may be due to other analytically related factors as discussed below.
A highly sensitive biomarker accurately identifies viable pregnancies (true positives)
and a highly specific biomarker identifies nonviable pregnancies (true negatives).
Clinically, it is critical to minimize false positive test results that incorrectly suggest
the absence of non-viable pregnancy (miscarriages and ectopics) and falsely reassure
the clinicians and patients. However this is achieved at the expense of decreased
sensitivity and more false negative results. In other words, the cost of unnecessary
intervention and close monitoring of unnecessary intervention with continuing
pregnancies but are falsely identified as a miscarriage or non-continuing pregnancy is
weighed against the health risks and hazards of falsely identifying a non-continuing
pregnancy as a continuing one. When the optimal cut-off value was chosen to
maximize specificity to detect 70% of all pregnancy failures, a serum HhCG level of
4846 pmol/L (~ 200 pg/L) had a sensitivity of 66% (i.e. 66% detection of the
"continuing pregnancy", or the predictive value positive). In urine, the same cut-off
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value of 200 p.g/L yielded a better detection of failures with a specificity of 78% but
with a lower sensitivity of 55%. Using the same cut-off value in serum, 100% of
ectopic pregnancies could be detected but at the expense of a very low sensitivity
(33%), showing high NPV to correctly identify miscarriages.
In summary, our study of a UAE population showed that HhCG levels were decreased
in the miscarriage group. However the diagnostic accuracy of the given
measurements is at best qualified as moderately applicable in predicting adverse
pregnancy outcome. Other forms of hCG, particularly serum hCG itself, were more
reliable markers.
3.7.5 Limitations of the UAE cohort study
3.7.5.1 Factors related to the study cohort
This study has a number of limitations. As the UAE samples were collected from
spontaneous pregnancies, there were insufficient data to evaluate HhCG levels before
the 6th week of gestation. HhCG is produced by the cytotrophoblast, and accounts for
the majority of the hCG immunoreactivity in serum and urine (up to 100%), at the
time of trophoblast invasion during implantation and weeks following it, with their
proportions rapidly declining with advancing gestation as a result of trophoblast
differentiation. This time interval is crucial to understanding the pathophysiological
mechanisms underlying the origins of many adverse pregnancy outcomes resulting
from defective implantation and placentation, which remains mostly uncaptured in
most studies of spontaneous conceptions. Trophoblast invasion is known to occur in
two phases, one which is very early during the pregnancy and a second wave occuring
during mid-gestation. Hence any pregnancy complication arising from a failure of the
first wave of invasion may exhibit altered hormonal levels for a short time only, after
which the cellular factors controlling the expression of hCG molecular forms may be
overtaken by compensatory mechanisms as gestation advances. Also, when
evaluating hormone values at 6- 24 weeks of gestation, as in this study, changes in
their levels occurring as result of a growing pregnancy may not be differentiated from
altered levels in the presence of disease. There is an exponential increase in placental
hCG concentration during the 1st trimester115 and throughout the first part of the
second trimester, and concentrations of hCG then decrease to approximately one-fifth
of the maximum by the 16th week of gestation and remain at this steady level until
term 95' 115. Relying on a single hCG cut-off value for the prediction of adverse
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pregnancy outcome using combined first and second trimester samples would be
ineffective and decrease the confidence interval of a result. For the same reason,
biochemical screening is normally performed during the early part of second
trimester, when the variation in hCG concentration is minimal.
This is a prospective study and therefore some data and variables that may be of
importance are incomplete. As discussed earlier, different pathophysiological
mechanisms may be operative in the onset of some pregnancy complications which
may differentially affect placental function, the pathophysiology of extreme
premature delivery may be different from moderately premature delivery 239'4401441.
The same may apply for low birth weight infants 239>451. There was insufficient
information about the severity of disease or gestational age at the onset of each
complication, nor any information about structural or chromosomal abnormality in the
fetus, placental weight and other variables to identify pathophysiological mechanisms
of underlying disease and explain changes in the levels of HhCG and other related
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molecules in relation to that
Many co-variables are known to influence first- and second-trimester markers,
including maternal body weight, gravidity, parity and fetal gender, ethnicity, insulin-
dependent diabetes mellitus, together with previous pregnancy screening results and
other pregnancy morbidities. Marker alterations due to these variables may lower the
i r t* • 2 404 440 452-454 412 tt I ,•
detection rate of pregnancy complications ' . However, data regarding
the effects of such variables on HhCG levels is scarce. In this study no statistically
significant difference was found between pregnancy outcome and other variables,
including previous miscarriage, ethnicity, BMI, blood group, haemoglobin and fetal
sex, except for age and parity, where 45% of women in the "non-continuing"
pregnancy group were more than 35 years of age compared to 21% of women less
than or equal to 35 years of age in the continuing group. The risk of spontaneous
miscarriage increased as parity increased (almost double amongst grand multiparas).
Since it is unknown whether these two variables, or any other variable, could
influence HhCG concentration. Thus, the only adjustment done in this study was to
correct for specific gravity of the urine, due to the lack of information on baseline
values and normal population-based parameters which may affect HhCG levels in the
UAE population. Only one previous population-based study in the same geographical
region was conducted to establish distribution parameters of first-trimester screening
markers in Saudi and non-Saudi women 45 . Their results showed that the phCG and
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PAPP-A values decreased with increasing maternal body weight and significantly
differ in various ethnicity backgrounds, with MoM values for hCGP 25.2% higher in
Africans and 19.4% higher in Orientals but 6.8% lower in other Arabian and Asian
(by 5.8) women 455. Such ethnic variations and the need for correction were also
reported previously 453-456"458 por a proper interpretation of data and to minimize the
variations that may arise from confounding variables, risk estimates and data analysis
should be made after correcting for known variables.
The UAE community is composed of diverse individuals from varying cultural,
religious, and socioeconomic backgrounds. According to the 1995 census (reviewed
by Malik et al. 409, the total population of the UAE was 2.7 million, of whom 20%
were UAE citizens, 25% were from other Arab countries, 50% were of South Asian
origin (predominantly from India and Pakistan) and 5% were from other countries,
mostly European and East Asian. The marked heterogeneity among this population
makes it a high-risk group for adverse obstetric and perinatal outcome (Multi-ethnic
high risk population) 2'409.
In populations that were deemed at high risk for pre-eclampsia, the use of biochemical
markers has a low predictive accuracy 448' 459. A study of the Danish population
assessing the risk of adverse obstetric outcomes in pregnancies with elevated maternal
serum AFP or hCG levels according to pre-pregnancy risk assessment showed no
differences between women classified as high- or low-risk of developing obstetric
complications 454. However, any differences have been attributed to differences in the
population groups being studied, or alternatively, differences in defining what
constitutes high risk 439.
As current obstetric practice calls for screening in low-risk populations, there is much
interest in investigating cost-effect, sensitive screening markers of low-risk
populations. A combined algorithm of urinary HhCG with ultrasound biometry was
shown to be substantially superior to the traditional triple screen and to the quadruple
screen tests for the detection of Down syndrome in high-risk populations 202, and
showed equally high screening performance in a small group of women who were
below 35 years of age. However, it was suggested that larger prospective multi-centre
trials should be conducted to test its screening performance in a low-risk population
202
Research based on cohorts identified by neonatal birth weights or birth centiles should
be interpreted with great caution as misclassification of newborn infants could occur
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for FGR. FGR is diagnosed when birth weight is below the 10th percentile of that
anticipated for a particular gestational age. In most cases, FGR is confirmed by one or
more of the following findings on U/S: low amniotic fluid index and fetal movement,
pathological uterine umbilical artery Doppler pulsatility index, or decreased growth
velocity on serial ultrasonogarphic biometry (at least a 14 day interval between
measurements) 460. The dilemma arises when early interruption of pregnancy occurs
due to spontaneous preterm labour or to CS due to abnormal antenatal fetal heart
traces. In such cases the provisional diagnosis cannot be confirmed
ultrasonographically, hence the clinician must rely only on birthweight centile.
Placental findings (including excess villous trophoblast, thickened trophoblast
basement membrane and villitis following delivery) can confirm FGR; unfortunately,
histo-pathological reports of placental examination were not obtained in this study.
The main problem with this definition is that it will include many healthy small-for-
gestational age (SGA) fetuses that are constitutionally small, and hence, it lacks the
sensitivity to identify small infants arising as a result of abnormal intrauterine growth
or placental dysfunction 420>461. Up to 70% of SGA infants are constitutionally small
simply due to maternal ethnicity, parity, weight, or height 42°. Hence, it is probably
more appropriate to use lower centile limits, (e.g. less than the 3rd percentile, or more
than 2 SD below the mean weight for age and sex) 461 or ponderal index, (defined as
birth weight in grams divided by the cube of the height in centimeters) 420 as a better
indicator of FGR in newborn infants. It has generally been assumed that fetuses
experiencing a sub-optimal environment such as nutrient limitation or placental
dysfunction during the first and early second trimester tend to be proportionally small
in both weight and length at birth (known as symmetric growth restriction). In
contrast, growth restriction that begins later in pregnancy results in disproportionate
asymmetric growth restriction (i.e. preservation of head growth occurs at the expense
of total body weight gain) 420'461. This has been disputed in the literature, but evidence
of different etiopathogenic mechanisms operating at different developmental stage of
fetal growth and their impact in the development of symmetry/asymmetry FGR, exist.
Patients with either early onset severe pre-eclampsia or pre-eclampsia superimposed
on chronic hypertension prior to 30 weeks gestation produced more symmetric than
asymmetric FGR infants 420 and in the Dutch winter famine of 1944-45, a severe
nutritional insult in the last trimester resulted in a low ponderal index at birth 372.
Hence abnormal placental marker levels such as HhCG or other hCG subunits may
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depend on the stage of development and the type of FGR. Furthermore, the risk of
low birth weight was increased when the difference between the observed and
expected crown-rump length was -7 to -2 days. Outside this range, the risk of low
birth weight was similar to the average for the whole group. They explained that these
differences are most likely due to an incorrect estimate of post-conception age which
largely obscures the variation related to growth 462. Unlike pregnancies conceived
through in vitro fertilization, the exact post-conception age at the time of
ultrasonography was unknown in our study. The size of the embryo or fetus in the
first trimester may also differ from the expected size because of variation in the
timing of ovulation. If ovulation occurred on day 17 and was followed by normal
conception, implantation, and growth, the fetus would be the equivalent of 3 days
smaller than would be expected if ovulation had taken place on day 14. If this fetus
was then born 41 weeks after the last menstrual period, gestational age would be the
post-conception equivalent of 40 weeks and 4 days, but the infant's birth weight
would be judged by the 41- week percentile 462.
Estimation of gestational age in spontaneous conceptions is not straight forward. In
cases of miscarriage, there is a tendency to underestimate age of gestation if
embryonic or gestation sac measurements are used as 30-70% of early miscarriages
are smaller than expected based on the date of the LMP 284'463. This could be related
to several factors, including retention of conception even after fetal demise, growth
disorganization or slower growth rate of an abnormal embryo in miscarriage 283'464.
However, dating of gestational age using LMP has its own drawbacks, as it is difficult
to determine the exact timing of ovulation, especially amongst women with irregular
bleeding and those who are lactating 465-467. Even among women who have regular
menstruations and are certain of their LMP dates, variations in day of ovulation still
occur and the use of LMP is likely to overestimate the true gestational age 465-468'469-
Last menstrual period estimates of the duration of gestation are subject to both
random error and a systematic tendency to overstate the duration of gestation, most
likely because of delayed ovulation 470. All of these may not only affect the diagnosis
of FGR but also influence the diagnosis of preterm birth. The limited number of FGR
and spontaneous preterm delivery cases in the current study, may have contributed to
the inconclusive results.
Whether preterm delivery was due to maternal or fetal cause (i.e. congenital
malformations, structural defects, or secondary to pre-eclampsia etc) was not clear. In
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one neonatal audit from the UAE, the mortality rate among very low birth weight
babies was higher and in 54 neonatal deaths out of 8083 live births (0.67%) weighing
> 500 grams, problems of preterm births, lethal malformations and asphyxia
accounted for 95% of the deaths, and half the malformations were autosomal
recessive syndromes 47Another annual report from the UAE cohort showed that
40% of infant mortality was caused by congenital anomalies, and 35% of cases were
associated with maternal disease during pregnancy 472. These observed high fetal
mortality rates were attributed to a high proportion of women of advancing age, along
with grand-multiparity, a high proportion of traditional consanguineous marriages,
and the lack of termination of pregnancies affected by fetal defects, due to religious
constrains. All these factors reflect the vast array of pregnancy complications inherent
to the heterogeneous UAE population.
Nine still births and neonatal deaths occurred in our study. This was not
representative of the general UAE population prenatal mortality rate (9.49 per 1000
472live births) . Again the higher rate was due to collection of samples from patients
who referred to the tertiary Fetal Medicine Unit of Mafraq Hospital and were already
receiving care while being admitted to an antenatal ward for conditions known to be
associated with adverse pregnancy outcome such as diabetes or hypertension. 8 of the
9 fetal deaths could be explained by an apparent direct cause or were associated with
a maternal condition known to have a high maternal and fetal mortality and morbidity,
such as hydrops fetalis (n=3), placental abruption associated with pre-eclampsia,
placenta previa, uncontrolled maternal diabetes. Only one fetal death was
unexplained, hence the association between HhCG levels and stillbirth is too weak to
reach any statistical significant conclusion.
3.7.5.2 Factors related to analytical procedures
The effect of storage and transport on the stability of these analytes over the time
must be considered in assessing the results achieved in this study, given that the serum
and urine specimens were stored for up to 3 years at -80°C until assayed.
Besides the heterogeneity of hCG and its related molecules and variations in the assay
methods, the differences in the assay results have also been attributed to the integrity
of these molecules in blood and urine samples during transport and storage, especially
in urine in which hCG molecules have significantly greater stability problems than in
serum. Early studies of the stability of HhCG show that it is stable at room
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temperature for up to 3 days, and can be stored at 2-8 C for up to one week from the
sample collection 202. When pure hCG (Batch P8 from pregnancy urine) and pure
HhCG (Batch C3-II from choriocarcinoma patient urine) were added to non-
pregnancy urine samples and stored for up to four weeks in room temperature, they
dissociated slowly at a rate of 1.6% and 4% per week, respectively 201. Long term
stability studies have shown variable results. No clear difference was found in HhCG
values when tested in nine fresh as well as frozen urine samples and no change was
found in HhCG MoM values or in Down syndrome detection rates in urine samples
when stored for up to three years in the freezer 473. They suggested that storing the
urine as well as serum samples at -70°C does not affect the HhCG immunoreactivity
over the period of 3 years. HhCG was stable in pooled urine and serum for a
minimum of 10 months at -70°C. Furthermore, HhCG was stable for 3 days at room
temperature and 7 days in the refrigerator, as well as after two rapid freeze-thaw
1f\
cycles . However losses in HhCG concentrations were seen after multiple freeze-
thaw cycles when the analyte was present in high concentrations 202. This was evident
in the study of Down syndrome specimens, wherein fresh urine samples were tested
before and after freeze-thawing and showed approximately 50% reduction in the
immunoreactivity when compared with specimens from pregnancies of normal
karyotype 202. These losses were more evident when the analyte was present at higher
concentrations 202. It was suggested that the reduction in the HhCG level in stored
Down syndrome urine specimens was probably due to differences in the carbohydrate
structure and conformation changes that make HhCG more susceptible to loss when
urine changes state during freezing and thawing.
Higher concentrations of HhCG in this study during the first trimester than the second
trimester (Figure 34-35, Table 15) as well as higher proportions of HhCG in urine
than in serum (Table 13) agrees with the overall data available data in literature on
HhCG 66'67,69' 13°. Furthermore, the serum and urine samples in the current study were
stored in -80 C and were shipped on dry ice to their final destination for the analysis,
it is unlikely that any variation in the temperature, that may have lead to slow freeze-
thawing, had taken place to have caused relative changes between analytes due to the
degradation, disassociation or other changes attributable to storage. Degradation of
hCG in urine and serurm samples in vitro leads to loss in the immunoreactivity via
nicking and/ or dissociation. These two possible mechanisms occur more rapidly in
urine due to the action of proteases present in urine samples and the addition of
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antimicrobials, diminishes nicking and slows the hCG dissociation pathway '
Adding sodium azide (5%) in all urine samples in the current study, may have helped
in the stabilization of hCG and its related molecules by impeding the possible action
of proteolytic enzymes and preventing microbial growth or contamination during
variation in the temperature, if any.
Another possible explanation for variation in HhCG results could be due to a change
in the composition of hCG carbohydrate side chain as a result of variations in the
sialic acid terminal residues which can be found in some adverse pregnancy
complications. This is seen in cases of Down syndrome in which the sialic acid
content is altered, causing loss of recognition of HhCG in some assays 29' 474.
Although variations in the number of HhCG-sialic acid residues would affect the
lectin-based assay more than the conventional immunoassays, which are relatively
unresponsive to carbohydrate changes 49' 77' 475, yet poor detection of sialic acid
deficient-HhCG has been reported in Nichols Advantage automated HhCG assay
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system
Glycosylation profile of hCG indicates a wider range of glycoforms, with evidence of
the presence of hyperglycosylation on hCGPcf and a-subunit of hCG 18'82'115. Since
the B152 antibody used in this study recognizes the core 2 glycan of hCGp 63'
presence of hyperglycosylation elsewhere in any of the pregnancy complication may
also result in a change in response of the assay. HhCG itself may exist in a variety of
forms, similar to the hCG forms found in neoplastic conditions, such as nicked HhCG
or nicked hyperglycosylated free P-subunit 39°. Hence, any variations in results may
probably be due to differences in the affinity/avidity of binding to different nicked
forms of HhCG to the B152 antibody. Cole et al. had shown that majority of
commercially available hCG assays, whether for serum testing in a laboratory or for
point-of-care use either under- or over-detected HhCG leading to a potential source of
hCG test disparity 68' 69' 208' 39°. Furthermore, differences in the Down syndrome
detection rates between assays were also attributed to the differences in their
incubation time, with microtitre plate assay, which has a longer incubation time,
yielding much better detection rate than the Nichols Advantage automated assay with
shorter incubation 80'389'474.
Pure HhCG (choriocarcinoma hCG batch C5), known to be 100% nicked, is calibrated
by aminoassay analysis and was used to standardize the assays in many studies 18'65'
69'208, where as in this study, JEG3 choriocarcinoma cell line HhCG standard was
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used which is not nicked 49'130' l8°. The variability in results may be attributable to
differences in calibration. Results for various forms of hCG may be compared by
expression of concentrations in mol/L and the equimolar recognition of the major
hCG molecular forms is suggested to be essential in improving between-method
comparability for hCG. The immunoreactivities of the molecular forms based on
molar concentrations can be estimated on the basis of their molecular weights and the
ratio between content in mass units and IU of the 3rd International Standard (IS) (i.e.
1 pig of hCG = 9.28 IU = 26.7 pmol) 84-213'476. t0 this end, conversion factor for
HhCG has not yet been established. When analyzed by the above method, Stenman in
an Editorial paper calculated the mean value of HhCG as; 900 U/L = 97 pig/h = 2590
pmol/L (i.e. 1 pig of HhCG = 26.7 pmol/L) . The HhCG conversion used in current
study (1 pg/L of HhCG = 24.3 pmol/L, based on the MW=41000 Daltons) is fairly
close to the value calculated by Stenman. Since the given molecular weight (MW) of
HhCG in literature varies from 39,000- 43,000 Daltons, the discrepancy in values tend
to occur depending on the MW used in conversion formula. Results reported by Cole
et al. suggest that conversion factors differ among different methods 208.
In this study, significant differences in concentration of HhCG were observed
between two immunoasay methods (DELFIA and Quest). The availability of a formal
HhCG standard would assist in improving between-method comparability. However,
using common pure hCG preparation help to minimize between-method variation but
does not eliminate it 208'260'477'47s.
The potential for error can be noted with extremely concentrated or dilute spot urine
samples. In the majority of urine studies 129>251, HhCG levels were normalized for
urine concentration wherein HhCG concentration (mg/L) was divided by the spot
creatinine concentration (mg/g creatinine). A relationship was observed between
normalized hyperglycosylated values and creatinine concentration. Samples with low
creatinine concentration gave unduly high creatinine-normalized values, and those
with high creatinine concentration were giving unduly low creatinine-normalized
values (i.e. up to 7.3- fold difference in HhCG values) 129'251. An equation was
derived to correct the error using following formula: c' = (0.877c) + 0.107, where (c)
is the actual creatinine concentration and (c') is the corrected value. Alfthan et al.
evaluated paired urine spot samples and serum samples from 21 women and found
that urinary concentrations of hCG corrected by specific gravity matched serum hCG
concentrations 215. In the current study urinary hormonal concentrations were also
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normalized using specific gravity (SG). However, since urine specimens collected
from the UAE population were spot samples rather than first morning voids, and
exhibited a wide range of densities due to hydration status and time since last
micturation, it is possible that SG normalization may have led to overestimation or
underestimation of values in samples with high or low specific gravidity. This could
explain the elevated serum and urinary levels of all hCG analytes in women with
Hyperemesis in this study, except for the hCGpcf levels which remained unchanged.
Smaller elevations were more evident molecules with tighter than with wider
distribution of values 479. Due to the wide variation of hCGPcf level in urine (4463-
3490085 pmol/L), when compared with HhCG (28.5- 228062 pmol/L) and hCG
(2990-1213527 pmol/L), any alteration in their levels may not be readily evident in an
immunoassay. Furthermore a slight increase in level may be masked by SG
correction. Currently, the majority of screening studies use spot creatinine levels to
normalize urinary hormonal levels, which is thought to be superior to SG for
correcting values of HhCG and other hCG related molecules. Further studies
comparing both methods are required to establish which is superior. Also, some
studies have reported diurnal variations in the secretion of hCG hormone and its
metabolites along with the influence of time of sample collection on the levels of
hormone 32'113-480-481 Future studies should explore the true effect of time of day and
correction of extremely dilute or concentrated samples on their final algorithms.
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CHAPTER 4. HYPERGLYCOSYLATED HCG LEVELS
FOLLOWING EMBRYO TRANSFER (THE
EDINBURGH COHORT)
153
4.1 Background to the Clinical Study in Edinburgh
The early phase of embryonic development is critical for successful implantation and
pregnancy survival and involves balanced interactions between fetal and maternal
hormones, cytokines, growth factors, cell adhesion molecules and transcription factors
144,183,482 yarious studies have addressed the question of early hCG values and their
potential use in the prediction of pregnancy in the IVF population 483-487. However,
serial evaluations of hCG along with U/S confirmation have so far been the mainstay
as the standard tool for following up the viability of pregnancy achieved through IVF.
Pregnancies obtained after in-vitro fertilization or intracytoplasmic sperm injection
IVF/ICSI and embryo transfer (ET) are at risk of adverse outcome compared with
natural conceptions, and hence require careful follow-up 488-490. The common
management of patients with suboptimal hCG levels involves several follow-up visits
for repeated hCG tests which is not only time consuming and costly, but also places
extra psychological pressure on an already vulnerable group 491. Thus, an early marker
that can accurately distinguish viable from non-viable pregnancies before the
verification of a live intrauterine pregnancy by transvaginal sonography, and
minimize the need of repeated follow-up samplings, is highly desirable amongst the
IVF population.
HhCG is produced by the invasive cytotrophoblast cells, very early during pregnancy
and in-vivo and in-vitro studies have shown that HhCG promotes cytotrophoblast and
72 74choriocarcinoma cell growth and invasion ' . Since invasion is vital for successful
implantation, the levels of HhCG may indicate successful implantation or identify
very early pregnancy abnormalities.
A retrospective observational study of an IVF cohort was undertaken to explore the
relationship between HhCG levels on day 14 following the oocyte retrieval (OR) and
pregnancy outcome, and to evaluate its usefulness (along with other hCG molecular
forms) in the prediction of adverse pregnancy outcome in this IVF population. The
levels of hCG and free- beta-subunits were also examined in order to compare the
diagnostic ability of these hCG-related molecules in the detection of adverse




Ethical approval was obtained from the Local Research Ethics Committee and written
informed consent was obtained from all participants prior to sample collection and
storage (See Appendix).
4.2.2 Study group
Serum collected in the year 2005 from 160 women undergoing IVF/ICSI treatment in
the Assisted Conception Unit (ACU) in the Edinburgh Fertility Centre, Scotland, were
used in this study. Only women with a known pregnancy outcome after the
completion of an IVF/ICSI-Embryo Transfer (ET) cycle were included.
Serum samples were analyzed for HhCG, hCG and hCGP from which outcomes were
available for 128 women and considered for this study. The recorded causes of
infertility were: male factors (42%), tubal factors (14%), endometriosis (6.25%),
unexplained (37.5%) and mixed male and female factors (11.7%). The median
(range) age of the participants was 35 years (Table 30).
4.2.3 Treatment protocols
Patients in the ACU underwent the IVF/ICSI and embryo transfer according to
protocols described in 218' 491. Pituitary down regulation with a gonadotrophin-
releasing hormone agonist (intranasal buserelin GnRHa) (Suprefact, Shire, Hants,
United Kingdom) was followed by ovarian stimulation using human menopausal
gonadotrophin (HMG) or follicle stimulating hormone (FSH) (Puregon, Organon, UK,
or Gonal-F, Serono, UK, respectively). Transvaginal ultrasound (TVS.) and serum
oestradiol (E2) concentrations were used to monitor the IVF cycle. When three or
more follicles reached a diameter exceeding 17 mm, 10000 units (500- 10000 IU) of
HCG ((Pregnyl, Organon, UK)) was administered subcutaneously to simulate theLH
surge of a natural cycle and induce ovulation. Oocyte aspiration was performed
approximately 35-36 h after the hCG injection using a standard transvaginal
ultrasound guided approach. Oocytes are fertilised in vitro by conventional IVF or by
single intracytoplasmic sperm injection (ICSI). The embryo then was transferred on
day second (D2) or third (D3) after the oocyte aspiration and a maximum of two
embryos were transferred. All patients receive had luteal phase support with
155
progesterone for 4 weeks, either as vaginal pessary or rectal suppositories (200 mg
BD) (Cyclogest, Shire Pharmaceuticals, UK). The women returned to the unit for a
pregnancy test (serum hCG) 14 days after the embryo transfer (ET). According to the
departmental protocol, if there was no bleeding and serum levels of hCG was > 40
U/L, the patients were recalled 3 weeks later for an ultrasonography scan (i.e. 5 weeks
post OR- 7 weeks of gestation) to confirm cardiac activity. Otherwise, if initial levels
of hCG were suboptimal or signs of bleeding exist, serial transvaginal ultrasound
examinations along with hCG testing were performed earlier, until a normal or
abnormal pregnancy was confirmed.
Day 14 post-OR correspond to 25-26 days of conception or the fourth week of
gestation because, by convention the 2 weeks of the proliferative phase before
ovulation is included when calculating gestation age 2I9.
4.2.4 Sample collection
The serum samples used in this study were collected from January- December 2005 in
conjunction with another prospective study. These samples were taken when the
patients came on Day 14 of oocyte recovery (OR) for pregnancy test. This
corresponded to Day 12 post embryo transfer (ET) for D2 transfers and Day 11 post
ET for D3 transfers). [For details see Sections 2.1.3 and 2.1.4],
4.2.5 Data collection
Baseline data collected from anonymised patient records included: age, cause of
infertility, assisted reproductive technology/treatment received, number of embryos
transferred, and the Day 2 or 3 of embryo transfer in relation to oocyte retrieval. The
outcome records included: Day 14 post OR pregnancy test results, U/S findings at 5
weeks post OR (~ 7 weeks of gestation), gestational week of miscarriage, weeks at
delivery, sex, weight, and evidence of structural abnormality of newborn. [See
Appendix for data collection forms.].
The clinical utility of HhCG hormone to discriminate between viable pregnancies
(containing singletons and twins) and nonviable pregnancies (containing biochemical
pregnancies and spontaneous miscarriages), was further analysed by testing the
performance of various cut-off values to maximize sensitivity and specificity using
the following definitions 218 [For details see Section 2.6]
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4.2.6 Pregnancy outcomes
Pregnancy test results in the ACU were obtained using the Siemens Immulite
immunoassay for hCG [Section 2.3.2],
Pregnancy outcomes were classified into the groups according to pregnancy status
(using the DPC immulite assay system): the non-pregnant (pregnancy test negative,
hCG: <5 IU) and the pregnant group (PT positive, hCG: >5 IU). In the Edinburgh
ACU, a positive pregnancy test was followed by the confirmation of presence of a
viable pregnancy on transvaginal ultrasound 5 weeks after the OR (or 3 weeks after
the 1st positive pregnancy test), provided that the patient was not bleeding. Patients
with suboptimal hCG results (<30 U/L) as well as patients with bleeding underwent
further repeated hCG tests and were monitored closely, until ectopic pregnancy was
ruled out or hCG levels fell to below 5 U/L.
The pregnant group were primarily classified into the following diagnostic groups:
Viable pregnancy; defined according to current World Health Organization (WHO)
definition of childbirth as a pregnancy resulting in delivery of at least one live fetus at
>24 weeks gestation, and included singleton as well as multiple pregnancies.
Non-viable pregnancies constituted biochemical pregnancies (defined as a temporary
rise in serum beta hCG, along with the absence of signs of intra- and extra-uterine
pregnancy by transvaginal ultrasonography) and miscarriages (defined as cessation of
development of intrauterine pregnancy seen in TVUS).
4.3 Results for the Edinburgh cohort
4.3.1 Comparison of the pregnant and non-pregnant groups
69 out of 128 women (54%) became pregnant following the IVF/ICSI treatment (hCG
test >5 IU). There were no differences in the age, aetiology of infertility, type of
treatment given, and day of the embryo transfer (ET) between the two groups.
However, a statistically significant difference (p=0.004 using Fisher's exact test) was
only found between embryo type and pregnancy outcome, since none of the women








Age, mean±SD 36.02 + 4.32 34.81 ±3.90 0.102










































Table 26 Paired comparison of pregnant and non pregnant IVF patients showing a
statistically significant difference between the groups only with fresh and frozen embryo
transfers.
Characteristics Single embryo transfer 2 embryo transfer P
(n= 10) (n=118) value
Age, mean±SD 37.2 ±2.1 35.2 ±4.2 0.023
N.S.
Aetiology of infertility
• Tubal factor 1 9
• Endometriosis 0 5
• Male factor 3 44 0.670
• Unexplained 2 38 N.S.
• Others 3 6
• Mixed 0 15
Type of treatment
• IVF 7 75 0.684
• ICSI 3 43 N.S.
Type of Embryo
• Fresh 9 112 0.442
• Frozen 1 6 N.S.
Pregnancy outcome
• Pregnant 5 54 0.796
• Non-pregnant 5 64 N.S.
Table 27 Comparison of the single vs. two embryo transfer groups
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There were also no statistical differences in the age, aetiology of infertility, type of
treatment given, the embryo type, and the pregnancy outcome between the single
embryo transfer and 2 embryo transfer groups (Table 27).
4.3.2 Levels of hCG analytes in viable and non viable pregnancy
Amongst the 69 pregnant women who received fresh embryo transfers, 45
pregnancies (65%) were viable and 24 (35%) were nonviable. The viable pregnancy
group included 38 (55%) singleton and 7 (10%) twin pregnancies, whereas the
nonviable pregnancy group comprised 15 (22%) biochemical pregnancies and 9
(13%) 1st trimester spontaneous miscarriages (mean gestational age= 10 weeks).
In the viable pregnancy group, 89 % (n= 40) delivered at term (>37 weeks of
gestation), and 11% delivered preterm (n=5) of which, 3 were twin pregnancies. Mean
gestational age at delivery in singleton pregnancies was 39 weeks + 6 days and mean
birth weight was 3338 grams, whereas for twin pregnancies, the mean gestational age
of delivery and birth weight were 36 weeks and 2282 grams, respectively. No
information on chromosomal abnormality was available; however, evidence of
structural abnormality was reported in two infants (one with pyloric stenosis along
with hypospadiasis, and one with extra digits on both hands). There were two
neonatal deaths; one was associated with prematurity (spontaneous preterm at 25
weeks) and the cause of second was unknown.
As seen in Table 28, the median (range) concentrations of HhCG, hCG, and hCGp in
viable pregnancies on 14 days post-OR were 374 (81-1120), 334 (108.5- 991), and 5
(1.8-26) pmol/L respectively, and 131 (23-350), 90 (13-313), and 1.4 (0.2-5) pmol/L
in non-viable pregnancies, respectively (Table 29). There was a statistically
significant difference between the concentrations of all three hCG in the non-viable
vs. the viable pregnancy group (P < 0.001) (Table 30, Figures 54-56). The
concentrations of HhCG (median with range) for the four groups including
biochemical pregnancies, spontaneous miscarriages, viable singletons and viable
twins were 49 (23- 191), 207 (100.5- 350), 368 (81- 1120), and 452 (226-619) pmol/L
respectively, with the lowest values seen in biochemical pregnancies (Table 31, Figure
54) . The levels of hCG and hCGp amongst these groups are shown in Table 31 and
Figures 55 and 56. Although the average hCG values in twin pregnancies was higher
than those in singleton pregnancies, however the difference was not statistically
significant.
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Total hCG immunoreactivity (HhCG + hCG + hCGP) showed large variations in the
viable as well as the nonviable pregnancy group (ranges of 1.3 to 1.7 and 0.8 to 1.5
respectively) with no statistical significant difference found between the two groups
(median= 1.2 in both groups). The ratios of hCGP to total hCG, and HhCG to hCGP
were similar in both groups (Tables 28-30). This clearly indicates the predominance
of HhCG production, compared to other hCG molecular forms, in the period of Day




N N* Mean StDev Minimum Q1 Median Q3 Maximum
HhCG 44 1 411.8 203.1 81.2 248.4 374.2 513.6 1120.4
hCG 45 0 338.8 169.2 108.5 197.4 334.4 405.1 990.9
hCGP 45 0 6.137 4.757 1.88 3.381 5.016 6.589 25.803
HhCG/(hCGP + hCG) 44 1 1.2231 0.2716 0.1385 1.0652 1.2118 1.388 1.7863
HhCG/hCGp 44 1 78.83 30.41 4.5 61.12 75.51 98.58 150.39
hCGp/(hCGp + hCG) 45 0 0.017708 0.006629 0.007433 0.013639 0.016605 0.020609 0.038973
Table 28 Descriptive statistics for singleton and twins combined in the viable pregnancy




N N* Mean StDev Minimum Q1 Median Q3 Maximum
HhCG 23 1 136.9 100.1 22.8 36.5 131 191 349.8
hCG 24
0
110.2 89.2 13 26.2 89.7 165.9 313.2
hCGP 24 0 1.932 1.393 0.21 0.941 1.493 3.007 4.876
HhCG/(hCGp + hCG) 23 1 1.2156 0.1712 0.8038 1.1054 1.2112 1.3675 1.5215
HhCG/hCGp 23 1 73.62 33.93 28.12 49.08 69.96 93.02 173.87
hCGp/(hCGp + hCG) 24 0 0.02146 0.01167 0.00462 0.01332 0.01732 0.02574 0.04918
Table 29 Descriptive statistics for biochemical pregnancies and spontaneous miscarriages
combined in the nonviable pregnancy group (median and range are highlighted).
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Not Viable Viable 95% CI for
difference P-valueN Median N Median
HhCG
23 131 44 374.2 (179.8- 329.4) <0.001
hCG 24 89.7 45 334.4 (149.4-270.3) <0.001
hCGp 24 1.49 45 5.02 ( 2.26- 4.2) <0.001
HhCG/(hCGp + hCG) 23 1.21 44 1.21 (0.10-0.12) 0.974
HhCG/hCGp 23 69.96 44 75.51 (8.8- 23.1) 0.409
hCGp/(hCG+hCGp) 24 0.02 45 0.02 ( 0.006- 0.002) 0.431
Table 30. Mann-Whitney test results showing differences in the various hCG levels and their












49(23-191) 207 (100.5- 350) 368 (81- 1120) 452 (226-619)
hCG pmol/L 39 (13-159) 181 (86-313)
301 (108.5-
991) 364(170-525)
hCGp pmol/L 1 (0.2- 5) 3(1.5-5) 5 (2- 25) 6(3.5- 10)



















Figure 54 HhCG levels in non-viable and viable pregnancies [0 =not a viable pregnancy
consisting of biochemical pregnancy and miscarriage, 1= viable pregnancy consisting of


































Figure 55 HCG levels in non-viable and viable pregnancies (0= not a viable pregnancy
consisting of biochemical pregnancy and miscarriage, 1= viable pregnancy consisting of





Figure 56 hCG(3 levels in non-viable and viable pregnancies (0 =not a viable pregnancy
consisting of biochemical pregnancy and miscarriage, 1= viable pregnancy consisting of
singletons and twins). P value= Significant (P < 0.001).
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Figure 59 Unaltered ratio of HhCG to hCGfl in non-viable vs. viable pregnancies, P-value=
NS
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4.3.3 hCG analytes at the day of embryo transfer in viable pregnancies
Mann-Whitney tests have been used to determine whether differences in the level of
any of the hormones exist between Day 2 and Day 3 embryo transfers. As seen in
Table 32, none of the hCG analytes showed any statistically significant difference in
their concentrations or their ratios between D2 to D3 embryo transfers. However only
the ratio of HhCG to hCGp was altered (median on D2= 73.3 and D3= 86.5)
indicating that the production of HhCG from the cytotrophoblast is more rapid than the
hCG(3 production from the syncytiotrophoblast.
Molecule
ET day 2 ET day 3 95% CI for
difference
P-
valueN Median N Median
hCG 26 336.8 19 317.3 (-42.1, 130.5) 0.513
hCGp 26 5.4 19 4.61 (-0.17, 2.76) 0.087
HhCG 25 368 19 396.5 (-104.3, 112.1) 0.962
HhCG/(hCGp +
hCG) 25 1.15 19 1.32 (-0.29, 0.01) 0.084
HhCG/hCGp 25 73.3 19 86.56 (-35.67, -1.45) 0.042
hCGp/(hCG+hCGp) 26 0.02 19 0.02 (-0.001, 0.007) 0.110
Table 32. Comparison of serum levels of three hormones and their ratios on Day 2 following
embryo transfer (ET) vs. Day 3 following embryo transfer. P-value only statistically
significant for the HhCG/hCGp.
4.3.4 ROC analysis
ROC curves plotted the sensitivity of HhCG and other hCG molecular forms
measured on the 14th post oocyte retrieval day vs. 1-specificity for a series of
multiple cut-off points. The AUC from the ROC curves were compared for HhCG,
hCG, and hCGp, to establish their diagnostic power in predicting the pregnancy
outcome amongst the IVF group. The performance of total hCG (pregnancy test
positive results obtained with the Siemens Immulite method) was also assessed, since
this assay is routinely used for pregnancy testing in the IVF population in the
Edinburgh Assisted Conception Unit. The model created by Due et al. 217 was used to
rank the accuracy of a diagnostic test in in this population. [See Section 2.6.2 for
details.]
In this study the significance of HhCG levels on Day 14 after the OR in predicting
viable from nonviable pregnancies amongst the IVF population was explored using
ROC analysis (Figure 60). According to the AUC, HhCG measurement was better
than other hCG molecular forms, including total hCG, in distinguishing viable from
nonviable pregnancies. However this observation was not statistically significant
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(Table 33). All four hCG analytes showed excellent diagnostic accuracy for predicting
the ongoing pregnancies (> 90%), but HhCG performed the best.
ROC Curve
1 - Specificity
Diagonal segments are produced by ties.
Figure 60 Receiver operator curve analysis for four hCG parameters, including HhCG
(yellow line), to assess their diagnostic ability to distinguish viable and nonviable pregnancy.
Test Result Variable(s) AUC Std. Error 95% CI Diagnostic accuracy (DA)
HhCG .925 .034 .859-.991 ++
hCG .922 .033 .857-.987 ++
hCG(3, .909 .036 .839-.980 ++
Pregnancy test +ve .907 .041 .826-.987 ++
Table 33 AUC: area under the curve, DA: diagnostic accuracy. ++ (Excellent)
A single cut-off point of 200 pmol/L for HhCG, based on the AUC of 0.925 (95% CI,
.859-.991) was most suitable for predicting viable from the nonviable pregnancy with
93% sensitivity, 80% specificity, 79% PPV (i.e. 55.5% of miscarriages and 100% of
biochemical pregnancies), a false-positive rate of 7% and a false-negative rate of
20%. For hCG, the best cut-off level was 165 pmol/L (~ 56 IU) with 90% sensitivity,
74% specificity, 75% of PPV (55.5% of miscarriages and 86.6% of biochemical
pregnancies), false-positive rate of 11%, and a false-negative rate of 25%.
Management of patients with low serum hCG levels (hCG <30 U/L at the Edinburgh
ACU) requires repeat hCG testing. In the current IVF cohort, total hCG
concentrations of 40 U/L had 100% sensitivity, but with half the specificity of HhCG
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(i.e. 40%). While the levels of > 40 U/L detected the entire viable pregnancy group
correctly, its PPV was significantly lower (49%) meaning that it is a good predictor of
ongoing pregnancy, but fails to efficiently identify women who are at risk of
spontaneous miscarriage. In comparison to HhCG, the detection rate for biochemical
pregnancy and spontaneous miscarriages was 66.6% and 11%, respectively.
Overall, these results suggest that a single Day 14 post OR level of HhCG is not only
diagnostic of pregnancy but also has good predictive value for pregnancy outcome
when compared with other serum hCG molecular forms.
4.3.5 Comparison of HhCG results from two methods
Similar to the observation in the UAE cohort, the poor between assay comparability
are likely to be related to calibration (Figure 61).
Bland-Altman Plot
Averages
Figure 61 Bland-Altman plot comparing serum HhCG results obtained in the Perkin-Elmer
DELFIA method and the Quest Diagnostics method.
4.4 Discussion of results for the Edinburgh cohort
4.4.1 HhCG levels in various pregnancy outcomes
Previous studies have shown that hCG can be detectable in serum as early as 8-9 days
post-gonadotrophin surge 492-493. There is also evidence of hCG secretion from the
embryo affecting the ovarian steroid secretion as early as 6 days following the
gonadotrophin surge, 346' 492' 494. However, hCG is not found in the maternal
circulation until there is direct contact and adhesion between the blastocyst and the
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endometrium. Hence, it is unlikely that transferred embryos would produce a
significant rise of hCG in the maternal circulation within a week, and any hCG-like
activity that is detected earlier is likely to be of pituitary origin or from the injected
hCG which is given as luteal support to women undergoing assisted conception 95'120'
495-497. HCG has been used as a surrogate LH surge due to the degree of homology
between the two hormones, and its biological activity and longer circulating half life
due to the abundance of sialic acid content 498. The administration of hCG at the end
of the stimulation phase with gonadotrophins triggers the maturation of the oocyte,
the resumption of meiosis and the expansion of the cumulus-oocyte complex "2.
Mannaerts et al. showed that 8 days after Pregnyl administration, serum hCG levels
had dropped to 10 U/L and when serum samples were tested for hCG on day 15 after
oocyte retrieval (day 17 after the Pregnyl injection), hCG values of greater than 5 U/L
were regarded as evidence of an invading trophoblast 497. A large study by Snider et al
showed that the 97.5th percentile of nonpregnant women of child-bearing age (18-40
years) had hCG levels of 2.5 U/L (i.e. only one woman had an hCG of 4.6 U/L) and
the other cases had undetectable hCG (<2 U/L), clearly emphasising the long-used
practice of taking 5 U/L hCG as a cutoff for the detection of pregnancy. However,
they suggested that caution must be applied in interpreting a positive hCG result in
peri-menopausal women (41-55 years) among whom "background" hCG ranged from
2- 7.7 U/L. They concluded that serum FSH measurement should be incorporated in
this group of women to assist in the interpretation of a positive hCG result, as their
data showed that pregnancy was unlikely in perimenopausal women with an hCG
between 5.0 and 14.0 U/L if the serum FSH was >20.0 U/L. An earlier study by
Alfthan et al. confirmed the higher upper limit of serum hCG in nonpregnant peri- and
postmenopausal women. Knowledge of the upper limit of "background" hCG is
relevant to the assisted conception population since increasing number of older
women are opting for it. From all of the above it can be seen that low positive levels
in the hCG test, in the IVF population poses a dilemma in terms of interpretation, as
well as introduces uncertainty as to the earliest day on which a pregnancy test can be
performed. Also, management of patients with suboptimal hCG levels involves
several follow-up visits for repeated hCG tests which is time consuming and not cost-
effective, and also places extra psychological pressures on an already vulnerable
group. In the Edinburgh Assisted Conception Unit, it is standard practice to perform
hCG testing, on Day 14 following the oocyte retrieval. Women with serum hCG < 40
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U/L have to undergo repeated serum hCG tests until an optimal rise in hCG is seen
and pregnancy is confirmed by the transvaginal ultrasound, or until serum hCG levels
fall to <5 U/L. A similar management practice is followed in many other centres. A
psychological study comparing functioning in women at different stages of the in
vitro fertilization treatment showed that hostility, depression, and state anxiety scores
were highest at the stage of the pregnancy test 491. Thus, an early marker that can
accurately distinguish viable from non-viable pregnancies before the verification of
live intrauterine pregnancy by the transvaginal sonography, and that would minimize
the need for repeated follow-up, is highly desirable for the IVF population.
HhCG is exclusively produced by phenotypically invasive cytotrophoblast cells which
are active at the time of implantation (and in invasive trophoblastic and non-
trophoblastic tumors) ™'72'74-175. There is no evidence of "background HhCG" from
the pituitary in nonpregnant women. Hence, alteration in hCG levels after ovarian
hyperstimulation and the manipulation of the pituitary-ovarian axis by GnRH
analogues and gonadotrophins is unlikely, making hCG a superior candidate for
pregnancy testing in an IVF population, compared to other hCG forms. Differential
expression of a number of hCG molecular forms, in urine as well as in serum which
carry to term and those destined for early pregnancy loss, has been well documented
in naturally conceived pregnancies 65'268-499 anci in the IVF population 66,67. Early
reports of changes in the temporal pattern of HhCG in continuing and failing
pregnancies in an IVF population was achieved using the ratio of hCG concentrations
measured by two radiolabeled assays; one with affinity for early pregnancy hCG
(B152-B207), asterisk means and the other (B109-B108) with affinity for the later
molecular forms of hCG 67. While the apparent values of hCG (normalized to
creatinine) in the B152 assay (i.e. recognizing mainly HhCG) were higher than in the
B109 assay in both IVF normal pregnancy and IVF losses, the proportion of each
isoform in relation to other (B152/B109 ratio) changed significantly with gestational
age and pregnancy outcome. Kovalevskaya et al. assayed the urine samples from the
day of embryo transfer until day 20 (1-4 weeks post ET) and found that the B152-
recognized molecular forms were first to appear on day 6.75 (range 5-20) from ET,
and there was a significant difference in B152/B109 ratio on Day 5-10 and Day 10-15
post ET between normal IVF pregnancy (single fetus) and IVF EPL . The data
suggested that HhCG accounts for the major proportion of total hCG
immunoreactivity during implantation at the time of trophoblast invasion and the
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weeks following it, whilst lower levels were associated with pregnancy losses.
However no parameters or cut-off values were described that would differentiate
between favourable and unfavourable IVF outcome. Using the same assay methods in
the spontaneous conceptions group, they showed that the B152 antibody was able to
detect 81% of clinical pregnancies and 36% of early pregnancy losses cycles (EPL) 65.
The corresponding figures for the molecular forms recognized by the B109 antibody
were 58 and 36%, respectively. The current study is among the first to evaluate the
usefulness of quantitative HhCG levels for clinical application in the prediction of
pregnancy outcome in an IVF population, by assessing the sensitivity, specificity, and
positive predictive value of the test. The present prospective study also included
measurements of hCG and hCGp, allowing us to directly compare the three hormonal
parameters in terms of their diagnostic accuracy in the prediction of IVF outcome.
Our results show that the concentration of HhCG was significantly higher on day 14
post oocyte retrieval (OR) for viable pregnancies (i.e. singletons and twins) compared
to nonviable ones (i.e. biochemical pregnancies as well as spontaneous miscarriages)
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confirming the findings of Kovalevskaya et al. ' (Figures 54 and 55 and Tables 29-
31). The concentration of HhCG in the nonviable group varied from 23 to 350 pmol/L
(median= 131 pmol/L). This was lower than the variation found in the viable group
(i.e. range 81- 1120 pmol/L, median= 374 pmol/L). The finding of lower levels of
HhCG in failing pregnancies has also been documented in naturally conceived
pregnancies in many reports 65'81 and is consistent with the present results from the
UAE cohort [Section 3.7], Similarly, the levels of hCG and hCGp in the viable
pregnancy group were higher than in the nonviable group, ranging from 108.5 to 991
pmol/L (median= 334 pmol/L) and 2 to 26 pmol/L (median= 5 pmol/L), respectively
(Figure 55 and 56 and Tables 28-31). This is also in agreement with many other
previous studies 218'424'485'486'500-503.
As seen from Tables 28-30 and Figure 57, 100% of total hCG immunoreactivity in
day 14 post-OR serum samples was HhCG ( HhCG/ hCG + hCG P, %) in both viable
and nonviable pregnancies. No difference in this ratio was observed between the two
groups (median of 1.2 in both), indicating the dominance of HhCG production from
the cytotrophoblast during the very early period of gestation, irrespective of the
pregnancy outcome. The ratio of hCGp/total hCG, and HhCG/ hCGp also remained
unchanged (Figures 58 and 59 and Table 28-30,). This is not surprising, considering
the dominance of HhCG-secreting cytotrophoblast cells during the early stages of
170
blastocyst differentiation. When cytotrophoblast cells fuse to form intermediate cells,
then syncytiotrophoblasts, the proportions of HhCG rapidly fall concurrently with
advancing gestation, as shown in the UAE cohort of this study and by many other
66 67 70 81
investigators ' ' ' . Indeed, it was previously shown that the shift in the relative
proportion of HhCG in relation to later hCG molecular forms as the gestation
progresses had a better power of discriminating between the continuing and non-
continuing IVF pregnancy groups than when the time-frame shift was eliminated,
suggesting that as gestation proceeds the biological activities of cellular factors
controlling the expression of hCG molecular forms and cytotrophoblast differentiation
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become apparent in both continuing as well as in failing-pregnancies ' . A later
study further emphasized that using proportion of HhCG at the time of implantation
was a stronger discriminator of failing and continuing pregnancies compared to the
HhCG or hCG alone 504 .
As discussed in previous chapters, serial measurements of serum hCG during early
gestation are critical for the evaluation and differentiation of normal from abnormal
pregnancies. Similar to the pattern of hCG rise in spontaneous pregnancies described
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by Kadar et al. and Barnhart et al. ' , several authors have tried to characterize the
pattern of serial hCG rise in an IVF cohort 487'506-507 \ mean hCG doubling time of
1.59 days for days 12-16 post-OR was shown by Richards et al. 485, 1.57 days for
days 11-23 post-OR by Zegers-Hochschild et al.508 and 1.6 days at day 12 to about 3
days at 24 days after ET by Stone et al. 507. Also in most studies, the curve was shown
to be quadratic with an earlier plateau (i.e. the rate of increase slows at ~24 days post-
oocyte retrieval, or a gestational age of 5 weeks and 3 days) but on average, an
increase of 50% in 1 day and 124% in 2 days is generally seen 509. The relatively early
plateau in hCG production may reflect differential rates of implantation of multiple
embryos transferred or resorption of non-viable embryos. Alternatively, it is possible
that the administration of exogenous progesterone given for luteal support, leads to a
diminished requirement for hCG-induced steroidogenesis by the corpora lutea 509.
Although the absolute hCG values are higher in multiple pregnancies, than in
singleton pregnancies, no difference in doubling time has been shown 508' 509.
However, data on hCG doubling time in miscarriages and ectopic pregnancies have
been conflicting. While some reported a slow rise of hCG (or delayed DT) 248'508,
others reported a normal rise and doubling time 51°. In both cases, the pattern of hCG
rise has been shown to be a poor indicator in discriminating miscarriages from ectopic
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pregnancies and it has been suggested that the rate of rise is dependent on many
factors such as multiple embryo transfer leading to multiple gestations, BMI, and the
syndrome of vanishing twins 487' 488'509'51Indeed, studies have shown that even
second-trimester maternal serum levels of hCG, AFP and unconjugated oestriol are
altered in pregnancies conceived by conventional IVF or ICSI 51 " 14. The false
positive rate in Down syndrome screening in these groups is found to be higher
compared to spontaneous pregnancies. The reason for level alterations in these
markers in pregnancies achieved through assisted reproduction remains unknown. The
fact that the median age of women becoming pregnant through assisted reproduction
is higher than in spontaneous pregnancies may be one possible reason for higher false
positive rates. Alternatively, it has been hypothesized that high hCG levels may be a
result of the higher levels of progesterone found in these pregnancies compared to
natural conceptions, which may have resulted from ovarian hyperstimulation and the
subsequent formation of multiple corpora lutea 514. However this hypothesis has been
disputed since hCG elevation was also observed in women who conceived after ovum
donation and frozen embryo transfer, where the possibility of excessive follicles and
multiple corpora lutea does not exist 512, 515' 516. Differences in the growth and
development of the fetus and sub-optimal placentation have been suggested an effect
of ICSI (embryos produced from ICSI have a tiny hole in the zona pellucida) and
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freeze-thawing of an embryo . Indeed, many studies (including our own) have
shown that the implantation potential of frozen-thawed embryos is lower than that of
fresh embryo. However, the reasons why frozen-thawed embryos following
implantation have increased hCG production in some studies is as yet unknown. The
mechanical and/or temperature related insult on the embryo may trigger a
compensatory hyper-reactive secretion by the growing trophoblast, although why the
placental markers alter is still not known. However, many authors agree that
appropriate adjustment for some variables is necessary in the screening programme
for assisted reproduction pregnancies 512-514.
Although the average levels of all hCG forms in multiple pregnancies were higher
than in singleton pregnancies in the current study, this difference was not statistically
significant (Table 31). This was probably due to the small number of twins along with
variations in the day of sample collected (Day 11 or 12 post ET). Performing the
study with a larger group may yield significantly higher hCG results for multiple
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pregnancies, as has been shown in many previous studies 218' 500'501'517, and which
represents higher hCG production from multiple implanted embryos.
4.4.2 Levels of hCG by the day of embryo transfer
Some researchers have recommended embryo transfer on Day 5 post-oocyte retrieval
(if certain criteria were met) because of the higher reported implantation and
pregnancy rates associated with blastocysts with 64+ cells on Day 5 518, although
there is no general agreement in the literature. During the early days of IVF, culture
media that were able to sustain embryonic development for days and provide the best
environment for the survival of the embryo were lacking, leading to embryos being
transferred 2 days following the OR at the 2- to 4-cell stage. The timing of the arrival
of the embryo in the uterus during that stage is premature compared with the situation
in spontaneous conceptions, where the embryo enters the uterus at the morula stage,
4-5 days after ovulation 183'519 (Figure 62). Advantages of prolonged embryo culture
lie in synchronization between embryos and endometrium, and transfer of embryos to
the uterus on Day 3 (or later) mimics more closely the physiologic time of uterine
entry than day 2 ET, and also allows better selection of viable embryos 519. While the
ideal time of embryo replacement remains debatable, many prospective and
retrospective data show that the mean embryo quality of D2 embryos is slightly better
than D3 embryos, and pregnancy and implantation rates are comparable in day 2 and
day 3- embryo transfers (or even day 5-6 transfers) 519-521. One study showed that an
hCG test on day 16 post-retrieval after blastocyst transfer a better predictor of clinical
outcome than a hCG value after a day 3 embryo transfer, and the probability of an
ongoing pregnancy was 90% using a hCG cut-off value of >100 U/L (for D3 post
OR), and 97% at a level of >300 U/L (for D5 post OR) 518. The current study data
failed to show any difference in pregnancy rate between the Day 2 (n=26) or Day 3
(n=19) embryo transfers (Table 32), or in any of the hormone levels on Day 14 post
OR (a pregnancy test on Day 14 of oocyte recovery for D2 transfers corresponds to
Day 12 after ET, whereas for D3 this corresponds to day 11 of ET). However, the
ratio of HhCG to hCGp was significantly altered (P=0.042) (Table 32). An increase in
the ratio from D2 to D2 transfers is likely to be due to the dramatic increase in HhCG
levels, compared to a slower increase in hCGp from an embryo which is in a
relatively more advanced developmental stage. Also, the higher ratio may reflect a
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higher rate of proliferation of cytotrophoblast cells on D3 compared to D2, with less
differentiation.
Figure 62 The early stages (shown as A-G above) of human development from fertilization to
blastocyst formation. Day 3 ET or later mimics the physiological time of embryo entry into
the uterus in spontaneous conceptions. [Figure adapted and extended from Reference 184.]
The number of embryos transferred is also critical to successful IVF/ICSI treatment
and many centres try to improve their "take-home-baby rate" per treatment cycle by
transferring more embryos. This leads to higher rates of multiple birth, without
necessarily improving the overall success rate, since the risk of adverse perinatal
outcome associated with multiple pregnancies such as preterm births and low birth
weights are higher 522-524. To reduce the incidence of higher-order multiple gestation,
methods such as single embryo transfer and/or transfer of embryo at the blastocyst
stage have been suggested 525' 526. However this is at the expense of reducing the
chances of live birth in an IVF cycle 523
4.4.3 Screening performance of HhCG in the Edinburgh cohort
In selecting one group for closer follow up on the basis of the hCG level measured on
Day 12-14 after embryo transfer, two things must be considered before choosing a
cut-off value, i.e. the lower the hCG value (lower sensitivity) the higher is the
likelihood of non-viable pregnancy (specificity), and the higher the hCG cut-off value,
the lower the likely positive predictive value (true spontaneous abortion) as a result of
Oocyte
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the increase in sensitivity and the reduction in specificity 2I8. Thus, setting a higher
cut-off point in order to increase sensitivity should not be a priority in the IVF
population, since this would decrease the specificity considerably. Hence, not only
will it not discriminate vital from potentially life-threatening ectopic pregnancies, but
it will also add to the psychological stress on an already vulnerable population by
giving them false reassurance. The same rule applies for conducting a hCG test before
Day 12-14 of ET, as the earlier the test is performed, the higher the rate of false-
negative tests. Selecting a single cutoff value for HhCG for each day of ET was not
possible in this study due to the small sample size of the positive pregnancy test group
in this study. Moreover, splitting the outcomes further into Day 11 or 12 of post-ET
would yield bias, or to a statistically non-significant result. Hence the diagnostic
performance for all hormonal cut-off values was calculated irrespective of the day of
ET.
The significance of HhCG levels on Day 14 after OR in predicting viable from
nonviable pregnancies in the IVF population by ROC analysis using the model
created by Due et al. 217 to rank the accuracy of a diagnostic test (Figure 60). It was
found that according to AUC analyses, HhCG measurement was superior to other
hCG molecular forms, including total hCG, in distinguishing viable from nonviable
pregnancies. However this observation was not statistically significant (Table 33). All
four hCG analytes showed excellent diagnostic accuracy for predicting ongoing
pregnancies (> 90%), but HhCG performed best. The cut-off level of 200 pmol/L
gave the best balance between sensitivity and specificity, based on an AUC of 0.925
(95% CI, .859-.991), and distinquished viable from nonviable pregnancies with 93%
sensitivity, 80% specificity, 79% PPV (i.e. 55.5% of miscarriages and 100% of
biochemical pregnancies), a false-positive rate of 7% and a false-negative rate of
20%. In contrast, the cut-off level for hCG (165 pmol/L) (~ 56 IU) yielded only 90%
sensitivity, 74% specificity, 75% of PPV (55.5% of miscarriages and 86.6% of
biochemical pregnancies), false-positive rate of 11%, and false-negative rate of 25%.
As the sensitivity of both molecules was similar, the choice of superiority of a marker
depends on weighing the cost of unnecessary intervention and close monitoring of
continuing pregnancies but are falsely identified as a miscarriage or non-continuing
pregnancy, against the health risks and hazards of falsely identifying a non-continuing
pregnancy as a continuing one. The latter choice of becomes more important in the
assisted conception population since pregnancies obtained after an IVF/ICSI and
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embryo transfer (ET) are at risk of adverse outcome compared to natural conceptions,
488 489
including the risk of ectopic pregnancy and spontaneous miscarriages ' . The
superiority of HhCG as a marker is due not only to its excellent diagnostic accuracy
for predicting the ongoing pregnancies, but to its higher PPV and lower false-positive
and false-negative rates. Even the criterion of our centre to follow up patients with
suboptimal levels of hCG (> 40 U/L) has the ability to correctly identify the entire
viable pregnancy group. However, with a PPV of 49%, it is a poor predictor of non-
continuing pregnancies and ectopics.
Different cutoff levels have been proposed by different authors. Bjercke et al. showed
that a cut-off value of 55 U/L had a 90% chance of a vital pregnancy after IVF and
embryo transfer, whereas the positive predictive value (i.e. the probability that a
patient will have an early pregnancy loss) was 60% 218. Lambers et al. proposed a cut¬
off point for Day 14 and 15 of 76 U/L and 142 U/L, respectively 503. Urbancsek et al.
suggested that a cut-off level of 50 U/L would predict pregnancy outcome with a
sensitivity of 75% and a specificity of 81%, while an hCG value >135 U/L would
predict a multiple ongoing pregnancy with a sensitivity of 80% and a specificity of
88% 501. Sugantha et al. reported a discriminatory hCG value of 50 U/L for day 14
517after oocyte retrieval, with a 79% of sensitivity and 78% specificity
The present study results are in agreement with previous studies showing low levels
of HhCG amongst pregnancies destined for failure, and has the ability to accurately
identify 100% of biochemical pregnancies, making it the most accurate single early
marker of biochemical pregnancy currently available 66'67'81
4.4.4 Limitations of the Edinburgh IVF / ICSI cohort study
The use of a single hCG cutoff value in an IVF setup remains controversial and may
not be generally applicable. Although many investigators have attempted to obtain the
best possible cutoff value to discriminate viable from non viable pregnancies using
hCG immunoassays, the results obtained from these studies are heterogeneous, with
differences in the definitions of pregnancy outcome, extrapolation of data, study
design, study population, risk factors, timing of hCG tests in relation to the day of
embryo transfer, and many other factors which may influence the hCG results in each
research study. Studies should include specific inclusion and exclusion criteria to
create a more homogeneous sample to determine the prognostic significance of hCG.
The IVF cohort studied was not representative of the whole IVF population, since the
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rate of non-viable pregnancy which included BP and EP was higher than for the
whole IVF cohort. Only patients with known outcomes were included which may
have produced an imbalance in the data, and may have been partly due to the criteria
used to define non-viable pregnancy. In this regard many studies have shown widely
differing incidences of adverse pregnancy outcome based on the definitions used and
studies reporting IVF success rates do not use a standardised definition of pregnancy.
Other limitations relevant to the spontaneous pregnancy cohort [see Section 3.9] may
also be applicable to the assisted conception cohort. These include the following:
1. Variables that influence the IVF outcome (e.g. parity, prior spontaneous abortions,
tobacco use, FSH levels, number of IVF cycles) were not assessed.
2. The study included a relatively small sample number and thus had limited power
to detect differences in subgroup analysis.
3. Data on the chromosomal abnormalities or any other maternal disease was not
available but might also have prognostic significance.
4. There is no International Standard for HhCG which may contribute to the poor
between assay comparability observed (Figure 61). Differences in assay protocols
may all influence the applicability of our finding in general population.
In summary, discriminatory hCG cutoff values may be useful in predicting
implantation outcome in IVF-ET cycles and may help to guide clinicians in
identifying pregnancies at risk for adverse outcomes to enable more intensive
surveillance of this population. Results suggest that a single Day 14 post OR level of
HhCG is not only diagnostic of pregnancy but also has good predictive value for the
pregnancy outcome, when compared with other serum hCG molecular forms. This
information also may be useful in providing counselling to IVF patients regarding
pregnancy prognosis and could also perhaps result in cost savings.
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CHAPTER 5. SDS-PAGE AND WESTERN BLOT
CHARACTERIZATION OF OLIGOSACCHARIDE
HETEROGENEITY IN HCG FROM DIFFERENT
SOURCES
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5.1 Background to the study of molecular heterogeneity
hCG is a glycoprotein containing N-linked and O-linked oligosaccharides which
exhibit high variation in their glycosylation pattern ranging from mono- to multi-
branched carbohydrate structures. The carbohydrate content of hCG changes in
different physiological and pathological situations. As glycosylation pattern of hCG
reflects the physiological or pathological state of trophoblastic cell, it has been
extensively investigated for its usefulness in the prediction of pregnancy complication
as well as in the diagnosis and monitoring the course of trophoblastic disease.
The purpose of the experiments undertaken here were to investigate the variation in
carbohydrate content of hCG purified from different sources including normal
pregnancy (Pregnyl) and hCG produced from cancer cell line (JEG3) using MAbs and
a panel of commercially available lectins. Qualitative differences in lectin binding
affinity for certain sugar residues that discriminate hCG glycoforms in urine samples
from women with normal pregnancy and molar pregnancy were also explored in order
to evaluate the usefulness of this method in the diagnosis and prognosis of pregnancy
complication and trophoblastic diseases.
5.2 Results of studies of molecular heterogeneity
5.2.1 Carbohydrate heterogeneity using different MAbs in hCG from
pregnancy sources and JEG3 cell lines
5.2.1.1 Studies with MAb8F11SMA
Directed to antigenic site of hCG which is available on hCG, hCGp, and the hCGPcf,
including hCG minus the CTP and hCGp missing the CTP.
Many protein bands at approximately 65, 50, 37, 25 and 23 kDa were identified in
non-reduced purified hCG (non-reduced Pregnyl), and additional higher bands of 150
and 96 kDa were detected in the non-reduced choriocarcinoma hCG (non-reduced
JEG3) (Figure 63)
After reduction, the purified hCG showed two distinctive bands of 36 and 24 kDa,
identified as the p-subunit of hCG and the P-subunit minus the CTP. However, no
bands were detected for reduced choriocarcinoma hCG indicating that carbohydrate
content of the hormone has altered during its mobility in the SDS-PAGE. Since upon
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reduction, the hCG dimer dissociates into its subunits, the earlier 50 and 37 kDa bands
detected under the non-reducing conditions can be identified as intact hCG dimer with
variation in sialic acid content. (Figure 64.











Figure 63 Probing of Pregnyl (P) and JEG3 (J) hCG with MAb 8F1 ISMA [Non-reducing conditions;












Figure 64 Probing of Pregnyl (P) and JEG3 (J) hCG with MAb 8F11SMA [Reducing conditions;
molecular weight markers (M) shown].
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5.2.1.2 Studies with MAb B152
Two bands of 46 and 37 kDa were detected in non-reduced Pregnyl as well as non-
reduced JEG using the B152 antibody indicating its ability to detect the hCG dimer
besides the hyperglycosylated form of hCG present in both purified as well as
choriocarcinoma hCG (Figure 65.
Upon reduction, purified hCG dissociated into two bands at about 35 and 30 kDa
identified as hCGP with heterogeneous carbohydrate composition, whereas reduced
JEG3-hCG showed bands at 50 and 37 kDa indicating that hCGP derived from














Figure 65 Probing of Pregnyl (P) and JEG3 (J) hCG with MAb B152. [Non-reducing conditions;













Figure 66 Probing of Pregnyl (P) and JEG3 (J) hCG with MAb B152 [Reducing conditions; molecular
weight markers (M) shown].
5.2.2 Examination of carbohydrate heterogeneity of Pregnyl and JEG3
by lectin-binding
Variations in lectin-binding patterns to hCG were seen between the pregnancy sample
as well as the hCG derived from JEG3 choriocarcinoma cell line for both non-reduced
and reduced forms. More pronounced binding pattern could be demonstrated in
reduced purified hCG upon reduction. Results of the lectin-binding are expressed in
terms of the intensity of the colored-bands visualized (++ dark band, + light band, and
± faint band). Lectins were classified into four groups according to their broad sugar
specificities, i.e. Group 1 GlcNAc-binding lectins: WGA, Solanum tuberosum,
Griffonia simplicifolia II, succinylated WGA, Lycopersicon esculentum, Phaseolus
vulgaris erythroagglutinin); Group 2 GalNAc-binding lectins: Jacalin, soya bean
agglutinin, Amaranthus caudatus lectin, Peanut agglutinin, Dolichos biflorus
agglutinin, Saphora japonica agglutinin Griffonia simplicifolia I, Erythrina cristagalli
lectin, Vicia villosa lectin; Group 3 Mannose/galactose/fucose-binding lectins
(neutral sugars): Lens culinaris agglutinin, Jacalin, Soya bean agglutinin, Lotus
tetragonolobulus lectin, Amaranthus caudatus lectin, Datura stramonium agglutinin,
peanut agglutinin, Con A, Ulex europaeus agglutinin I, Phaseolus vulgaris
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leucoagglutinin, Pisum sativum agglutinin, Saphora japonica agglutinin, Griffonia
simplicifolia I lectin, Lathyrus odoratus lectin, Erythrina cristagalli lectin, Phaseolus
vulgaris erythroagglutinin; Group 4 Sialic acid-binding lectins: WGA, succinylated
WGA, Sambucus nigra agglutinin, Solanum tuberosum and Lens culinaris agglutinin
5.2.2.1 Lectin binding to Pregnyl
Non-reduced hCG bound to lectins recognizing neutral sugar components of a- and/or
(3-N-linked chains of hCG (Figures 67 and 68). Reduced hCG bound to all of the
lectins except soya bean agglutinin and Griffonia simplicifolia I and II (Figures 69
and 70).
5.2.2.2 Lectin binding to JEG3 hCG
Since lectins bound more to purified hCG after reduction, affinity to lectin binding
was tested only on the reduced JEG3 hCG forms which showed affinity to either
neutral sugar or sialic acid binding (Figures 71 and 72). JEG3 hCG bound to lectins
identifying mannose, N-acetylgalactosamine, a-linked L-fucose and N-
acetylglucosamine.
From these results, the heterogeneous glycoform patterns of hCG from different
sources is evident. Pregnancy hCG appears to more sialylated than the
choriocarcinoma hCG. Both Solanum tuberosum and Sambucus nigra agglutinin
showed bands at 20 kD confirming the presence of sialic acid in the hCG-CTP region
of hCG from normal pregnancy.
A faint band is also seen at the 36 kD region in Pregnyl with results for the Sambucus
nigra agglutinin lectin indicating hCGp is sialylated. In comparison to hCG from
Pregnyl, JEG3-hCG appears to be more fucosylated. The fucose-binding lectin Lotus
tetragonolobulus shows bands in hCG-CTP region and hCGp, at 25 kD and 36 kD,
respectively. Triantennary branching on hCGp was observed in choriocarcinoma hCG
but not normal pregnancy hCG.
No difference in the mannose binding lectins was observed in the hCG preparations
from the two sources, lectins recognizing terminal N-acetylgalactosamine and
galactose bound more strongly to Pregnyl hCG.
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Code Lectin Abbrevn Specificity Pregnyl JEG3







3 Wheat germ agglutinin WGA




















7 Soya bean agglutinin SBA
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ACL Galactosyl ((3-1,3) N-















15 Peanut agglutinin PA Galactosyl ((31 -3) N-acetylgalactosamine (T-antigen) +(25)

















PHA-L (3(1 —6) triantennary branching(Ca2+ and Mg2+essential) +(37)
22 Pisum sativum agglutinin PSA
a-linked glucose or mannose
(Ca2+ and Mg2+essential)
+(25), ++(26),
























27 Succinylated wheat germ
agglutinin
WGA-S N-acetylglucosamine ++(25), +(37) +(25), +(37)








acetylglucosamine ++(25), +(37) +(37)










Table 34 List of lectins used with their binding specificities and results of lectin-probing in
Pregnyl as well as JEG3. (Gal, galactose; GalNAc, N-acetylgalactosamine; GlcNAc, N-
acetylglucosamine; NeuNAc, N-acetylneuraminic acid; Man: mannose).
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Figure 67 Lectin probing of Pregnyl. For lectin codes see Table 34.
[NR, non-reducing conditions; molecular weight markers (M) shown].
Figure 68 Lectin probing of Pregnyl. For lectin codes see Table 34.
[NR, non-reducing conditions; molecular weight markers (M) shown].
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Figure 69 Lectin probing of Pregnyl. For lectin codes see Table 34
[R, reducing conditions; molecular weight markers (M) shown].














I |22 23 24, 25 , 2 27 29 12 31 32 34
Figure 70 Lectin probing of Pregnyl. For lectin codes see Table 34
[R, reducing conditions; molecular weight markers (M) shown].
Figure 71 Lectin probing of JEG3 hCG. For lectin codes see Table 34.
[R, reducing conditions; molecular weight markers (M) shown].
Figure 72 Lectin probing of JEG3 hCG. For lectin codes see Table 34.
[R, reducing conditions; molecular weight markers (M) shown].
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The lower molecular weights in the Western blots may represent high mannose-type
carbohydrate, while the higher molecular weight bands may be due to a more
complex-type bi- or triantennary sugar chain branches.
5.2.3 Carbohydrate heterogeneity using different MAbs in hCG from
patient samples
Similar studies were performed on human pregnancy samples to determine whether
lectin and/or MAb B152 binding studies could helpfully contribute to diagnosis of
failing pregnancies. Nine stored urine samples which had been collected at different
gestational ages from women in the UAE cohort who had a successful pregnancy
outcome were randomly selected. Samples 1-3 were from gestations <6 weeks long, ,
4-6 from 7-12 weeks and 7-9 were from the 2nd trimester (Table 35). Three urine
samples from molar pregnancies were also selected (Samples 10-12, Table 35).
Western blotting was performed using MAbs B152 and 8F11SMA as described
previously [Section 2.5.4],
Sample Gestation
no (weeks) Total hCG Dilution Sample Buffer Creatinine
(pmol/L) (PL) m mmol/L
Normal pregnancy samples
1 <6 162548 8.4 100 740 2.4
2 <6 25836 1.3 100 34 2.0
3 <6 19317 1.0 100 0 1.3
4 7- 12 144618 7.5 100 649 1.5
5 7- 12 1279871 66.3 10 653 4.4
6 7- 12 254309 13.2 100 1220 7.7
7 > 13 97340 5.0 100 404 8.2
8 > 13 422079 21.9 10 209 16.0
9 > 13 193703 10.0 100 903 4.4
Molar pregnancy samples
10 8 9690 0.5 100 0 1.5
11 9 1449932 75.1 10 740 9.6
12 16 5918619 306.4 4 1220 16.9
Table 35 Urinary hCG and creatinine levels in patient samples that were probed with lectins
and MAbs [Section 5.2.4],
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In reduced samples, all hCG positive samples containing immunoreactive forms with
an approximate molecular weight of 37 kDa were identified as hCGp or hCGPn, those
of 20-25 kDa as hCGP missing the C-terminal peptide and those of 10-15 kDa as
hCGPcf. Except for hCGpcf, all these forms were present in the non-reduced samples
as was the intact heterodimer (molecular weight 50 kDa or more).
5.2.3.1 Studies with MAb 8F11SMA
The carbohydrate structures of choriocarcinoma hCG resembled that of normal
pregnancy hCG in reduced conditions when probed with MAb 8F11SMA (Figures 73
and 74). Bands with molecular weights of 37 kDa (probably hCGP) were seen in all
normal and molar pregnancy samples (Samples 1-12). Additional bands of 20 kDa
and 15 kDa were only seen in the 2nd trimester urine samples and in all molar
pregnancy samples and probably represent the C-terminal extension of hCG and
hCGPcf, respectively.
5.2.3.2 Studies with MAb B152
Comparison of the gel electrophoretic patterns of hCG from normal pregnancy patient
urine and pregnancy samples by immunoblot analysis with B152, prepared in reduced
conditions, shows that HhCG is present in urine of pregnant women (Figures 75 and
76). When MAb B152 was used at a 1/5000 dilution to probe the neat urine samples, a
37 kDa band representing HhCGp, was detected in 8 of the 9 pregnancy samples
(Figure 75). Meanwhile, the immunostained band of 37 kD was seen only in 1st
trimester urine samples when samples were diluted (Table 35) and a higher
concentration of MAb B152 used (i.e. at a dilution of 1/2500) (Figure 76). This
supports the results of obtained using the DEFFIA assay system, which showed early









Figure 73 Neat urine Samples 1-12 (Table 35) probed with MAb 8F11SMA (1/5000 dilution).











Figure 74 Diluted urine Samples 1-12 (Table 35) probed with MAb 8F11SMA (1/2500 dilution).
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Figure 75 Neat urine Samples 1-12 (Table 35) probed with MAb B152 (1/5000 dilution). [Reducing













Figure 76 Diluted urine Samples 1-12 (Table 35) probed with MAb B152 (1/2500 dilution). [Reducing
conditions; molecular weight markers (M) shown].
5.2.4 Examination of carbohydrate heterogeneity of urine samples from
patients with normal or molar pregnancy using lectin-binding
Lectin analysis of urine samples from different gestational stages and using the
Sambucus nigra agglutinin, Lotus tetragonolobulus, Con A, and Phaseolus vulgaris
leucoagglutinin, in conjunction with an avidin-biotin peroxidase complex, showed
heterogeneous binding patterns. Con A and Sambucus nigra agglutinin revealed both
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high and low molecular weight immunoreactive bands indicating variation in
mannose as well as the sialic acid content in the N-linked sugar chains of hCG in most
samples irrespective of gestational age (Figure 77 and 78). Lotus tetragonolobulus
lectin reacted strongly in only two pregnancy samples, suggesting fucose-containing
oligosaccharides may not be present in pregnancy urine (Figure 79). Lectin
recognizing the tri-antennary oligosaccharides (e.g. Phaseolus vulgaris
leucoagglutinin) reacted with the majority of normal pregnancy samples, including




Figure 77 Con A lectin probing of patient urine Samples 1-12 (Table 35).











Figure 78 Sambucus nigra lectin probing of patient urine Samples 1-12 (Table 35).











Figure 79 Lotus tetragonolobulus lectin probing of patient urine Samples 1-12 (Table 35).
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Figure 80 Phaseolus vulgaris leucoagglutinin lectin probing of patient urine Samples 1-12 (Table 35).
[R, reducing conditions; molecular weight markers (M) shown].
5.3 Discussion of results of molecular heterogeneity studies
5.3.1 Carbohydrate heterogeneity identified by different MAbs in hCG
from different sources
The molecular size and carbohydrate content of hCG varies in normal and in
pathological conditions. However, Western blotting with MAb B152 (Figures 65 and
66) shows that the same protein bands were detected in hCG from a pregnancy source
(Pregnyl) as in JEG3 choriocarcinoma cell lines. This suggests that the protein profile
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of hCG does not provide a reliable marker for disease prognosis. Elliot et al. showed
that O-linked oligosaccharides of 1st trimester normal pregnancy urine hCG contained
12.3-19% hexasaccharide structures while choriocarcinoma urine hCG contained 48-
18100% . Site-specific glycan analysis of hCG by liquid chromatography and
electrospray mass spectrometry of commercial hCG preparation similar to the one
studied here, showed high proportions of core-2 glycan indicating that the preparation
was mainly derived from first-trimester urine 77. The same study showed that N-
glycan structures of JEG3-derived hCG resembles that from early pregnancy,
including the degree of fucosylation and the content of triantennary glycan structures.
The reactivity of both choriocarcinoma-derived hCG and pregnancy-derived hCG
with MAb B152 in the current study may be explained in similar manner. As Pregnyl
is purified from pooled urines of pregnant women during various gestational ages,
these larger sugar chains in Pregnyl may have originated from very early pregnancy
urine samples or even from choriocarcinoma hCG contamination within the pooled
urine can not be ruled out 84 208'527_
In non-reduced samples, B152 showed a band at 50 kDa which may be hCG and a 37
kDa band which may be either the hCG minus the CTP or the nicked/nicked free (3-
subunit of hCG. It is unlikely that the 37 kDa band represents the hCG minus the CTP
since the B152 antibody has shown to specifically detect the hexasaccharide O-linked
oligosaccharides on the C-terminal peptide of choriocarcinoma-derived hCG, hence
making the presence of hCG CTP mandatory for immunoreactivity 49'M. Moreover, a
darker band at 37 kDa in JEG3 hCG (Figure 65) confirms the presence of hCG(3
which is produced more abundantly in gestational trophoblastic tumours than in
normal pregnancy 28'75'175-344'390'528.
Interestingly, a higher molecular weight band of 50 kDa was seen in JEG3-derived
hCG but not in Pregnyl, in addition to the 30- 37 kDa band seen in both hCG under
the reduced condition. This confirms that choriocarcinoma-hCG is hyperglycosylated.
As hCG dimer dissociates into free-subunits following the addition of reducing agent,
it is unlikely that this 50 kDa band is HhCG. The higher band may represent an
oligosaccharide of HhCGP with variations in its sugar content. As is the case in
tumour-derived hCG wherein Core-2 type O-glycans have increased fucosylation of
the Asn-13-linked glycan and the presence of these large glycans has been suggested
to inhibit the association of the a- and P-subunits thereby increasing the proportion of
HhCGP present77.
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Using MAb 8F11SMA, which recognizes hCGp, hCGpcf and hCG, the relative
intensity of immunostaining of choriocarcinoma and pregnancy hCG differed under
the reduced and non-reduced conditions (Figures 63 and 64). While bands at 50, 37,
and 25 kDa were seen in both JEG3 and Pregnyl preparations, Pregnyl showed
stronger immunoreactivity towards the MAb 8F11SMA. While the nature of this
antibody is not yet characterized, it appears that it binds to a conformational epitope
present on most molecular forms of hCG. However, the epitope it recognizes may be
located in a region near the cystine knot motif of the CTP which is known to be
-37 1 QO
mobile, not visible on the crystal structure of hCG , and variably truncated . MAb
8F11SMA may preferentially bind to hCG and hCGp but not to the nicked forms.
This may explain why stronger immunostaining was seen for Pregnyl (Figure 63) than
for JEG3 hCG, which is known to be heavily nicked 49'119'121-529.
Reducing conditions are known to destroy the tertiary three-dimensional structure of
07 1 QO
hCG molecular forms ' ' . This may explain the complete absence of
immunoreactivity with JEG3 hCG and the reduction in the immunostaining of
pregnancy-derived hCG (Figure 64) that is observed when MAb 8F11SMA was used
in the current study. Unlike MAb 8F11SMA, MAb B152 binds to HhCG irrespective
of the state of nicking of the polypeptide chain and its sialic acid content ' , so
immunoreactivity was seen for both choriocarcinoma and pregnancy hCG under both
reduced and non-reduced conditions (Figures 65 and 66).
Comparison of gel electrophoretic migration sizes of the hCG from normal pregnancy
patient urine belonging to various gestational ages as well as molar pregnancy
samples by immunoblot analysis with MAb B152, prepared in reduced conditions,
shows that HhCG is present in urines of pregnant women (Figures 75 and 76). When
MAb B152 was tested in the neat urine samples with no dilution, i.e. 1/5000
concentration, the 37 kDa band representing HhCGp was detected in 8 of the 9
pregnancy samples (Figure 75). Meanwhile, the immunostained band of 37 kD was
limited to the 1st trimester urine samples when samples were diluted (Table 35) and a
higher concentration of MAb B152 (i.e. 1/2500) used (Figure 76). This finding
supports the results described earlier for both for the spontaneous pregnancy cohort
(Chapter 3) and pregnancies achieved through assisted conception (Chapter 4). This
confirms that higher concentrations of HhCG immunoreactivity are observed in the 1st
than in the 2nd trimester. This may reflect the limited differential status of trophoblast
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cells whereby HhCG is produced by the stem cytotrophoblasts and hCG is produced
by differentiated syncytiotrophoblasts 67,70,180-244
Comparison of the above data (i.e. MAb B152 diluted by 1/5000 in neat urine samples
vs. 1/2500 in diluted samples) suggests that using a 1/2500 concentration of MAb
B152 in a neat sample may produce stronger immunoreactive bands in early
pregnancy samples (<6 weeks gestation) as compared with later pregnancy samples,
mirroring the time-shift frame of HhCG production.
In contrast to normal pregnancy, no difference was seen in the immunoreactive bands
of molar pregnancy samples using the two different concentrations of MAb B152 as
only one of the three samples showed a positive band of HhCGP at 37 kDa (Figures
75 and 76). This sample belonged to a patient diagnosed with partial mole while the
other two were from histologically confirmed complete molar pregnancies.
Interestingly, the intensity of the band detected by MAb B152 did not correlate with
the HhCG concentrations of each sample. The positively stained band of the sample
from the partial molar pregnancy contained less HhCG (476 pmol/L) than the two
complete mole samples (93744 pmol/L and 143042 pmol/L, respectively). This
suggests that Western blotting may be detecting additional denatured proteins as it
immobilizes the denatured hCG on a membrane surface, and perhaps enhances the
binding of MAb to the antigenic region of hCG. Minor molecular differences in hCG
glycosylation have little or no influence on the overall immunoreactivity of hCG
molecular forms in immunoassay systems 47-207-213. However, problems of inter-assay
variations have been reported in assay systems not recognizing HhCG forms that are
deficient in their sialic acid content 474. Heterogeneity of hCG due to differences in
the sialic acid content has often been described 31 '82>498.
Immunoblot analysis with MAb 8F11SMA in reduced conditions, demonstrated bands
of 37 kDa molecular weight in all twelve pregnancy samples, presumably
representing hCGp (Figures 73 and 74). Additional molecular weight bands of 20 kDa
and 15 kDa were seen in 2nd trimester urine samples and in all molar pregnancy
samples, probably reflecting the C-terminal extension of hCG and hCGPcf. This is in
accord with literature reports that other hCG molecular forms, including hCGPcf,
increase as gestation progresses as well as during trophoblastic disease !U-l13-530'531
Increasing the concentrations of antibody from 1/5000 to 1/2500 revealed additional
bands at about 25 kDa position and no bands in the 7-12 weeks in urine pregnancy
Samples 4-6. This may be due to differences in nicking of the polypeptide chain
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and/or sialic acid content which may be differentially detected by MAb 8F11SMA or
to changes in the tertiary conformation.
From the Western blotting results, it can be concluded that the size of Pregnyl hCG
resembles that of JEG3 hCG. In reduced samples, variations in the observed staining
pattern highlight the heterogeneous nature of hCG and the specificities of the MAbs
used but failed to show differences between normal and molar pregnancies, indicating
that this approach is not ideal for clinical use.
5.3.2 Carbohydrate heterogeneity identified using lectin binding in hCG
from different sources
Lectin-binding patterns have been used to study the invasive potential of cells and
neoplastic transformations associated with changes in the expression of various hCG
forms. The present study was undertaken to investigate whether qualitative
differences in lectin binding patterns can discriminate glycoforms of hCG produced
very early during gestation and in molar pregnancies from later pregnancy hCG. The
type of sugar and their linkage pattern in oligosaccharides were studied. Binding
patterns of 26 lectins to hCG at various gestational stages of normal pregnancy was
compared to those for hCG from urine samples from patients with partial or complete
hydatidiform mole, and from hCG from choriocarcinoma cell line JEG3 (Table 34).
The lectin-binding pattern of non-reduced hCG in Pregnyl confirms the presence of
oligosaccharides containing P-galactosyl N-linked sequences containing either trimers
or tetramers of N-acetylgalactosamine and tri-antennary sugar branches (Figures 67
and 68). These bands appeared at molecular weights corresponding to hCGP and the
hCG minus the CTP. Addition of reducing agent not only cleaves hCG into the two
subunits but also separates the N-glycosylated amino terminal portion from the O-
glycosylated carboxy-terminal portion exposing further binding sites 82' 532. Hence
when Pregnyl was probed with lectins after being reduced, more lectins revealed
immuno-positive staining (Figures 69 and 70). The binding pattern in reduced
samples confirms the presence of neutral sugars containing core mannose and/or
galactose-linked residues, a- and P- galactosyl N-linked sequences containing trimers
or tetramers of N-acetylglucosamine and N-acetylgalactosamine, and/or terminal
sialic acid molecules. The carbohydrate structures of choriocarcinoma hCG resembled
those of normal pregnancy hCG in reduced conditions (Table 1 and Figures 71 and
72). While the sugar chains of both purified hCG preparations studied here are
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sialylated, Pregnyl hCG showed stronger binding to sialic acid binding lectins (Table
34) as compared to JEG3 hCG. This is in agreement with other structural studies of
hCG during pregnancy, Down syndrome, trophoblastic diseases as well as other
malignant tumours, showing HhCG to be mostly deficient in sialic acid 18'20-22'24-27-28>
55,78,131,474,533,534 jj. suggeste(j deficiency of terminal sialic acid residues
allows N-acetylglucosaminyl transferases to initiate the addition of bi- or trisaccharide
sugars to the oligosaccharide side chains, making the molecule hyperglycosylated
Con A commonly binds to asparagine-linked oligosaccharides in both a- and (3-
subunits ending with mannose residues, but these are substituted with N-
acetylglucosamine, galactose, and sialic acid antennae the binding is weakened 27.
Even if pregnancy hCG contains mannose structures at both glycosylation sites,
failure to bind with Con A lectin may indicate presence of other complexed sugars
(Figures 67-70). The opposite mechanism maybe operating in the JEG3 hCG wherein
higher sugar branches contribute to tight interaction of hCG with Con A (Figure 71).
Lectin recognizing core fucosylated, bi- or tri-antennary oligosaccharides (Lotus
tetragonolobulus +ve) was only seen in JEG3 hCG. This supports previous reports
that the activity of fucosyl transferase is increased in invasive mole and in
choriocarcinoma 18' 121' 402. Similarly, the presence of triantennary sugar chains in
JEG3 hCG (Phaseolus vulgaris leucoagglutinin +ve) indicates enhanced activity of
N-acetylglucosaminyl transferase IV, which is responsible for the formation of the
GlcNAcp-4Manal-3 sugar chain group 402. The presence of fucosylation has shown to
alter carbohydrate mobility in the SDS-PAGE system by preventing binding of the
C-5/T
lectins with affinity for a-/p-linked N-acetylglucosamine . This may explain why
some of the lectins in the current study failed to react with a-/p-linked N-
acetylglucosamine sugars in JEG3 hCG although they did with Pregnyl hCG. Jacalin
lectin which is specific for O-linked sugar chains on the CTP bound to both Pregnyl
(Figures 67 and 69) and JEG3-hCG (Figure 71) suggesting that this sugar is present in
both pregnancy and choriocarcinoma hCG.
Probing of MAb B152 in patient samples (Table 35) (Figures 75 and 76), and in
Pregnyl (Figure 65) and JEG3 hCG (Figure 66), resulted primarily in a band of 37
kDa molecular weight, confirming that the B152 epitope lies within the CTP region of
the P-subunit 49'63-64.
Although hCG and hCGp are used to assess the progression of trophoblastic disease,
they do not always correct disease progression or regression 217' 390'537"542. For this
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reason, lectin-binding pattern was evaluated as a possible alternative method for early
detection of disease. Lectin analysis of urine samples from different gestational stages
and from normal and molar pregnancies showed different hCG binding patterns
(Figures 77-80). Sambucus nigra agglutinin reacted with pregnancy samples
irrespective of the gestational age, indicating variation in the sialic acid content
(Figure 78). The sialylation pattern observed for hCG reflects the length of gestation
78. 82, 474^ penological conditions (e.g. gestational trophoblastic disease or Down
syndrome) 29-78-475-543; source (e.g. urine, serum, tissue or cell culture), 160-498'532 as
well as the methods used for detection 29'77-78-82>534_
Con A showed high as well as low molecular weight immunoreactive bands
indicating variation in the mannose content in the N-linked chain of the hCG in
pregnancy samples irrespective of their gestational age (Figure 77). During the
glycosylation process, high mannose sugar residues are first attached to glycosylation
sites on the peptide chain which are then modified to form complex type structures
33 90that give rise to final "matured" glycosylated protein '
Compared to normal pregnancy, in hCG produced during trophoblastic diseases levels
of N-linked fucosylated biantennary oligosaccharide, fucosylated triantennary
oligosaccharide, and tetrasaccharide core structure are increased due to higher activity
of branching enzymes 18-24'35'61-402 Here, the triantennary branching on the P-subunit
was only evident for one partial molar pregnancy sample as it reacted weakly with
Phaseolus vulgaris leucoagglutinin (Figure 80).
Hydatidiform mole is generally a benign lesion, but some moles show more malignant
characteristics such as invasion in the surrounding tissues and metastasis leading to
alterations in the levels and structure of hCG sugar chains associated with the
l • l ~ 28,34, 75, 175,217, 243, 336, 349, 352, 537,538,542, 544-547 r™ ■ , r-pathological process . The importance of
identifying patients at risk of developing gestational trophoblastic disease following
the evacuation of hydatidiform mole has been highlighted in earlier chapters. The lack
of qualitative differences between the normal pregnancy and molar pregnancy
samples found in the current study using either MAb B152 or lectin binding profiles
indicates that this method is not suitable for identifying women at risk of developing
persistent disease. Kelly et al. developed a lectin-based immunoassay comparing the
glycosylation patterns of hCG in urine specimens from normal pregnancy, invasive
mole, choriocarcinoma, and male germ cell tumours using a panel of eight lectins.
Two lectins (Galanthus nivalis agglutinin and Maackia amurensis lectin)
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preferentially bound to pregnancy-derived hCG, while WGA preferentially bound to
hCG from male germ cell tumours and malignant gestational trophoblastic neoplasia
78. Higher intensity of binding of Jack fruit lectin was noted in patients with persisting
gestational trophoblastic disease and showed close correlation with the regressing
pattern of serum hCG 547. Lectin analysis of the receptors in normal placenta and
trophoblastic disease showed increased binding of Con A and WGA in samples from
patients with hydatidiform mole, invasive mole and choriocarcinoma as compared to
normal pregnancy placenta. It was concluded that the reactivity with ConA and WGA
was generally associated with increased growth and proliferation of trophoblasts
rather than malignant transformation of cells 532. Normal placenta, partial and
complete mole showed pronounced binding with peanut agglutinin after
neuraminidase treatment, as compared to invasive mole and choriocarcinoma. It was
suggested that in some malignant trophoblasts, sialic acid is missing from the terminal
carbohydrate groups resulting in the exposure of N-acetylgalactosamine. Any
hyperproliferation of placental cells during various stages of pregnancy may be
associated with a loss of sialic acid content thereby exposing the glycoprotein side
COO
chains
Increased triantennary structures linked to Asn-30 as well as fucosylation of the Asn-
13-bound glycan were found in the P-subunit of cancer-derived hCG when compared
to hCG from normal pregnancy 77. This observation is confirmed in the current study
where using lectins with affinity for fucose-linked sugar chains, positively stained
bands were seen in JEG3 hCG (Figure 71) but not Pregnyl (Table 34). Probing of
pregnancy urine with Lotus tetragonolobulus lectin showed darker stained bands only
in 1st trimester samples (Figure 79) This contradicts previous reports suggesting that
the proportion of highly branched, fucosylated oligosaccharides increases as gestation
27,31
progresses
In summary, Western blotting experiments were carried out to identify hCG bands by
means of antibody-antigen interaction. The results presented here are generally in
good accord with evidence in the literature. The present results provide information
about oligosaccharide composition of pregnancy hCG and confirm the complex
structure and heterogeneity of the carbohydrate structure of hCG l8'21'24'35'61'66'67'77'
402,532 0f apparent qualitative differences using MAb B152 or lectin binding
profiles in patient samples may reflect the low concentrations of relevant sugar
residues and indicates the need for more sensitive detection methods.
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CHAPTER 6. FUTURE DIRECTIONS AND SUMMARY
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6.1 Future Directions
6.1.1 Pregnancy test and early pregnancy outcome
This study has confirmed that the majority of total hCG immunoreactivity in serum
and urine samples during early pregnancy is due to HhCG. Most commercially
available hCG tests 69'340-548-549 have been calibrated with hCG and not HhCG and do
not optimally recognize the HhCG. Since 2006 Quest Diagnostics Inc. have owned
the patent rights to MAb B152 55°, but the official commercial release of a HhCG
assay system is still awaited.
The availability of an assay that appropriately detects HhCG is not only important in
the detection of pregnancy, but can be extended in monitoring of early pregnancy
outcome. Both, single cut-off value as well as doubling time, should be further
explored not only to distinguish normal pregnancies from failing pregnancies, but also
can be used as a better discriminator between ectopic pregnancy and spontaneous
miscarriage. Efforts should be made to define the 'discriminatory zone' for HhCG,
like the one available for hCG 3I2' 505'551, in order to make a quick accurate early
diagnosis of ectopic pregnancy even when the sac is not visualized on ultrasound.
Placenta accreta, placenta increta and placenta percreta represent a spectrum of
abnormal implantation by the placenta, in which there is abnormal attachment of the
placenta to the uterine wall that may lead to massive obstetrics hemorrhage and the
need of extensive life-saving surgical interventions such as hysterectomy and ligation
cco
#
of major pelvic vessels . HhCG may be used for early recognition of the condition
which may improve the outcome, since it provides the obstetrician the opportunity to
deal more effectively with this obstetrical emergency.
It is not easy to assign cause and effect from the data presented in this thesis, it is
tempting to speculate that decreased levels of HhCG in the placenta may lead to early
pregnancy failures and spontaneous miscarriages. Future research will need to address
the exact role of HhCG in implantation and its mechanism of action throughout
pregnancy in order to develop new therapeutic strategies to prevent and treat
pregnancy-related disorders such as spontaneous miscarriages and pre-eclampsia.
Application ofMAbs against HhCG for passive immunization, in cases of emergency
202
contraception, could also be explored. The present lack of availability of highly
purified and well-characterized HhCG preparations limits further progress in this area.
6.1.2 HhCG as a tumour marker and treatment of malignancy
A role for HhCG in promoting both growth and invasion by pregnancy
cytotrophoblast and choriocarcinoma cells in vivo and in vitro has been shown 74'253.
HhCG may be a specific promoter or stimulant of cytotrophoblast and
choriocarcinoma invasion in vitro and choriocarcinoma growth and development in
vivo and blockage of HhCG with MAbs may obstruct choriocarcinoma
tumourigenesis and growth and development in vivo. MAbs with the same specificity,
or appropriately modified mouse antibodies, or antagonists of HhCG could be
clinically useful as a treatment for choriocarcinoma and gestational trophoblastic
disease. They could also be clinically useful in the prevention of persistence of
hydatidiform mole or of recurring trophoblastic diseases. HhCG might have potential
as a vaccine to promote endogenous production of human antibodies. Potential
angiogenic function should also be explored for HhCG, since HhCG-antagonists
could serve as a potential approach for angiostatic therapy in malignancy.
6.2 Conclusions
Even with the results of the present study, together with all the currently available
data in the literature, it is not possible to predict whether maternal screening for
obstetrics complication with HhCG will become a clinical reality. The test
undoubtedly has potential for detecting early pregnancy failures and spontaneous
miscarriages. Its true clinical value as a screening marker remains to be determined.
However it is tempting to speculate that measurement of HhCG could provide a
'contingency screen' to follow the outcome of early pregnancy, and, in combination
with other tests, an 'integrated screen' for following up the prognosis of later
gestation, both of which need to be verified in future prospective studies.
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Conclusion: Havingreviewedllaspectsofth sprojecttcommitteecon lud dath rr neitherethicaloscientificreasonswhytstudys uldn tproceed.
DR.GE ALDSTILES Chairman Ethical&In erpersonalCommittee MafraoHospital
PROF.HANSG UNDSELL SeniorConsultant&Head Obs&GynaeDepartm nt MafraoHospital-
MRS.LINDAJACK ON DirectorofNursing NursingDepartment MafragHospital
Consent Form For Defining the Screening and Diagnostic strategies of
Hypcrglvcosvlated hCG in detection Of Pregnancy Related Disorders
I agree to participate in the project for detecting the screening and diagnostic efficiency
of hyperglycosylated hCG in detecting pregnancy related disorders: a study to help
identifying high risk pregnancies before the onset signs and symptoms ofany disorder. I
understand that I will complete a brief questionnaire about my health and obstetrical
history. I agree to provide my urine and blood samples for the above mentioned project. 1
understand that the first urine and blood samples will be taken during an early ante natal
booking (i.e. between 8-14 weeks) followed by the second urine and blood samples,
which would be taken at 15-20 weeks ofmy pregnancy. I am aware that these samples
will be then stored and analyzed once the pregnancy outcome is available. My only
discomfort will be related to the needle prick for drawing the 3 cc blood, and the most
common adverse is bruising around the vein from where the blood sample is drawn.
1 understand that my participation in the study is entirely voluntary. All information
gathered for this study will be used by the investigators exclusively for the research
purposes and will not he used to generate a profit. I will not be identified in any published
report. 1 am free to refuse to participate or withdraw from the study at any time, without
jeopardizing my future ante natal care. If I have any question, I may contact Dr. Nahla
Kazim. Mafraq Hospital, on telephone number 02-5031537 and Pager no. 208.
I agree to participate in the project defining the efficiency of H-hCG in detecting
pregnancy related disorders.
Subject Name Subject Signature Date
Witness Name Witness Signature Date
Dr. Nallla Kazim
G.P. / Obstetrics ami Gynecology Dept.
Mafraq Hospital
Characteristics of study group



















I I Threatened abortion
1 I Missed abortion
I I Incomplete Abortion
I I Spontaneous abortion






I | On diet 0 On insulin
Hypertensive disorders
I IPIH 0 Pre-eclampsia 0 Eclampsia
Preterm












































Telephone 0131 536 9000










Facsimile: 0131 536 9346
Prof Andrew A Caider
Head of Department- Obstetrics and Gynaecology
Department of Reproductive and Developmental Sciences
Simpson centre for Reproductive t tealth
61 Little France Crescent i
EH1343A
Dear Prof. Caider
Full title of study: Hyperglycosylated hCG(H-hCG) Levels following
Embryo Transfer(ET): A potential marker of successful
implantation and uneventful pregnancies?
REC reference number: 05/S1101/33
Thank you for your letter of 11 October 2005 received 25 January 2006. responding to the
Committee's request for further information ort the above research and submitting revised
documentation.
The further information was considered by the chan on Dehalf of the LREC1.
Confirmation of ethical opinion
On behaff of the Committee, i am pleased to confirm a favourable ethical opinion for the
above research on the basis described in the application form protocol and supporting
documentation as revised.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form.
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the
attached document. You are advised to study the conditions carefully.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows
Version Date









U08 290B 14:5# FAX 0131 S3« #34« SECKfclAJtlAT
2ooi
OS'S-101/33 Pago 2
fPeer Review 07 December 2004 I
11 October 2005 |
11 October 2005
GP/Consultant Icfwrnation Sheets
| Participant information Sheet
i Participant Consent Form
i Response to Request for Further information
1 01 August 2005 i
11 October 2005 j
Research governance approval
The study should not commence at any NHS site until the local Principal Investigator has
obtained final research governance approval from tno R&D Department for the relevant NHS
care organisation.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001} and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK
j 0S/S1101/33 Please quote this number on all correspondence
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Hyperglycosylated hCG levels following embryo transfer
N/A
The above project has undergone an assessment of risk to the Division and review of
resource and financial implications. I am satisfied that all the necessary arrangements have
been set in place and that all Departments contributing to the project have been informed.
I note that this is a single centre study sponsored by University of Edinburgh.




























♦ The study involves the use of patient tissue or samples. You must be familiar with
NHS Lothian's Tissue Policy and abide by its conditions and also with all
regulations in place at the time. Approval is subject to the prevailing legal
requirements.
♦ Approval for the use of tissue is restricted to the protocol associated with this
application, but may include additional collaborators within University of
Edinburgh. Collaborators who are not named in the original protocol require to be
notified to local REC.
♦ If material is to be transferred to academic collaborators outwith University of
Edinburgh or to any commercial entity then a material transfer agreement must
be obtained from the R&D Office and signed by all relevant parties prior to
transfer of the material. Such collaborations must be fully discussed with the
R&D Office.
♦ I note that additional samples will be taken for the study and that this will be done
with the patient's explicit consent.
On behalf of the Chief executive and Medical Director, I am happy to grant management
approval from NHS Lothian - University Hospitals Division to allow the project to commence,
subject to the approval of the appropriate Research Ethics Committee(s) having also been
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obtained. You should note that any substantial amendments must be notified to the relevant
Research Ethics Committee and to R&D Management with approval being granted from
both before the amendments are made.
Please note that under Section A, Q35, NHS Lothian provides indemnity for negligence for
NHS and Honorary clinical staff for research associated with their clinical duties. It is not
empowered to provide non-negligent indemnity cover for patients. Lothian University
Hospitals Division does not provide indemnity against negligence for healthy volunteer
studies. This is the personal responsibility of both NHS and honorary employees and is
usually arranged with a medical defence organisation or through the University of
Edinburgh.
This letter of approval is your assurance that the Division is satisfied with your study. As
Chief Investigator or local Principal Investigator, you should be fully committed to your
responsibilities within the Research Governance Framework for Health and Community
Care, an extract of which is attached to this letter.
Yours sincerely
Dr Heather A Cubie
R&D Director
enc Research Governance Certificate
NRR authorisation
Tissue Policy (if applicable)
MTA (if applicable) J (to be signed and relumed)
cc Administrators, Research Ethics Committee
ProfessorAndrew Calder, Obstetrics/Gynaecology, RIE






- □ D 2
" □ D 3
Indication for treatment
- □ Tubal factor
- □ Endometriosis
























None (Negative pregnancy test)
Biochemical pregnancy
Ectopic pregnancy
Positive fetal heart on U/S x
Miscarriage at weeks
(* No. of felal hearts)
Remarks
Delivery outcome
Delivered at I Weeks
I lM/1 IF Grams
I lM/1 |F Grams (* Applicable for multiple births)
Others (i.e. chromosomal anomaly or any other complications)
Procedure Details
Date of oocyte recovery
Date of Embryo transfer






Determination of Hvperglycosylated Human Chorionic Gonadotropin
(H-hCG) levels in Implantation and Early Pregnancy following Embryo
Transfer
You are being invited to take part in a research study. Before you decide it
is important for you to understand why the research is being done and what
it will involve. Please take time to read the following information carefully.
Please do not hesitate to contact on the number given below if there is
anything that is not clear or if you would like more information. Take time
to decide whether or not you wish to take part.
Thank you for reading this.
What is the purpose of the study?
H-hCG is a hormone that is abundant in very early pregnancy (i.e. 3-
4weeks). It is produced by placental cells which are necessary for successful
implantation. The role of H-hCG in implantation is unclear, but its levels
may help doctors to identify successful implantation.
We thus aim to study levels of H-hCG during early pregnancy, as a possible
marker for successful implantation and uneventful pregnancy.
Why have I been chosen?
As you are attending the assisted conception unit for the procedure of
Embryo Transfer, your follow up blood samples will provide useful
information about levels of H-hCG during implantation period.
W hat will happen to me if I take part?
The IVF clinic will ask you to come back 2 weeks after the procedure for a
Pregnancy Test. If you agree to participate, then an extra two teaspoonfuls of





Patient Identification Number for this trial:
CONSENT FORM
Hyperglycosylated hCG Levels Following Assissted Conception
Name of Researcher: Nahla Kazim
Please initial box
1. I confirm that I have read and understand the information sheet dated 01/08/2005
(version 4.1) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, without my medical care or legal rights being affected.
□
□
3. I understand that sections of any of my medical notes may be looked at by responsible
individuals from [Assisted Conception Unit ] or from regulatory authorities where it is relevant to
my taking part in research. I give permission for these individuals to have access to my records.





Name of Patient Date Signature
Name of Person taking consent Date Signature
(If different from researcher)
Researcher Date Signature




Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research
will be kept strictly confidential. Your blood samples collected will be
appropriately coded and will have no details identifying you.
Who has reviewed the study?
The local Research Ethics Committee has reviewed the study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take
part you will be given this information sheet to keep and will be asked to
sign a consent form. Should you decide to take part, you are still free to
withdraw at any time and without giving a reason. A decision to withdraw
at any time, or a decision not to take part, will not affect the standard of care
you receive.
Will my CP be informed?
If you agree to participate, then a letter will be sent to your G.P informing
them about your participation in this study.
Contact for Further Information
I f you have any queries, do feel free
Dr Nahla Kazim (0131-2422693) or
looking after you.
Thank you for your time
to contact Dr J Thong (0131-2422446),
any other member of the staff in the unit
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Dear Dr ,
Re: Your patient
Study title: Hyperglycosylated hCG levels following Assisted Conception
Your patient has recently agreed to participate in the above study which is
taking place in the Assisted Conception Unit of Edinburgh Fertility and
Reproductive Endocrine Centre. Details of the study are outlined in the
enclosed patient information sheet.
If you require any further information please do not hesitate to contact me on
0131-2422693 or any member of assisted other member of the staff in the
assisted conception unit.
Yours sincerely,
Dr Nattla'Kazim (M.B.B.S, MSc)
i- M: •; >• i • •. isj< >n v \ •• t l.i .
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